Neoplasms

• 

  Subject Areas on Research

  • "Job Lock" Among Long-term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 
  • "More than conquerors": a qualitative analysis of war metaphors for patients with cancer. 
  • "Shouldn't You Spend Your Time Curing Cancer or Something?" Why an African American Female Physician Chose a Career in Palliative Care. 
  • "Treat us with dignity": a qualitative study of the experiences and recommendations of lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients with cancer. 
  • "What concerns me is..." Expression of emotion by advanced cancer patients during outpatient visits. 
  • "You have to be sure that the patient has the full picture": Adaptation of the Best Case/Worst Case communication tool for geriatric oncology. 
  • "You start feeling comfortable, you just start sharing:" A qualitative study of patient distress screening in Black and White patients with endometrial cancer. 
  • 'What do they know about it?' How the North Carolina public views cancer clinical trials: implications for primary care doctors. 
  • 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. 
  • 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA. 
  • 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. 
  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. 
  • 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 
  • 3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity. 
  • 3D traction stresses activate protease-dependent invasion of cancer cells. 
  • 5-Fluorouracil in childhood solid tumors. 
  • miR-146a -Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression. 
  • A 10-year review of research on chaplains and community-based clergy in 3 primary oncology nursing journals: 1990-1999. 
  • A Comparison of Late Mortality Among Survivors of Childhood Cancer in the United States and United Kingdom. 
  • A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments. 
  • A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. 
  • A Monte Carlo investigation of dual-energy-window scatter correction for volume-of-interest quantification in 99Tcm SPECT. 
  • A Multidisciplinary Consensus Recommendation on a Synoptic Radiation Treatment Summary: A Commission on Cancer Workgroup Report. 
  • A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease. 
  • A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction Among Childhood Cancer Survivors. 
  • A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. 
  • A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. 
  • A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. 
  • A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. 
  • A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. 
  • A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 
  • A Pilot Study of a Mobile Health Pain Coping Skills Training Protocol for Patients With Persistent Cancer Pain. 
  • A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. 
  • A Prospective Cohort Study of Stability in Preferred Place of Death Among Patients With Stage IV Cancer in Singapore. 
  • A Prospective Study of Community Mediators on the Risk of Sepsis After Cancer. 
  • A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. 
  • A Research Agenda for Communication Between Health Care Professionals and Patients Living With Serious Illness. 
  • A Roadmap for a New Academic Pathway for Global Radiation Oncology. 
  • A SMART approach to optimizing delivery of an mHealth intervention among cancer survivors with posttraumatic stress symptoms. 
  • A Sensitized Screen for Genes Promoting Invadopodia Function In Vivo: CDC-42 and Rab GDI-1 Direct Distinct Aspects of Invadopodia Formation. 
  • A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. 
  • A Socio-Ecological Framework for Cancer Prevention in Low and Middle-Income Countries. 
  • A Standardized Education Checklist for Parents of Children Newly Diagnosed With Cancer: A Report From the Children's Oncology Group. 
  • A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. 
  • A Systematic Literature Review of Animal-Assisted Interventions in Oncology (Part I): Methods and Results. 
  • A TCP model incorporating setup uncertainty and tumor cell density variation in microscopic extension to guide treatment planning. 
  • A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients? 
  • A View from the past into our collective future: the oncofertility consortium vision statement. 
  • A Web-based communication aid for patients with cancer: the CONNECT Study. 
  • A brief relaxation intervention for pain delivered by palliative care physicians: A pilot study. 
  • A cancer incidence survey in Tianjin: the third largest city in China-between 1981 and 2000. 
  • A case-control comparison of durability and cost between implanted reservoir and percutaneous catheters in cancer patients. 
  • A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. 
  • A clinical decision and economic analysis model of cancer pain management. 
  • A clinical review of nutritional support of the patient. 
  • A comparison of attitudes toward length and quality of life between community-dwelling older adults and patients with advanced cancer. 
  • A comparison of cancer survivors from the PROMIS study selecting telephone versus online questionnaires. 
  • A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. 
  • A comparison of randomized concurrent control groups with matched historical control groups: are historical controls valid? 
  • A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. 
  • A comparison of temperatures in canine solid tumours during local and whole-body hyperthermia administered alone and simultaneously. 
  • A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. 
  • A copula approach for detecting prognostic genes associated with survival outcome in microarray studies. 
  • A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. 
  • A daily activities list and its relation to measures of adjustment and early environment. 
  • A data-driven approach to modeling cancer cell mechanics during microcirculatory transport. 
  • A decision exercise to engage cancer patients and families in deliberation about Medicare coverage for advanced cancer care. 
  • A design alternative for two-stage, phase II, multicenter cancer clinical trials. 
  • A dual-emissive-materials design concept enables tumour hypoxia imaging. 
  • A fast dose calculation method based on table lookup for IMRT optimization. 
  • A genetic algorithm for variable selection in logistic regression analysis of radiotherapy treatment outcomes. 
  • A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. 
  • A genomic strategy to elucidate modules of oncogenic pathway signaling networks. 
  • A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. 
  • A global approach to tumor immunology. 
  • A granuloma of the testis of unknown etiology. 
  • A heterogeneous human tissue mimicking phantom for RF heating and MRI thermal monitoring verification. 
  • A histopathologic study of 716 unselected eyes in patients with cancer at the time of death. 
  • A hypothesis: indirect cell death in the radiosurgery era. 
  • A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. 
  • A loss-of-function RNA interference screen for molecular targets in cancer. 
  • A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. 
  • A map of human cancer signaling. 
  • A mathematical model of tumor oxygen and glucose mass transport and metabolism with complex reaction kinetics. 
  • A message from the Editor-in-Chief. 
  • A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. 
  • A meta-analysis of the relationship between social constraints and distress in cancer patients. 
  • A method to convert MRI images of temperature change into images of absolute temperature in solid tumours. 
  • A method to generate genetically defined tumors in pigs. 
  • A methodology for utilization of predictive genomic signatures in FFPE samples. 
  • A model for RAS mutation patterns in cancers: finding the sweet spot. 
  • A model for the shared care of elderly patients with cancer. 
  • A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. 
  • A multicenter analysis of the ED diagnosis of pneumonia. 
  • A multisite, community oncology-based randomized trial of a brief educational intervention to increase communication regarding complementary and alternative medicine. 
  • A new era for cancer treatment: gold-nanoparticle-mediated thermal therapies. 
  • A nomogram for individualized estimation of survival among patients with brain metastasis. 
  • A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies. 
  • A novel EGFR isoform confers increased invasiveness to cancer cells. 
  • A novel digital tomosynthesis (DTS) reconstruction method using a deformation field map. 
  • A novel evolutionary-concordance lifestyle score is inversely associated with all-cause, all-cancer, and all-cardiovascular disease mortality risk. 
  • A novel immunocompetent murine tumor model for the evaluation of RCAd-enhanced RDAd transduction efficacy. 
  • A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. 
  • A path to translation: How 3D patient tumor avatars enable next generation precision oncology. 
  • A pathway-based approach to identify molecular biomarkers in cancer. 
  • A patient-independent CT intensity matching method using conditional generative adversarial networks (cGAN) for single x-ray projection-based tumor localization. 
  • A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. 
  • A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. 
  • A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. 
  • A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. 
  • A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. 
  • A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. 
  • A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. 
  • A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. 
  • A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. 
  • A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. 
  • A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. 
  • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 
  • A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. 
  • A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. 
  • A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. 
  • A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. 
  • A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. 
  • A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. 
  • A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. 
  • A phase I surrogate endpoint study of SU6668 in patients with solid tumors. 
  • A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. 
  • A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. 
  • A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy. 
  • A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. 
  • A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. 
  • A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. 
  • A pilot study on the influence of an individualized and experiential training on cancer caregiver's self-efficacy in home care and symptom management. 
  • A pleiotropic ATM variant (rs1800057 C>G) is associated with risk of multiple cancers. 
  • A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. 
  • A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. 
  • A predictive model for neutropenia associated with cancer chemotherapy. 
  • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. 
  • A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer. 
  • A prospective cohort study of decision-making role preferences of patients with advanced cancer and their family caregivers. 
  • A prospective study of dietary patterns and cancer mortality among Blacks and Whites in the REGARDS cohort. 
  • A prospective study of psychological distress among patients with advanced cancer and their caregivers. 
  • A prospective study of the epidemiology of adverse drug reactions in pediatric hematology and oncology patients. 
  • A protocol for a discrete choice experiment: understanding preferences of patients with cancer towards their cancer care across metropolitan and rural regions in Australia. 
  • A public database for gene expression in human cancers. 
  • A randomized comparative effectiveness study of Healthy Directions 2--a multiple risk behavior intervention for primary care. 
  • A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). 
  • A rationale for the targeted treatment of oligometastases with radiotherapy. 
  • A realistic complication analysis of 70 sural artery flaps in a multimorbid patient group. 
  • A review of Kenya's cancer policies to improve access to cancer testing and treatment in the country. 
  • A review of cancer immunotherapy toxicity. 
  • A review of relative dose intensity and survival in patients with metastatic solid tumors. 
  • A review of the application of inflammatory biomarkers in epidemiologic cancer research. 
  • A role for biological optimization within the current treatment planning paradigm. 
  • A role for secondary V(D)J recombination in oncogenic chromosomal translocations? 
  • A seat at the table: redesigning cancer care. 
  • A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. 
  • A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. 
  • A single-site pilot feasibility randomized trial of a supportive care mobile application intervention for patients with advanced cancer and caregivers. 
  • A sociology of precision-in-practice: The affective and temporal complexities of everyday clinical care. 
  • A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. 
  • A study on community perceptions of common cancers, determinants of community behaviour and program implementation in New Delhi, India. 
  • A surveillance system for monitoring, public reporting, and improving minority access to cancer clinical trials. 
  • A survey of monitoring practices in cancer clinical trials. 
  • A survey of multidisciplinary healthcare providers utilizing the KNOWintegrativeoncology.org educational platform. 
  • A systematic review of the factors affecting accuracy of SUV measurements. 
  • A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. 
  • A systems biology view of cancer. 
  • A theoretical model for the effects of reduced hemoglobin-oxygen affinity on tumor oxygenation. 
  • A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation. 
  • A unifying hypothesis to explain the retardation of aging and tumorigenesis by caloric restriction. 
  • A unique role of the DNA fragmentation factor in maintaining genomic stability. 
  • A widespread length-dependent splicing dysregulation in cancer. 
  • A word of caution in the use of neuron-specific enolase expression in tumor diagnosis. 
  • A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. 
  • A year of successful cancer vaccines points to a path forward. 
  • ACLY and ACC1 Regulate Hypoxia-Induced Apoptosis by Modulating ETV4 via α-ketoglutarate. 
  • ACRIN fellowship 2004: personal perspectives. 
  • AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease. 
  • AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. 
  • AMPK signaling and its targeting in cancer progression and treatment. 
  • ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. 
  • ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. 
  • ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. 
  • ATM: genome stability, neuronal development, and cancer cross paths. 
  • Abdominal radiation and diabetes: one more piece in the puzzle. 
  • Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. 
  • Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. 
  • Abl kinases are required for invadopodia formation and chemokine-induced invasion. 
  • Abnormalities of leukocyte chemotaxis in human disease. 
  • Abrogation of P53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumour cells to ionizing radiation. 
  • Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors. 
  • Acanthosis nigricans: a practical approach to evaluation and management. 
  • Accelerated aging among cancer survivors: from pediatrics to geriatrics. 
  • Accelerated repopulation: friend or foe? Exploiting changes in tumor growth characteristics to improve the "efficiency" of radiotherapy. 
  • Acceptability of a Dyadic Psychoeducational Intervention for Patients and Caregivers. 
  • Accepting risk in the acceleration of drug development for rare cancers. 
  • Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa. 
  • Accuracy incentives and framing effects to minimize the influence of cognitive bias among advanced cancer patients. 
  • Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. 
  • Accuracy of mutational signature software on correlated signatures. 
  • Accurate in vivo tumor detection using plasmonic-enhanced shifted-excitation Raman difference spectroscopy (SERDS). 
  • Acetate Metabolism in Physiology, Cancer, and Beyond. 
  • Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. 
  • Achieving the goals of effective, safe, and individualized cancer care. 
  • Actin cytoskeletal network in aging and cancer. 
  • Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop. 
  • Activation of RalA is critical for Ras-induced tumorigenesis of human cells. 
  • Activation of the PI3K/Akt pathway and chemotherapeutic resistance. 
  • Activation of tyrosine kinases in cancer. 
  • Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug. 
  • Actively targeting solid tumours with thermoresponsive drug delivery systems that respond to mild hyperthermia. 
  • Activities and accomplishments of the cancer and leukemia group B genitourinary committee. 
  • Activities, function, and health-related quality of life (HRQOL) of older adults with cancer. 
  • Activity and distribution of the cysteine prodrug activating enzyme, 5-oxo-L-prolinase, in human normal and tumor tissues. 
  • Actual and Missed Opportunities for End-of-Life Care Discussions With Oncology Patients: A Qualitative Study. 
  • Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. 
  • Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. 
  • Adaptation of the Possibilities for Activity Scale for women encountering cancer (PActS-W). 
  • Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic. 
  • Adaptive radiation therapy: technical components and clinical applications. 
  • Addressing Issues of Cancer Disparities, Equity, and Inclusion Through Systemized Quality Improvement. 
  • Addressing overdiagnosis and overtreatment in cancer: a prescription for change. 
  • Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease. 
  • Adeno-associated virus vectors: potential applications for cancer gene therapy. 
  • Adenovirus vaccine immunotherapy targeting WT1-expressing tumors. 
  • Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study. 
  • Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. 
  • Adherence to cancer prevention guidelines in 18 African countries. 
  • Adherence to cancer prevention guidelines in South Africa is associated with health care access. 
  • Adjunctive agents in systemic chemotherapy. 
  • Adjusting for misclassification in a stratified biomarker clinical trial. 
  • Admissible two-stage designs for phase II cancer clinical trials. 
  • Admission to the intensive care unit and well-being in patients with advanced chronic illness. 
  • Adnexal Masses in Pregnancy. 
  • Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Adolescent and Young Adult Perspectives on Quality and Value in Health Care. 
  • Adolescent and young adult cancer: a revolution in evolution? 
  • Adolescent and young adult oncology, version 2.2014. 
  • Adolescent and young adult oncology. Clinical practice guidelines in oncology. 
  • Adolescent cancer patients: sperm storage, consent and emotion 
  • Adolescent/Young Adult Perspectives of a Therapeutic Music Video Intervention to Improve Resilience During Hematopoietic Stem Cell Transplant for Cancer. 
  • Adrenocortical hyperplasia occurring with metastatic carcinoma of the prostate: report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion. 
  • Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. 
  • Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Adult cancer pain. 
  • Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. 
  • Advanced Cancer Patients' Prognostic Awareness and Its Association With Anxiety, Depression and Spiritual Well-Being: A Multi-Country Study in Asia. 
  • Advanced Practice Providers and Survivorship Care: They Can Deliver. 
  • Advanced imaging and hospice use in end-of-life cancer care. 
  • Advances in current cancer treatment: an overview. 
  • Advances in inherited cancers: Introduction. 
  • Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. 
  • Advocacy skills training for young adult cancer survivors: the Young Adult Survivors Conference at Camp Māk-a-Dream. 
  • Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. 
  • Age cutoff in lymphoma diagnosis. 
  • Age, gender, and cancer but not neurodegenerative and cardiovascular diseases strongly modulate systemic effect of the Apolipoprotein E4 allele on lifespan. 
  • Age-dependent changes in health status in the Childhood Cancer Survivor cohort. 
  • Age-related declines in activity level: the relationship between chronic illness and religious activities. 
  • Age-related macular degeneration and cancer mortality in the atherosclerosis risk in communities study. 
  • Aging and cancer. 
  • Aging and neoplasia. 
  • Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. 
  • Agreement Between Child Self-report and Caregiver-Proxy Report for Symptoms and Functioning of Children Undergoing Cancer Treatment. 
  • Akt-dependent and -independent mechanisms of mTOR regulation in cancer. 
  • Alcohol and Cancer: Existing Knowledge and Evidence Gaps across the Cancer Continuum. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • Algorithm-based decision support for symptom self-management among adults with Cancer: results of usability testing. 
  • Alkylation of the tumor suppressor PTEN activates Akt and β-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. 
  • Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer. 
  • Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens. 
  • Altered metabolism in cancer. 
  • Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. 
  • Alternative fuels for cancer cells. 
  • Alternative models for the heterogeneity of mortality risks among the aged. 
  • American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. 
  • American Society of Clinical Oncology guidance statement: the cost of cancer care. 
  • American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. 
  • American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. 
  • American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. 
  • American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. 
  • Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study. 
  • An AOTF-based dual-modality hyperspectral imaging system (DMHSI) capable of simultaneous fluorescence and reflectance imaging. 
  • An Exploratory Factor Analysis of the Scale Structure of the Patient Care Monitor Version 2.0. 
  • An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. 
  • An accelerated pathway for targeted cancer therapies. 
  • An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. 
  • An analysis of missing items in real-world electronic patient reported outcomes data: implications for clinical care. 
  • An analysis of the heterogeneity of U.S. nursing home patients. 
  • An analytic model of pinhole aperture penetration for 3D pinhole SPECT image reconstruction. 
  • An assessment of cancer clinical trials vocabulary and IT infrastructure in the U.S. 
  • An examination of the dental utilization practices of adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. 
  • An exploration of relative health stock in advanced cancer patients. 
  • An exploratory study of end-of-life prognostic communication needs as reported by widowed fathers due to cancer. 
  • An exploratory study of environmental and medical factors potentially related to childhood cancer. 
  • An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. 
  • An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. 
  • An integrated encyclopedia of DNA elements in the human genome. 
  • An integrated physical map of 210 markers assigned to the short arm of human chromosome 11. 
  • An integrated widefield imaging and spectroscopy system for contrast-enhanced, image-guided resection of tumors. 
  • An intervention to improve cancer patients' understanding of early-phase clinical trials. 
  • An investigation of kV mini-GRID spatially fractionated radiation therapy: dosimetry and preclinical trial. 
  • An item response theory-based pain item bank can enhance measurement precision. 
  • An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. 
  • An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. 
  • An outlook on precision surgery. 
  • An outpatient Urgent Care Bay within a pediatric cancer and hematology center. 
  • An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. 
  • An overview of naturally occurring histone deacetylase inhibitors. 
  • An ultra-sensitive method to detect mutations in human RAS templates. 
  • Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. 
  • Analysis of co-aggregation of cancer based on registry data. 
  • Analysis of dermatologic events in patients with cancer treated with lapatinib. 
  • Analysis of image quality for real-time target tracking using simultaneous kV-MV imaging. 
  • Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis. 
  • Analysis of prognostic variables which influence early and long-term response of pet animal tumors to radiation alone and radiation plus heat. 
  • Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. 
  • Anchorage-independent cell growth signature identifies tumors with metastatic potential. 
  • Anemia and Functional Disability in Older Adults With Cancer. 
  • Anemia and cancer in older persons. 
  • Anesthesia for pediatric external beam radiation therapy. 
  • Angiogenesis pathway inhibitors. 
  • Angiostatin and anti-angiogenic therapy in human disease. 
  • Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. 
  • Annotating nonspecific SAGE tags with microarray data. 
  • Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. 
  • Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. 
  • Anti-VEGF therapies in the clinic. 
  • Anti-idiotypic antibodies as vaccine candidates. The immune network. 
  • Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. 
  • Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. 
  • Anti-tumor immunity: myeloid leukocytes control the immune landscape. 
  • Anti-tumour activity and store operated calcium entry: new roles in immunology. 
  • Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. 
  • Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. 
  • Anticholinergic Drug Burden in Noncancer Versus Cancer Patients Near the End of Life. 
  • Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. 
  • Antihypertensive Drugs and Cancer Risk. 
  • Antiinflammatory effects of neoplasms. 
  • Antiinflammatory proteins associated with human and murine neoplasms. 
  • Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. 
  • Anxiety and Depressive Symptoms Among Two Seriously Medically Ill Populations and Their Family Caregivers: A Comparison and Clinical Implications. 
  • Apoptosis: inhibitor or instigator of carcinogenesis? 
  • Appendectomy Versus Observation for Appendicitis in Neutropenic Children With Cancer. 
  • Application of Mie theory to determine the structure of spheroidal scatterers in biological materials. 
  • Application of a new multinomial phase II stopping rule using response and early progression. 
  • Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens. 
  • Application of an antibody biochip for p53 detection and cancer diagnosis. 
  • Application of new technology in clinical hyperthermia. 
  • Application of optical imaging and spectroscopy to radiation biology. 
  • Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. 
  • Applications of RNA interference high-throughput screening technology in cancer biology and virology. 
  • Applications of elastin-like polypeptides in drug delivery. 
  • Applying Behavioral Economics to Improve Adolescent and Young Adult Health: A Developmentally-Sensitive Approach. 
  • Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult Cancers: Review and Research Recommendations. 
  • Approach to evaluation of fever in ambulatory cancer patients receiving chemotherapy: A systematic review. 
  • Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. 
  • Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. 
  • Appropriate chemotherapy dosing in obese patients with cancer. 
  • Aptamer applications for targeted cancer therapy. 
  • Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. 
  • Aptamers as Therapeutics. 
  • Aptamers in immunotherapy. 
  • Are care experiences associated with survival among cancer patients? An analysis of the SEER-CAHPS data resource. 
  • Are chemotherapy patients' HRQoL importance weights consistent with linear scoring rules? A stated-choice approach. 
  • Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. 
  • Are we finally ready for outpatient management of febrile neutropenia? 
  • Are we ready to predict late effects? A systematic review of clinically useful prediction models. 
  • Arti Hurria and the progress in integrating the geriatric assessment into oncology: Young International Society of Geriatric Oncology review paper. 
  • Artifactual frame-shift p53 mutation at codon 249 detected with the Cyclist DNA sequencing method. 
  • Artificial Intelligence in Radiotherapy Treatment Planning: Present and Future. 
  • Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling. 
  • Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. 
  • Assays for monitoring cellular immune responses to active immunotherapy of cancer. 
  • Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. 
  • Assessing Depressive Symptoms in Patients With Cancer Treated With Interleukin-2: A Comparison of 2 Measures. 
  • Assessing Psychological Toxicity and Patient-Reported Distress as the Sixth Vital Sign in Cancer Care and Clinical Trials. 
  • Assessing Religious Commitment in a Multicultural Inpatient Setting: A Psychometric Evaluation of the 10-item Belief into Action Scale. 
  • Assessing effects of pressure on tumor and normal tissue physiology using an automated self-calibrated, pressure-sensing probe for diffuse reflectance spectroscopy. 
  • Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. 
  • Assessing matched normal and tumor pairs in next-generation sequencing studies. 
  • Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? 
  • Assessing responsiveness over time of the PROMIS® pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease. 
  • Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment. 
  • Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. 
  • Assessing the cost and economic impact of tertiary-level pediatric cancer care in Tanzania. 
  • Assessing whether there is a cancer premium for the value of a statistical life. 
  • Assessment of Changes in Symptoms Is Feasible and Prognostic in the Last Weeks of Life: An International Multicenter Cohort Study. 
  • Assessment of follow-up completeness and notification preferences for imaging findings of possible cancer: what happens after radiologists submit their reports? 
  • Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. 
  • Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study. 
  • Assessment of selection bias in clinic-based populations of childhood cancer survivors: a report from the childhood cancer survivor study. 
  • Association Between Delivery System Structure and Intensity of End-of-Life Cancer Care. 
  • Association Between Patient Satisfaction and Short-Term Outcomes After Major Cancer Surgery. 
  • Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. 
  • Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis. 
  • Association between XPF polymorphisms and cancer risk: a meta-analysis. 
  • Association between body mass index and in-hospital outcomes: Analysis of the nationwide inpatient database. 
  • Association between low dietary folate intake and suboptimal cellular DNA repair capacity. 
  • Association between obesity and biomarkers of inflammation and metabolism with cancer mortality in a prospective cohort study. 
  • Association between patient-reported hearing and visual impairments and functional, psychological, and cognitive status among older adults with cancer. 
  • Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death. 
  • Association between tea consumption and risk of cancer: a prospective cohort study of 0.5 million Chinese adults. 
  • Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis. 
  • Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. 
  • Association of Balance Function With All-Cause and Cause-Specific Mortality Among US Adults. 
  • Association of Bariatric Surgery and Risk of Cancer in Patients With Morbid Obesity. 
  • Association of Delivery System Integration and Outcomes for Major Cancer Surgery. 
  • Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. 
  • Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis. 
  • Association of Leukocyte Telomere Length With Mortality Among Adult Participants in 3 Longitudinal Studies. 
  • Association of Practice-Level Hospital Use With End-of-Life Outcomes, Readmission, and Weekend Hospitalization Among Medicare Beneficiaries With Cancer. 
  • Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults. 
  • Association of Smartphone Ownership and Internet Use With Markers of Health Literacy and Access: Cross-sectional Survey Study of Perspectives From Project PLACE (Population Level Approaches to Cancer Elimination). 
  • Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. 
  • Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. 
  • Associations between Anxiety, Poor Prognosis, and Accurate Understanding of Scan Results among Advanced Cancer Patients. 
  • Associations between antibiotic exposure during pregnancy, birth weight and aberrant methylation at imprinted genes among offspring. 
  • Associations between diabetes, leanness, and the risk of death in the Japanese general population: the Jichi Medical School Cohort Study. 
  • Associations between leisure-time physical activity and health-related quality of life among adolescent and adult survivors of childhood cancers. 
  • Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort. 
  • Associations of Insurance Churn and Catastrophic Health Expenditures With Implementation of the Affordable Care Act Among Nonelderly Patients With Cancer in the United States. 
  • Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis. 
  • Associations of cancer and other chronic medical conditions with SF-6D preference-based scores in Medicare beneficiaries. 
  • Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. 
  • Associations of toothbrushing behaviour with risks of vascular and nonvascular diseases in Chinese adults. 
  • Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. 
  • Astatine-211: production and availability. 
  • Atherosclerosis and cancer: common molecular pathways of disease development and progression. 
  • Atherosclerosis: a cancer of the blood vessels? 
  • Atrial Fibrillation in Cancer Patients: Recognizing Gaps in Care. 
  • Attachment in Couples Coping with Cancer: Associations with Observed Communication and Long-Term Health. 
  • Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration. 
  • Author's Reply. 
  • AutoCSA, an algorithm for high throughput DNA sequence variant detection in cancer genomes. 
  • Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. 
  • Autologous tumor rejection in humans: trimming the myths. 
  • Automated next-generation profiling of genomic alterations in human cancers. 
  • Automated temperature scanning for hyperthermia treatment monitoring. 
  • Availability of experimental therapy outside oncology randomized clinical trials in the United States. 
  • Aversion to ambiguity regarding medical tests and treatments: measurement, prevalence, and relationship to sociodemographic factors. 
  • Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. 
  • Awareness and Utilization of Palliative Care Among Advanced Cancer Patients in Asia. 
  • Awareness of Cancer Risk Factors and Its Signs and Symptoms in Northern Tanzania: a Cross-Sectional Survey in the General Population and in People Living with HIV. 
  • Awareness of and preference for disease prognosis and participation in treatment decisions among advanced cancer patients in Myanmar: Results from the APPROACH study. 
  • Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population. 
  • B cells and cancer. 
  • B cells in the pathophysiology of myasthenia gravis. 
  • B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. 
  • BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. 
  • BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. 
  • BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. 
  • Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. 
  • Balancing the benefits and costs of colony-stimulating factors: a current perspective. 
  • Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. 
  • Barriers and facilitators of risk-based health care for adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Barriers to follow-up care of survivors in the United States and the United Kingdom. 
  • Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. 
  • Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. 
  • Basic population and cancer genetics and their use in the assessment of cancer risk. 
  • Bayesian modeling of multiple lesion onset and growth from interval-censored data. 
  • Beliefs of cancer patients in Saudi Arabia. 
  • Benefit Finding in Maternal Caregivers of Pediatric Cancer Survivors: A Mixed Methods Approach. 
  • Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia. 
  • Benefits of smoking cessation for longevity. 
  • Best Practices in Oncology Distress Management: Beyond the Screen. 
  • Best supportive care in clinical trials: review of the inconsistency in control arm design. 
  • Better Palliative Care for All: Improving the Lived Experience With Cancer. 
  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. 
  • Bevacizumab biosimilars: scientific justification for extrapolation of indications. 
  • Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. 
  • Beyond Resilience: A Concept Analysis of Human Flourishing in Adolescents and Young Adults With Cancer. 
  • Beyond angiogenesis: the role of endothelium in the bone marrow vascular niche. 
  • Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. 
  • Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Bioavailability of metalloporphyrin-based SOD mimics is greatly influenced by a single charge residing on a Mn site. 
  • Biological Aspects of Cancer Health Disparities. 
  • Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death. 
  • Biological Role and Therapeutic Potential of IDH Mutations in Cancer. 
  • Biological and clinical aspects of hyperthermia in cancer therapy. 
  • Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. 
  • Biology of aging as related to cancer. 
  • Biomarkers of response and resistance to antiangiogenic therapy. 
  • Biosimilars: are they ready for primetime in the United States? 
  • Bispecific antibodies engage T cells for antitumor immunotherapy. 
  • Black Patients Experience Highest Rates of Cancer-associated Venous Thromboembolism. 
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. 
  • Blood Epigenetic Age may Predict Cancer Incidence and Mortality. 
  • Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer. 
  • Blood perfusion measurements in human tumours: evaluation of laser Doppler methods. 
  • Blood pressure and mortality risk in the elderly. 
  • Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. 
  • Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents. 
  • Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer. 
  • Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. 
  • Body weight is not always a good predictor of longevity in mice. 
  • Bone marrow transplantation. Part II--autologous. 
  • Bone morphogenetic proteins and cancer: review of the literature. 
  • Boron-containing aptamers to ATP. 
  • Bottom up design of nanoparticles for anti-cancer diapeutics: "put the drug in the cancer's food". 
  • Brain metastases: epidemiology. 
  • Breast cancer after chest radiation therapy for childhood cancer. 
  • Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. 
  • Bridging the gap between financial distress and available resources for patients with cancer: a qualitative study. 
  • Brief report: psychosocial functioning of fathers as primary caregivers of pediatric oncology patients. 
  • Bringing comfort to endobronchial ultrasound bronchoscopy. 
  • Broaching goals-of-care conversations in advancing pediatric cancer. 
  • Broad regulation of gene isoform expression by Wnt signaling in cancer. 
  • Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. 
  • Building the palliative care evidence base: Lessons from a randomized controlled trial of oxygen vs room air for refractory dyspnea. 
  • Burden and well-being among a diverse sample of cancer, congestive heart failure, and chronic obstructive pulmonary disease caregivers. 
  • C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 
  • CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. 
  • CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. 
  • CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. 
  • CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. 
  • CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? 
  • CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. 
  • CEA loaded dendritic cell vaccines. 
  • COVID-19 Challenges Confronted by Smoking Cessation Clinical Trials for People Living With HIV: The Experience of Grantees of the US National Cancer Institute. 
  • COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study. 
  • COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. 
  • COVID-19, Mental Health and Cancer. 
  • CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. 
  • Ca2+-dependent demethylation of phosphatase PP2Ac promotes glucose deprivation-induced cell death independently of inhibiting glycolysis. 
  • Cadmium and lead in autopsy tissues. 
  • Calciphylaxis from nonuremic causes: a systematic review. 
  • Calcium channel blockers and cancer. 
  • Call for Greater Adoption of Recommended Standards during Cancer Drug Development to Improve Cancer Care with CKD. 
  • Call for action: expanding global access to hereditary cancer genetic testing. 
  • Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? 
  • Can Steps per Day Reflect Symptoms in Children and Adolescents Undergoing Cancer Treatment? 
  • Can screening older patients for cancer save lives? 
  • Can you tBID on it? 
  • Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. 
  • Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. 
  • Cancer Among Women Treated in the Veterans Affairs Healthcare System. 
  • Cancer Cachexia: Beyond Weight Loss. 
  • Cancer Care Coordination: a Systematic Review and Meta-Analysis of Over 30 Years of Empirical Studies. 
  • Cancer Cells Enter an Adaptive Persistence to Survive Radiotherapy and Repopulate Tumor. 
  • Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. 
  • Cancer Data Science and Computational Medicine. 
  • Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update. 
  • Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes. 
  • Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. 
  • Cancer Informatics: New Tools for a Data-Driven Age in Cancer Research. 
  • Cancer Liquid Biopsy: Is It Ready for Clinic? 
  • Cancer Moonshot Data and Technology Team: Enabling a National Learning Healthcare System for Cancer to Unleash the Power of Data. 
  • Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. 
  • Cancer Nursing's Potential to Reduce the Growing Burden of Cancer Across the World. 
  • Cancer Screening in Older Adults. 
  • Cancer after spinal fusion: the role of bone morphogenetic protein. 
  • Cancer and COVID-19. 
  • Cancer and leukemia group B gastrointestinal cancer committee. 
  • Cancer and noncancer mortality among aluminum smelting workers in Badin, North Carolina. 
  • Cancer and the functional status of the elderly. 
  • Cancer and thrombosis: back to the future renewed interest in an old problem. 
  • Cancer as "rejuvenescence". 
  • Cancer cachexia: Are we ready to take a step forward? 
  • Cancer characterization and feature set extraction by discriminative margin clustering. 
  • Cancer chemotherapy in older adults. A tolerability perspective. 
  • Cancer clocks in tumourigenesis: the p53 pathway and beyond. 
  • Cancer control research 2001. 
  • Cancer diagnosed in the Emergency Department of a Regional Health Service. 
  • Cancer epidemiology in the Far East--contrast with the United States. 
  • Cancer genes disfavoring T cell immunity identified via integrated systems approach. 
  • Cancer genomics: integrating form and function. 
  • Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. 
  • Cancer in adolescents and young adults: treatment and outcome in Victoria. 
  • Cancer in children of parents exposed to hydrocarbon-related industries and occupations. 
  • Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. 
  • Cancer in rodents: does it tell us about cancer in humans? 
  • Cancer in the elderly. Epidemiologic and clinical implications. 
  • Cancer in the elderly: to screen or not to screen? 
  • Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. 
  • Cancer incidence among union carpenters in New Jersey. 
  • Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases. 
  • Cancer incidence in relation to body fatness among 0.5 million men and women: Findings from the China Kadoorie Biobank. 
  • Cancer mortality in IBM Endicott plant workers, 1969-2001: an update on a NY production plant. 
  • Cancer mortality, aging, and patterns of comorbidity in the United States: 1968 to 1986. 
  • Cancer nursing: a caring commitment to the future. 
  • Cancer outcomes research. 
  • Cancer pain at the end of life: a biopsychosocial perspective. 
  • Cancer patient preferences for quality and length of life. 
  • Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. 
  • Cancer prevention and early detection: reported activities of nurses. 
  • Cancer prevention and screening practices of siblings of childhood cancer survivors: a report from the Childhood Cancer Survivor Study. 
  • Cancer registration needs assessment at a tertiary medical centre in Kilimanjaro, Tanzania. 
  • Cancer risk in childhood-onset systemic lupus. 
  • Cancer risk in children and adolescents with birth defects: a population-based cohort study. 
  • Cancer risk in men exposed in utero to diethylstilbestrol. 
  • Cancer risk in women exposed to diethylstilbestrol in utero. 
  • Cancer risk in women prenatally exposed to diethylstilbestrol. 
  • Cancer screening in the elderly. 
  • Cancer spectrum in HIV-infected patients: A zonal hospital experience in Tanzania. 
  • Cancer statistics for adults aged 85 years and older, 2019. 
  • Cancer survivors' health worries and associations with lifestyle practices. 
  • Cancer survivors' uptake and adherence in diet and exercise intervention trials: an integrative data analysis. 
  • Cancer susceptibility: epigenetic manifestation of environmental exposures. 
  • Cancer systems biology: exploring cancer-associated genes on cellular networks. 
  • Cancer therapy costs influence treatment: a national survey of oncologists. 
  • Cancer therapy-related complications in the bowel and mesentery: an imaging perspective. 
  • Cancer treatment cost in the United States: has the burden shifted over time? 
  • Cancer vaccines. 
  • Cancer's insatiable appetite. 
  • Cancer, Religious Philosophy, Death and Dying. 
  • Cancer, clots and consensus: new understanding of an old problem. 
  • Cancer, comorbidities, and health-related quality of life of older adults. 
  • Cancer- and chemotherapy-induced anemia. 
  • Cancer- and chemotherapy-induced anemia. 
  • Cancer- and treatment-related anemia. 
  • Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. 
  • Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Cancer-Related Fatigue, Version 2.2015. 
  • Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. 
  • Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. 
  • Cancer-related cognitive changes in children, adolescents and adult survivors of childhood cancers. 
  • Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. 
  • Cancer-related fatigue. 
  • Cancer-related fatigue: scientific progress has been made in 40 years 
  • Cancer-related loneliness mediates the relationships between social constraints and symptoms among cancer patients. 
  • Cancer-related risk factors and incidence of major cancers by race, gender and region; analysis of the NIH-AARP diet and health study. 
  • Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network's Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup. 
  • Capturing the young child's reports of cancer treatment tolerability: Does our practice reflect an assumption that they cannot report? 
  • Carcinogenic effects of hyperthermia. 
  • Carcinogenic effects of wood dust: review and discussion. 
  • Carcinogenicity of inhaled benzene in CBA mice. 
  • Cardiac evaluation of mitoxantrone. 
  • Cardio-Oncology Education and Training: JACC Council Perspectives. 
  • Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. 
  • Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond. 
  • Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. 
  • Cardio-oncology in clinical studies and real life. 
  • Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. 
  • Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. 
  • Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. 
  • Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. 
  • Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. 
  • Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. 
  • Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study. 
  • Care and Cancer Screening of the Transgender Population. 
  • Care of cancer survivors. 
  • Care of the pregnant patient with cancer should include unfettered access to abortion. 
  • Caregiver Burden as a Mediator Between Emotional Distress and Concentration Problems in Patients With Cancer. 
  • Caregiver-Reported Roles in Treatment Decision Making in Advanced Cancer and Associated Caregiving Burden and Psychological Distress: A Longitudinal Study. 
  • Caregiver-guided pain coping skills training for patients with advanced cancer: Results from a randomized clinical trial. 
  • Caring for survivors of childhood cancer: it takes a village. 
  • Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. 
  • Casein kinase 1: Complexity in the family. 
  • Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers. 
  • Caspase-8-mediated PAR-4 cleavage is required for TNFα-induced apoptosis. 
  • Causal effects of cardiovascular risk factors on onset of major age-related diseases: A time-to-event Mendelian randomization study. 
  • Cause specific mortality patterns among the oldest old: multiple cause of death trends 1968 to 1980. 
  • Cell and extracellular matrix growth theory and its implications for tumorigenesis. 
  • Cell cycle control and cancer. 
  • Cell death-stimulated cell proliferation: a tissue regeneration mechanism usurped by tumors during radiotherapy. 
  • Cell invasion through basement membrane: the anchor cell breaches the barrier. 
  • Cell invasion through basement membranes: an anchor of understanding. 
  • Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. 
  • Cell surface GRP78 signaling: An emerging role as a transcriptional modulator in cancer. 
  • Cell-Based Biohybrid Drug Delivery Systems: The Best of the Synthetic and Natural Worlds. 
  • Cell-cycle checkpoints and cancer. 
  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. 
  • Cell-penetrating peptide enhanced intracellular Raman imaging and photodynamic therapy. 
  • Cell-programmed nutrient partitioning in the tumour microenvironment. 
  • Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens. 
  • Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit. 
  • Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. 
  • Challenges after curative treatment for childhood cancer and long-term follow up of survivors. 
  • Challenges after curative treatment for childhood cancer and long-term follow up of survivors. 
  • Challenges and Emerging Opportunities for Targeting mTOR in Cancer. 
  • Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. 
  • Challenges and opportunities for in vivo imaging in oncology. 
  • Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. 
  • Challenges associated with the integration of immuno-oncology agents in clinical practice. 
  • Change in self-efficacy partially mediates the effects of the FRESH START intervention on cancer survivors' dietary outcomes. 
  • Changes in Newly Identified Cancer Among US Patients From Before COVID-19 Through the First Full Year of the Pandemic. 
  • Changes in criteria for tumor response. 
  • Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act. 
  • Changes in the Delivery of Veterans Affairs Cancer Care: Ensuring Delivery of Coordinated, Quality Cancer Care in a Time of Uncertainty. 
  • Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. 
  • Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. 
  • Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. 
  • Changing multidisciplinary cancer treatment through ACOSOG trials. 
  • Changing the Course of Cancer Care With Greater Precision. 
  • Chaplaincy, Cancer, Aged Care and COVID-19. 
  • Chaplaincy, Clergy, Prayer, Cancer and Measuring Religion and Health. 
  • Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. 
  • Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism. 
  • Characteristics and treatment options of elderly Chinese patients with cancer as determined by Comprehensive Geriatric Assessment (CGA). 
  • Characteristics of Advance Care Planning in Patients With Cancer Referred to Palliative Care. 
  • Characteristics of cancer diagnoses and staging in South Western Victoria: a rural perspective. 
  • Characteristics of cancer patients presenting to an integrative medicine practice-based research network. 
  • Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. 
  • Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. 
  • Characterization of polycyclic aromatic hydrocarbons (PAHs) in vegetables near industrial areas of Shanghai, China: Sources, exposure, and cancer risk. 
  • Characterization of the usage of the serine metabolic network in human cancer. 
  • Characterization of tumour temperature distributions in hyperthermia based on assumed mathematical forms. 
  • Characterizing firefighter's exposure to over 130 SVOCs using silicone wristbands: A pilot study comparing on-duty and off-duty exposures. 
  • Checkpoint controls and cancer. Introduction. 
  • Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with ⁵⁷ Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. 
  • Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing. 
  • Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. 
  • Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer. 
  • Chemistry. Nanomaterials for drug delivery. 
  • Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. 
  • Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. 
  • Chemotherapy dose intensity and quality cancer care. 
  • Chemotherapy dosing in overweight and obese patients with cancer. 
  • Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. 
  • Chemotherapy-induced emergencies. 
  • Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. 
  • Chemotherapy-related cognitive impairment in older patients with cancer. 
  • Cherenkov emissions for studying tumor changes during radiation therapy: An exploratory study in domesticated dogs with naturally-occurring cancer. 
  • Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. 
  • Chicago 2014--30 years of γδ T cells. 
  • Childhood cancer and occupational radiation exposure in parents. 
  • Childhood cancer survivors and primary care physicians. 
  • Childhood cancer survivors' perceived barriers to improving exercise and dietary behaviors. 
  • Childhood cancer survivors, late effects, and a new model for understanding survivorship. 
  • Childhood cancer survivorship educational resources in North American pediatric hematology/oncology fellowship training programs: a survey study. 
  • Childhood cancer survivorship research in minority populations: A position paper from the Childhood Cancer Survivor Study. 
  • Childhood cancer, endocrine disorders, and cohort studies. 
  • Childhood cancers: incidence, etiology, diagnosis, and treatment. 
  • Children's coping strategies for chemotherapy-induced nausea and vomiting. 
  • Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors. 
  • Chronic Health Conditions and Neurocognitive Function in Aging Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. 
  • Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. 
  • Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. 
  • Chronic health conditions in adult survivors of childhood cancer. 
  • Cigarette smoking and health-related quality of life in Medicare beneficiaries. 
  • Circular ecDNA promotes accessible chromatin and high oncogene expression. 
  • Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. 
  • Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. 
  • Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Cirrhosis of the liver in long-term marrow transplant survivors. 
  • Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. 
  • Classifying the evolutionary and ecological features of neoplasms. 
  • Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 
  • Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. 
  • Clinical Course of Preseptal and Orbital Cellulitis in 50 Immunocompromised Patients with Cancer. 
  • Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients. 
  • Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. 
  • Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. 
  • Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. 
  • Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study. 
  • Clinical and Pre-clinical Methods for Quantifying Tumor Hypoxia. 
  • Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. 
  • Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). 
  • Clinical applications of PET in oncology. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical benefits of pegylated proteins in oncology. 
  • Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. 
  • Clinical characteristics of patients with cancer referred for outpatient physical therapy. 
  • Clinical correlation of previously undetected cancer-related incidental findings on CT planning scans for radiation therapy. 
  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. 
  • Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. 
  • Clinical experience with a multi-element ultrasonic hyperthermia system: analysis of treatment temperatures. 
  • Clinical field testing of an enhanced-activity intervention in hospitalized children with cancer. 
  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. 
  • Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. 
  • Clinical oncologic positron emission tomography: an introduction. 
  • Clinical outcome after hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors. 
  • Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. 
  • Clinical physics, applicator choice, technique, and equipment for electron intraoperative radiation therapy. 
  • Clinical research in the older cancer patient. 
  • Clinical results in cachexia therapeutics. 
  • Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. 
  • Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. 
  • Clinical trial accrual in older cancer patients: The most important steps are the first ones. 
  • Clinical trial recruitment challenges with older adults with cancer. 
  • Clinical trials data collection: when less is more. 
  • Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. 
  • Clinical use of transcatheter electrocoagulation. 
  • Clinical uses of pegylated pharmaceuticals in oncology. 
  • Clinical utility of a Web-enabled risk-assessment and clinical decision support program. 
  • Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. 
  • Clinician Perspectives on Managing Chronic Pain After Curative-Intent Cancer Treatment. 
  • Clustered Arg–Gly–Asp peptides enhances tumor targeting of nonviral vectors 
  • Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging. 
  • Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine. 
  • Co-occurrence of pneumoconiosis with COPD, pneumonia and lung cancer. 
  • Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis. 
  • Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. 
  • Coexistence of urinary incontinence and major depressive disorder with health-related quality of life in older Americans with and without cancer. 
  • Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer. 
  • Cognitive and Affective Symptoms Experienced by Cancer Patients Receiving High-Dose Intravenous Interleukin 2 Therapy: An Integrative Literature Review. 
  • Cognitive functioning in cancer patients: effect of previous treatment. 
  • Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • Coincidence imaging with a dual-head scintillation camera. 
  • Colony stimulating factors for chemotherapy induced febrile neutropenia. 
  • Colony-stimulating factor use in the context of refined risk and benefit assessments. 
  • Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. 
  • Colony-stimulating factors: clinical applications. 
  • Colorectal cancer prevention for low-income, sociodemographically-diverse adults in public housing: baseline findings of a randomized controlled trial. 
  • Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. 
  • Combination strategies to maximize the benefits of cancer immunotherapy. 
  • Combinations of Bevacizumab With Cancer Immunotherapy. 
  • Combining cancer vaccines with chemotherapy. 
  • Combining classification trees using MLE 
  • Combining immunotherapy and radiotherapy for the STAR treatment. 
  • Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. 
  • Comment regarding benefit in phase 1 oncology trials. 
  • Commentary: tackling the challenges of developing targeted therapies for cancer. 
  • Common Germline Risk Variants Impact Somatic Alterations and Clinical Features across Cancers. 
  • Common cancer biomarkers. 
  • Common cancers in India: knowledge, attitudes and behaviours of urban slum dwellers in New Delhi. 
  • Common electrolyte imbalances associated with malignancy. 
  • Common responses of tumors and wounds to hypoxia. 
  • Communicating Research to Non-Researcher Audiences: A Panel Discussion From the National Cancer Institute's Future of Cancer Health Economics Research Conference. 
  • Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool. 
  • Communication Challenges in Korean Families Coping With Adolescent Cancer. 
  • Communication around palliative care principles and advance care planning between oncologists, children with advancing cancer and families. 
  • Comorbidity and chronic conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2. 
  • Comorbidity and functional status are independent in older cancer patients. 
  • Comorbidity in older adults with cancer. 
  • Comorbidity of depression with other medical diseases in the elderly. 
  • Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality. 
  • Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. 
  • Comparative Effectiveness of Tumor Response Assessment Methods: Standard of Care Versus Computer-Assisted Response Evaluation. 
  • Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. 
  • Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. 
  • Comparative effectiveness research in oncology. 
  • Comparative effectiveness research in oncology: an overview. 
  • Comparative effectiveness research in oncology: the need for clarity, transparency and vision. 
  • Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. 
  • Comparative effectiveness research: moving medical oncology forward. 
  • Comparing Quality of Life in Cervical Spondylotic Myelopathy with Other Chronic Debilitating Diseases Using the Short Form Survey 36-Health Survey. 
  • Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design. 
  • Comparing patient, parent, and staff descriptions of fatigue in pediatric oncology patients. 
  • Comparing the Palliative Care Needs of Patients With Hematologic and Solid Malignancies. 
  • Comparing the Palliative Care Needs of Those With Cancer to Those With Common Non-Cancer Serious Illness. 
  • Comparing three life-limiting diseases: does diagnosis matter or is sick, sick? 
  • Comparing unmet needs between community-based palliative care patients with heart failure and patients with cancer. 
  • Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians. 
  • Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. 
  • Comparison of futility monitoring guidelines using completed phase III oncology trials. 
  • Comparison of outcomes for cancer patients discussed and not discussed at a multidisciplinary meeting. 
  • Comparison of preferences for end-of-life care among patients with advanced cancer and their caregivers: A discrete choice experiment. 
  • Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. 
  • Comparison of short bowel syndrome acquired early in life and during adolescence. 
  • Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. 
  • Comparison of urinary-free cortisol in depressed and nondepressed patients with malignancy. 
  • Compartment model approach to the estimation of tumor incidence and growth: investigation of a model of cancer latency. 
  • Compartment model approaches for estimating the parameters of a chronic disease process under changing risk factor exposures. 
  • Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. 
  • Complexity of Delivering Precision Medicine: Opportunities and Challenges. 
  • Compliance With Price Transparency Rules at US National Cancer Institute-Designated Cancer Centers. 
  • Compliance and noncompliance in cancer patients. 
  • Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. 
  • Comprehensive Characterization of Cancer Driver Genes and Mutations. 
  • Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. 
  • Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. 
  • Comprehensive care of the elderly patient with cancer. 
  • Comprehensive long-term follow-up programs for pediatric cancer survivors. 
  • Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. 
  • Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. 
  • Computational models of cancer cell transport through the microcirculation. 
  • Computational techniques for fast hyperthermia temperature optimization. 
  • Computer-controlled delivery of 3D conformal radiation treatments. 
  • Concentration-Independent Multivalent Targeting of Cancer Cells by Genetically Encoded Core-Crosslinked Elastin/Resilin-like Polypeptide Micelles. 
  • Concepts of oxygen transport at the microcirculatory level. 
  • Concerns underlying treatment preferences of advanced cancer patients with children. 
  • Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. 
  • Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells. 
  • Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board. 
  • Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis. 
  • Confidence intervals and survival estimates: a systematic review of 3 oncology journals. 
  • Conflict of interest disclosure in off-label oncology clinical trials. 
  • Conformance with supportive care quality measures is associated with better quality of life in patients with cancer receiving palliative care. 
  • Connecting copper and cancer: from transition metal signalling to metalloplasia. 
  • Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. 
  • Consensus statement on depression, anxiety, and oncology. 
  • Consensus-based standards for best supportive care in clinical trials in advanced cancer. 
  • Considerations for Long-Term Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and Cancer. 
  • Considerations of psychosocial illness phase in cancer survival. 
  • Construct validity and reliability of a real-time multidimensional smartphone app to assess pain in children and adolescents with cancer. 
  • Construct validity of the PROMIS® sexual function and satisfaction measures in patients with cancer. 
  • Continued parental attendance at a clinic for adult survivors of childhood cancer. 
  • Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments. 
  • Contrast-detail analysis of three flat panel detectors for digital radiography. 
  • Control beliefs and risk for 4-year mortality in older adults: a prospective cohort study. 
  • Controlled apoptosis by a thermally toggled nanoscale amplifier of cellular uptake. 
  • Coping Skills Training and Acceptance and Commitment Therapy for Symptom Management: Feasibility and Acceptability of a Brief Telephone-Delivered Protocol for Patients With Advanced Cancer. 
  • Coping with cancer. 
  • Coping with sexual concerns after cancer: the use of flexible coping. 
  • Correlates of health information seeking between adults diagnosed with and without cancer. 
  • Correlation between initial and long-term responses of spontaneous pet animal tumors to heat and radiation or radiation alone. 
  • Correspondence Between Clinician Ratings of Vulvovaginal Health and Patient-Reported Sexual Function After Cancer. 
  • Correspondence re: Geradts J, Wilentz RE, Roberts H. Immunohistochemical detection of the alternate ink4a-encoded tumor suppressor protein p14(arf) in archival human cancers and cell lines using commercial antibodies: correlation with p16(ink4a) expression. Mod pathol 2001;14:1162-68. 
  • Cost effectiveness of myeloid growth factors in cancer chemotherapy. 
  • Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. 
  • Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. 
  • Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. 
  • Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. 
  • Cost-related health literacy: a key component of high-quality cancer care. 
  • Costimulation blockade: towards clinical application. 
  • Costimulation, coinhibition and cancer. 
  • Costs and outcomes evaluation of patient navigation after abnormal cancer screening: evidence from the Patient Navigation Research Program. 
  • Costs associated with febrile neutropenia in the US. 
  • Costs of Cancer Care Across the Disease Continuum. 
  • Counting the costs of cancer care. 
  • County-level cumulative environmental quality associated with cancer incidence. 
  • Couple-based communication interventions for cancer: moving beyond a 'one size fits all' approach. 
  • Creating a Blueprint of Well-Being in Oncology: An Approach for Addressing Burnout From ASCO's Clinician Well-Being Taskforce. 
  • Creating a cadre of junior investigators to address the challenges of cancer-related health disparities: lessons learned from the community networks program. 
  • Criteria for the use of Sartwell's incubation period model to study chronic diseases with uncertain etiology. 
  • Crowdfunded Cancer Care-A Reflection on Health Care Delivery in the US. 
  • Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort. 
  • Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. 
  • Cumulative minutes with T90 greater than Tempindex is predictive of response of superficial malignancies to hyperthermia and radiation. 
  • Curbing potential radiation-induced cancer risks in oncologic imaging: perspectives from the 'image gently' and 'image wisely' campaigns. 
  • Cure me even if it kills me: preferences for invasive cancer treatment. 
  • Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions. 
  • Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. 
  • Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models. 
  • Current concepts. Cancer in children. 
  • Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. 
  • Current insights on the biology and clinical aspects of VEGF regulation. 
  • Current status of dendritic cell immunotherapy of malignancies. 
  • Cutaneous manifestations of internal malignancies: an overview. 
  • Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. 
  • Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors. 
  • Cytokine and immuno-gene therapy for solid tumors. 
  • Cytokine polymorphism and its possible impact on cancer. 
  • Cytokines and immune response in the tumor microenvironment. 
  • Cytoprotection for radiation-associated normal tissue injury. 
  • Cytotoxic T-lymphocyte-associated antigen-4. 
  • DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing. 
  • DC-CIK as a widely applicable cancer immunotherapy. 
  • DNA and RNA modified dendritic cell vaccines. 
  • DNA array-based gene profiling in tumor immunology. 
  • DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. 
  • DNA repair phenotype and cancer susceptibility--a mini review. 
  • DNA repair: a double-edged sword. 
  • DNA-based animal models of human disease: from genotype to phenotype. 
  • Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. 
  • Daily well-being of cancer survivors: the role of somatic amplification. 
  • Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. 
  • Danger ahead: the burden of diseases, injuries, and risk factors in the Eastern Mediterranean Region, 1990-2015. 
  • Data Harmonization for a Molecularly Driven Health System. 
  • Data standards in pediatric oncology: Past, present, and future. 
  • De Novo Visceral Malignancies in Renal Transplant Recipients: A Single Center Experience of 2054 Recipients for More Than 30 Years. 
  • Death service ratio: a measure of hospice utilization and cost impact. 
  • Deciphering the Mechanics of Cancer Spheroid Growth in 3D Environments through Microfluidics Driven Mechanical Actuation. 
  • Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. 
  • Decision making about cancer screening: an assessment of the state of the science and a suggested research agenda from the ASPO Behavioral Oncology and Cancer Communication Special Interest Group. 
  • Decision making and quality of life in the treatment of cancer: a review. 
  • Decision making in pediatric oncology: who should take the lead? The decisional priority in pediatric oncology model. 
  • Decline in physical activity level in the Childhood Cancer Survivor Study cohort. 
  • Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. 
  • Defeating Cancers' Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer's Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. 
  • Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement. 
  • Defining Value of Cancer Therapeutics-A Health System Perspective. 
  • Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. 
  • Defining quality, disseminating evidence, and enforcing guidelines for cancer treatment. 
  • Delaying surgery for patients with a previous SARS-CoV-2 infection. 
  • Delays Experienced by Patients With Pediatric Cancer During the Health Facility Referral Process: A Study in Northern Tanzania. 
  • Delays in cancer care for children in low-income and middle-income countries: development of a composite vulnerability index. 
  • Delivery catheter entrapment during deployment of expandable metal stents. 
  • Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells. 
  • Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement. 
  • Dementia and cancer: a comparison of spouse caregivers. 
  • Dendritic cell gene therapy. 
  • Dendritic cell maturation in active immunotherapy strategies. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Dendritic cell-based immunization for cancer therapy. 
  • Dendritic cell-based immunotherapy. 
  • Dendritic cell-tumor cell fusion vaccines. 
  • Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. 
  • Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. 
  • Depletion of human regulatory T cells. 
  • Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. 
  • Depression in radiation oncology patients: a preliminary evaluation. 
  • Deregulated transcription factors in cancer cell metabolisms and reprogramming. 
  • Dermatopathology of the foreskin: an institutional experience of over 400 cases. 
  • Design and Evaluation of a Computational Phenotype to Identify Patients With Metastatic Breast Cancer Within the Electronic Health Record. 
  • Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling. 
  • Design, mechanism of action, bioavailability and therapeutic effects of mn porphyrin-based redox modulators. 
  • Designing a broad-spectrum integrative approach for cancer prevention and treatment. 
  • Designing phase II studies in cancer with time-to-event endpoints. 
  • Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. 
  • Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. 
  • Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. 
  • Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach. 
  • Detectable clonal mosaicism from birth to old age and its relationship to cancer. 
  • Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. 
  • Detection and follow-up of important extra-arterial lesions with helical CT angiography. 
  • Detection and localization of surgically resectable cancers with a multi-analyte blood test. 
  • Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. 
  • Detection of circulating tumor DNA in early- and late-stage human malignancies. 
  • Determinants of delayed childhood cancer care in low- and middle-income countries: A systematic review. 
  • Determination of local oxygen consumption rates in tumors. 
  • Developing a cancer-specific geriatric assessment: a feasibility study. 
  • Developing a research program on fatigue in children and adolescents diagnosed with cancer. 
  • Developing and assessing electronic checklists for safety mindfulness, workload, and performance. 
  • Developing international consensus for late effects screening and guidance. 
  • Developing, Implementing, and Validating a Social Toxicity Assessment Tool of Cancer. 
  • Development and Validation of Models to Predict Poor Health-Related Quality of Life Among Adult Survivors of Childhood Cancer. 
  • Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long-Term Childhood Cancer Survivors. 
  • Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer. 
  • Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. 
  • Development and clinical evaluation of a three-dimensional cone-beam computed tomography estimation method using a deformation field map. 
  • Development and implementation of an online program to improve how patients communicate emotional concerns to their oncology providers. 
  • Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. 
  • Development and validation of a predictive model for chemotherapy-associated thrombosis. 
  • Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. 
  • Development of Novel ¹⁸ F-PET Agents for Tumor Hypoxia Imaging. 
  • Development of a fertility risk calculator to predict individualized chance of ovarian failure after chemotherapy. 
  • Development of a neuro-fuzzy technique for automated parameter optimization of inverse treatment planning. 
  • Development of a telemedicine model for emerging countries: a case study on pediatric oncology in Brazil. 
  • Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. 
  • Development of enhanced ethanol ablation as an alternative to surgery in treatment of superficial solid tumors. 
  • Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. 
  • Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. 
  • Development of the NIH PROMIS ® Sexual Function and Satisfaction measures in patients with cancer. 
  • Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). 
  • Development of the Serious Illness Care Program: a randomised controlled trial of a palliative care communication intervention. 
  • Development of two instruments examining stress and adjustment in children with cancer. 
  • Developments in Molecular Testing and Biosimilars. 
  • Diabetes management and self-care education for hospitalized patients with cancer. 
  • Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. 
  • Diagnosing night sweats. 
  • Diagnosis of major depression in cancer patients according to four sets of criteria. 
  • Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. 
  • Diagnostic value of three tumor markers determined in pleural effusions. 
  • Dichotomous roles of TGF-β in human cancer. 
  • Diet and Exercise in Cancer Metabolism. 
  • Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. 
  • Dietary counseling and quality of life. 
  • Dietary intake polycyclic aromatic hydrocarbons (PAHs) and associated cancer risk in a cohort of Chinese urban adults: Inter- and intra-individual variability. 
  • Dietary supplement use among elderly, long-term cancer survivors. 
  • Differences between patients with cardiovascular disease and cancer referred for palliative care. 
  • Differences in Sociodemographic Correlates of Human Papillomavirus-Associated Cancer Survival in the United States. 
  • Differences in understanding of specialist palliative care amongst service providers and commissioners in South London. 
  • Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. 
  • Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas. 
  • Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. 
  • Digital tomosynthesis with an on-board kilovoltage imaging device. 
  • Diode-based transmission detector for IMRT delivery monitoring: a validation study. 
  • Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? 
  • Direct and Label-Free Detection of MicroRNA Cancer Biomarkers using SERS-Based Plasmonic Coupling Interference (PCI) Nanoprobes. 
  • Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials. 
  • Discordance Between Advanced Cancer Patients' Perceived and Preferred Roles in Decision Making and its Association with Psychological Distress and Perceived Quality of Care. 
  • Discovery and characterization of small molecules that target the GTPase Ral. 
  • Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. 
  • Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor. 
  • Discussing the Evidence for Upstream Palliative Care in Improving Outcomes in Advanced Cancer. 
  • Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. 
  • Disease drivers of aging. 
  • Disease-associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct mechanisms. 
  • Disorders of leukocyte chemotaxis. 
  • Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. 
  • Disparities in end-of-life outcomes among advanced cancer patients in Sri Lanka: Results from the APPROACH study. 
  • Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736). 
  • Disparities in telemedicine during COVID-19. 
  • Disruption of crosstalk between mesenchymal stromal and tumor cells in bone marrow as a therapeutic target to prevent metastatic bone disease. 
  • Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. 
  • Disruption of lysosome function promotes tumor growth and metastasis in Drosophila. 
  • Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer. 
  • Disseminated zygomycosis: report of four cases and review. 
  • Distance-Based Education for Nurses Caring for Children With Cancer in Sub-Saharan Africa. 
  • Distinct Sleep Disturbance Profiles in Patients With Gastrointestinal Cancers Receiving Chemotherapy. 
  • Distinct Stress Profiles Among Oncology Patients Undergoing Chemotherapy. 
  • Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation. 
  • Distinct requirements for Ras oncogenesis in human versus mouse cells. 
  • Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways. 
  • Distress associated with cancer as measured by the illness distress scale. 
  • Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. 
  • Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. 
  • Do Radiologists Have Stage Fright? Tumor Staging and How We Can Add Value to the Care of Patients with Cancer. 
  • Do macrophages destroy nascent tumors? 
  • Do palliative care interventions reduce emergency department visits among patients with cancer at the end of life? A systematic review. 
  • Do patient attributes predict oncologist empathic responses and patient perceptions of empathy? 
  • Do patients participating in clinical trials want to know study results? 
  • Does A History of Malignancy Lead to Worse Outcomes in a Single-center Burn Unit? 
  • Does Cancer Treatment-Related Financial Distress Worsen Over Time? 
  • Does a helping hand mean a heavy heart? Helping behavior and well-being among spouse caregivers. 
  • Does amifostine have a role in chemoradiation treatment? 
  • Does comparative effectiveness research promote rationing of cancer care? 
  • Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee. 
  • Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. 
  • Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. 
  • Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. 
  • Dose of prophylactic platelet transfusions and prevention of hemorrhage. 
  • Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. 
  • Dose sculpting with generalized equivalent uniform dose. 
  • Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. 
  • Dosimetric assessment of rigid setup error by CBCT for HN-IMRT. 
  • Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. 
  • Dosimetric study using different leaf-width MLCs for treatment planning of dynamic conformal arcs and intensity-modulated radiosurgery. 
  • Double agents in the war on cancer: leukocytes govern ovarian cancer progression. 
  • Double antibody radioimmunoassay for monitoring metastatic breast cancer. 
  • Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. 
  • Down-regulation of MHC class I antigen presentation by HCMV; lessons for tumor immunology. 
  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. 
  • Drug delivery to solid tumors by elastin-like polypeptides. 
  • Dyadic psychosocial interventions for patients with cancer and their caregivers: an update. 
  • Dynamic fractal signature dissimilarity analysis for therapeutic response assessment using dynamic contrast-enhanced MRI. 
  • Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies. 
  • Dysfunctional T cell metabolism in the tumor microenvironment. 
  • Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. 
  • Dysregulated metabolism contributes to oncogenesis. 
  • Dysregulation of hemostasis by cancer. 
  • Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. 
  • E proteins in lymphocyte development and lymphoid diseases. 
  • EDITORIAL COMMENT. 
  • EGF mutant receptor vIII as a molecular target in cancer therapy. 
  • ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. 
  • EMT and MET: necessary or permissive for metastasis? 
  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. 
  • Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. 
  • Early integration of palliative care into the care of patients with cancer. 
  • Early onset of spontaneous renal preneoplastic and neoplastic lesions in young conventional rats in toxicity studies. 
  • Early-life prevention of non-communicable diseases. 
  • Echocardiography Core Laboratory Reproducibility of Cardiac Safety Assessments in Cardio-Oncology. 
  • Economics of new oncology drug development. 
  • Editorial Comment. 
  • Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today. 
  • Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. 
  • Educating Families of Children Newly Diagnosed With Cancer. 
  • Educational Preparation of Nurses Caring for Older People with Cancer: An International Perspective. 
  • Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study. 
  • Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. 
  • Effect of Temporal Changes in Therapeutic Exposure on Self-reported Health Status in Childhood Cancer Survivors. 
  • Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. 
  • Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study. 
  • Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. 
  • Effect of cancer screening and desirable health behaviors on functional status, self-rated health, health service use and mortality. 
  • Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. 
  • Effect of gamma interferon on the hypothalamic-pituitary-adrenal system. 
  • Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. 
  • Effect of patient and patient-oncologist relationship characteristics on communication about health-related quality of life. 
  • Effect of pazopanib on tumor microenvironment and liposome delivery. 
  • Effect of residential air cleaning interventions on risk of cancer associated with indoor semi-volatile organic compounds: a comprehensive simulation study. 
  • Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 
  • Effect of spiritual counseling on spiritual well-being in Iranian women with cancer: A randomized clinical trial. 
  • Effect of the COVID-19 Pandemic on Place of Death Among Medicaid and Commercially Insured Patients With Cancer in Washington State. 
  • Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs. 
  • Effective knowledge management in translational medicine. 
  • Effective learning strategies for real-time image-guided adaptive control of multiple-source hyperthermia applicators. 
  • Effects and potential mechanisms of exercise training on cancer progression: a translational perspective. 
  • Effects of an Individualized Caregiver Training Intervention on Self-Efficacy of Cancer Caregivers. 
  • Effects of brief pain education on hospitalized cancer patients with moderate to severe pain. 
  • Effects of cancer history and comorbid conditions on mortality and healthcare use among older cancer survivors. 
  • Effects of cancer history on functional age and mortality. 
  • Effects of dependency among causes of death for cause elimination life table strategies. 
  • Effects of enhanced caregiver training program on cancer caregiver's self-efficacy, preparedness, and psychological well-being. 
  • Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations. 
  • Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. 
  • Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. 
  • Effects of tobacco smoking and nicotine on cancer treatment. 
  • Effects of tumor growth on host defenses. 
  • Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. 
  • Efficacy and cost-effectiveness of an outcall program to reduce carer burden and depression among carers of cancer patients [PROTECT]: rationale and design of a randomized controlled trial. 
  • Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. 
  • Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. 
  • Efficacy of a telephone outcall program to reduce caregiver burden among caregivers of cancer patients [PROTECT]: a randomised controlled trial. 
  • Efficient independent planar dose calculation for FFF IMRT QA with a bivariate Gaussian source model. 
  • Elastin-Like Polypeptides for Biomedical Applications. 
  • Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. 
  • Electromagnetic thermal therapy power optimization for multiple source applicators. 
  • Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603). 
  • Electronic Health Records (EHRs) in the oncology clinic: how clinician interaction with EHRs can improve communication with the patient. 
  • Electronic reminders for cancer prevention: factors associated with preference for automated voice reminders or text messages. 
  • Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy. 
  • Electronic toxicity monitoring and patient-reported outcomes. 
  • Electrophoretic evaluation of sera from dogs with cancer. 
  • Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. 
  • Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. 
  • Embolization in the external carotid artery. 
  • Emerging Models of Providing Oncology Palliative Care. 
  • Emerging Opportunities To Manipulate Metal Trafficking for Therapeutic Benefit. 
  • Emerging pharmacotherapy for cancer patients with cognitive dysfunction. 
  • Emotional distress among survivors of adolescent and young adult cancer or adult cancer. 
  • Empirical Bayes procedures for stabilizing maps of U.S. cancer mortality rates. 
  • Employment characteristics and cause-specific mortality at automotive electronics manufacturing plants in Huntsville, Alabama. 
  • Employment outcomes among cancer patients in the United States. 
  • End of life experiences of patients with advanced cancer in Myanmar: Results from the APPROACH study. 
  • End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. 
  • Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 
  • Endocrine and Metabolic Disorders in Survivors of Childhood Cancers and Health-Related Quality of Life and Physical Activity. 
  • Endocytosis of red blood cells or haemoglobin by activated macrophages inhibits their tumoricidal effect. 
  • Endocytosis proteins and cancer: a potential link? 
  • Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy. 
  • Endoglin Targeting: Lessons Learned and Questions That Remain. 
  • Endoreplication and polyploidy: insights into development and disease. 
  • Endpoint surrogacy in oncology Phase 3 randomised controlled trials. 
  • Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. 
  • Engaging Patient Advocates and Other Stakeholders to Design Measures of Patient-Centered Communication in Cancer Care. 
  • Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. 
  • Enhanced mobilization of iron from body stores in malnourished patients during intravenous nutritional support. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Enhancing Health Care of Survivors of Childhood Cancer With Tailored Education. 
  • Enhancing communication between oncologists and patients with a computer-based training program: a randomized trial. 
  • Enhancing meaning in the face of advanced cancer and pain: Qualitative evaluation of a meaning-centered psychosocial pain management intervention. 
  • Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina. 
  • Enrollment and events of hospice patients with heart failure vs. cancer. 
  • Ensuring treatment fidelity in a multi-site behavioral intervention study: implementing NIH Behavior Change Consortium recommendations in the SMART trial. 
  • Environmental factors in cancer: focus on air pollution. 
  • Enzyme redesign guided by cancer-derived IDH1 mutations. 
  • EpCAM: A new therapeutic target for an old cancer antigen. 
  • Epidemiology and Psychiatric Correlates of Cancer among Homeless and Unstably Housed Veterans in the VA Health Care System. 
  • Epidemiology of hormone-associated cancers as a reflection of age. 
  • Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity. 
  • Epigenetics and cancer metabolism. 
  • Epithelial cell plasticity: breaking boundaries and changing landscapes. 
  • Epithelial-mesenchymal transition in cancer progression. 
  • Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding? 
  • Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. 
  • Equally inequitable? A cross-national comparative study of racial health inequalities in the United States and Canada. 
  • Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. 
  • Erdheim-Chester disease collides with myelodysplastic neoplasm in bone marrow. 
  • Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. 
  • Erythropoiesis-stimulating agents in cancer. 
  • Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. 
  • Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. 
  • Erythropoiesis-stimulating protein support and survival. 
  • Erythropoietin biology in cancer. 
  • Erythropoietin for oncology supportive care. 
  • Erythropoietin: high profile, high scrutiny. 
  • Escaping G1 restraints on neoplasia--Cdk4 regulation by Ras and NF-kappa B. 
  • Esophageal disease among childhood cancer survivors-A report from the Childhood Cancer Survivors Study. 
  • Estimand framework: Are we asking the right questions? A case study in the solid tumor setting. 
  • Estimates of U.S. multiple cause life tables. 
  • Estimating Tumor Growth Rates In Vivo. 
  • Estimation of cell survival in tumours heated to nonuniform temperature distributions. 
  • Estimation of therapeutic gain in clinical trials involving hyperthermia and radiotherapy. 
  • Estrogen-related receptor alpha as a therapeutic target in cancer. 
  • Etanercept plus standard therapy for Wegener's granulomatosis. 
  • Ethical issues in gamete preservation for children undergoing treatment for cancer. 
  • Evaluating Correlates of Awareness of the Association between Drinking Too Much Alcohol and Cancer Risk in the United States. 
  • Evaluating High-Dimensional Machine Learning Models to Predict Hospital Mortality Among Older Patients With Cancer. 
  • Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis. 
  • Evaluating a couple communication skills training (CCST) intervention for advanced cancer: study protocol for a randomized controlled trial. 
  • Evaluating bioactive food components in obesity and cancer prevention. 
  • Evaluating physician performance in oncology: moneyball becomes impactball. 
  • Evaluating the Contribution of Patient-Provider Communication and Cancer Diagnosis to Racial Disparities in End-of-Life Care Among Medicare Beneficiaries. 
  • Evaluation of "The Many Faces of Pain": a chronic cancer pain management education program. 
  • Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. 
  • Evaluation of Pillars4life: a virtual coping skills program for cancer survivors. 
  • Evaluation of a cancer survivorship protocol: transitioning patients to survivors. 
  • Evaluation of agreement between physicians' notation of 'no evidence of disease' (NED) and patients' report of cancer status. 
  • Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. 
  • Evaluation of coping as a mediator of the relationship between stressful life events and cancer-related distress. 
  • Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. 
  • Evaluation of the Measuring and Improving Quality in Palliative Care Survey. 
  • Evaluation of the Use of Cancer Registry Data for Comparative Effectiveness Research. 
  • Evaluation of the effect of respiratory and anatomical variables on a Fourier technique for markerless, self-sorted 4D-CBCT. 
  • Evaluation of the effectiveness of UK community pharmacists' interventions in community palliative care. 
  • Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. 
  • Evidence for an alternative glycolytic pathway in rapidly proliferating cells. 
  • Evidence-based Management of Cancer Pain. 
  • Evidence-based oncology in cancer treatment reviews. 
  • Evidence-based systematic review: Oropharyngeal dysphagia behavioral treatments. Part IV--impact of dysphagia treatment on individuals' postcancer treatments. 
  • Evidence-based use of colony-stimulating factors in elderly cancer patients. 
  • Evolution of a longitudinal, multidisciplinary, and scalable patient navigation matrix model. 
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. 
  • Evolution of resistance and progression to disease during clonal expansion of cancer. 
  • Evolutionary dynamics of tumor progression with random fitness values. 
  • Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment. 
  • Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. 
  • Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. 
  • Examining the Effect of Travel Distance to Pediatric Cancer Centers and Rurality on Survival and Treatment Experiences: A Systematic Review. 
  • Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. 
  • Excess of Solid Cancers After Prasugrel: The Food and Drug Administration Outlook. 
  • Exercise and Patients With Cancer-Is It Time to Get Heavier With the Dose? 
  • Exercise as Adjunct Therapy in Cancer. 
  • Exercise rehabilitation in patients with cancer. 
  • Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer. 
  • Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment. 
  • Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. 
  • Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. 
  • Experiences with health care practitioners among advanced cancer patients and their family caregivers: A longitudinal dyadic study. 
  • Experiencing the SARS-CoV-2 Pandemic Whilst Living With Cancer. 
  • Experimental Delineation of Mutational Signatures Is an Essential Tool in Cancer Epidemiology and Prevention. 
  • Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans. 
  • Exploring Nurse and Patient Experiences of Developing Rapport During Oncology Ambulatory Care Videoconferencing Visits: Qualitative Descriptive Study. 
  • Expression of a melanoma-tumor-associated antigen as demonstrated by a monoclonal antibody (D6.1) in cytopathologic preparations of human tumor cells from effusions and needle aspirates. 
  • Expression of erythropoietin receptor splice variants in human cancer. 
  • Expression of two type II-like tumor hexokinase RNA transcripts in cancer cell lines. 
  • Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. 
  • Extracellular Vesicles: A Brief Overview and Its Role in Precision Medicine. 
  • Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. 
  • FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors. 
  • FDG PET/CT in patients with HIV. 
  • Facilitators Associated With Building and Sustaining Therapeutic Alliance in Advanced Pediatric Cancer. 
  • Factors affecting patient access in Thailand: understanding delay in care seeking for patients with cancer. 
  • Factors associated with African Americans' enrollment in a national cancer genetics registry. 
  • Factors associated with biomedical research participation within community-based samples across 3 National Cancer Institute-designated cancer centers. 
  • Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. 
  • Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: A report from the childhood cancer survivor study (CCSS). 
  • Factors contributing to delayed childhood cancer care in low- and middle-income countries: A systematic review protocol. 
  • Family caregivers of advanced cancer patients: self-perceived competency and meaning-making. 
  • Family history of cancer and risk of sporadic differentiated thyroid carcinoma. 
  • Family influences on hopelessness among children early in the cancer experience. 
  • Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. 
  • Fast temperature optimization of multi-source hyperthermia applicators with reduced-order modeling of 'virtual sources'. 
  • Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. 
  • Fatigue in 7- to 12-year-old patients with cancer from the staff perspective: an exploratory study. 
  • Fatigue in children and adolescents with cancer. 
  • Fatigue in children and adolescents with cancer: evolution of a program of study. 
  • Fatigue in older cancer patients: etiology, assessment, and treatment. 
  • Fatty acid transport protein 2 reprograms neutrophils in cancer. 
  • Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. 
  • Feasibility of Cancer Clinical Trial Enrollment Goals Based on Cancer Incidence. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature. 
  • Feasibility of neurobehavioral screening following diagnosis of pediatric cancer. 
  • Features associated with successful recruitment of diverse patients onto cancer clinical trials: report from the American College of Surgeons Oncology Group. 
  • Feeling Heard and Understood: A Patient-Reported Quality Measure for the Inpatient Palliative Care Setting. 
  • Fertility Preservation and Financial Hardship among Adolescent and Young Adult Women with Cancer. 
  • Fibrinogen kinetics in patients with neoplastic disease. 
  • Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. 
  • Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells. 
  • Field distribution and DNA transport in solid tumors during electric field-mediated gene delivery. 
  • Filgrastim in patients with neutropenia: potential effects on quality of life. 
  • Financial Burden in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 
  • Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. 
  • Financial Toxicity and Equitable Access to Clinical Trials. 
  • Financial Toxicity of Cancer Care: It's Time to Intervene. 
  • Financial burden among older, long-term cancer survivors: Results from the LILAC study. 
  • Financial burden for caregivers of adolescents and young adults with cancer. 
  • Financial burden of healthcare for cancer patients with social medical insurance: a multi-centered study in urban China. 
  • Financial difficulties are associated with greater total pain and suffering among patients with advanced cancer: results from the COMPASS study. 
  • Financial hardships and psychosocial outcomes among parents of children who die of cancer. 
  • Financial toxicity, Part I: a new name for a growing problem. 
  • Financial toxicity, Part II: how can we help with the burden of treatment-related costs? 
  • First international association of hyperthermic oncology Tsudomu Sugahara award. 
  • First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. 
  • Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. 
  • Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. 
  • Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. 
  • Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. 
  • Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. 
  • Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. 
  • Frequency-dependent absorption of electromagnetic energy in biological tissue. 
  • Fresh fruit consumption and all-cause and cause-specific mortality: findings from the China Kadoorie Biobank. 
  • From Assessment to Implementation and Beyond in Cancer and Aging Research. 
  • From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers. 
  • From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. 
  • From single site to societal belief: the impact of pediatric oncology nursing research. 
  • From the RSNA refresher courses: MR imaging in hyperthermia. 
  • From the guest editor: an integrated multidisciplinary view of tumor metabolism. 
  • Full disclosure--out-of-pocket costs as side effects. 
  • Function in elderly cancer survivors depends on comorbidities. 
  • Functional and molecular image guidance in radiotherapy treatment planning optimization. 
  • Functional assay to guide precision radiotherapy by assessing individual patient radiosensitivity. 
  • Functional selection of protease inhibitory antibodies. 
  • Functional significance of Tie2 signaling in the adult vasculature. 
  • Functional status and the elderly cancer patient. 
  • Fundamentals of quantitative dynamic contrast-enhanced MR imaging. 
  • Fungal infections in transplant and oncology patients. 
  • Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. 
  • Future directions in hyperthermia biology. 
  • Future directions in toxicity prevention. 
  • Future directions in toxicity prevention. 
  • GABAergic signaling beyond synapses: an emerging target for cancer therapy. 
  • GRP78: a chaperone with diverse roles beyond the endoplasmic reticulum. 
  • Gadolinium-conjugated gold nanoshells for multimodal diagnostic imaging and photothermal cancer therapy. 
  • Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach. 
  • Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI). 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Gender differences in the psychosocial experience of parents of children with cancer: a review of the literature. 
  • Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy. 
  • Gene expression profiling of anticancer immune responses. 
  • Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. 
  • Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. 
  • Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. 
  • Gene polymorphisms and susceptibility to coronary artery disease. 
  • Gene profiling of immune responses against tumors. 
  • Gene-environment interactions in cancer epidemiology: a National Cancer Institute Think Tank report. 
  • General anaesthesia or conscious sedation for painful procedures in childhood cancer: the family's perspective. 
  • General internists' preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. 
  • Generalists and oncologists show similar care practices and outcomes for hospitalized late-stage cancer patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks for Treatment. 
  • Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis. 
  • Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. 
  • Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. 
  • Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. 
  • Genetic Risk for Overall Cancer and the Benefit of Adherence to a Healthy Lifestyle. 
  • Genetic engineering of mesenchymal stem cells and its application in human disease therapy. 
  • Genetic instability and tumorigenesis: introduction. 
  • Genetic mechanisms of solid tumor oncogenesis. 
  • Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. 
  • Genetic selection for enhanced serine metabolism in cancer development. 
  • Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. 
  • Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. 
  • Genetic variants in 5-HTTLPR, BDNF, HTR1A, COMT, and FKBP5 and risk for treated depression after cancer diagnosis. 
  • Genetically Encoded Stealth Nanoparticles of a Zwitterionic Polypeptide-Paclitaxel Conjugate Have a Wider Therapeutic Window than Abraxane in Multiple Tumor Models. 
  • Genetically Encoding Albumin Binding into Chemotherapeutic-loaded Polypeptide Nanoparticles Enhances Their Antitumor Efficacy. 
  • Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model. 
  • Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis. 
  • Genetics of physiological dysregulation: findings from the long life family study using joint models. 
  • Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors. 
  • Genome-Wide Association Study of Pregnancy in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. 
  • Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. 
  • Genome-wide analysis of genetic predisposition to common polygenic cancers. 
  • Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. 
  • Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. 
  • Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. 
  • Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. 
  • Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. 
  • Genomic medicine: a decade of successes, challenges, and opportunities. 
  • Genomic medicine: genetic variation and its impact on the future of health care. 
  • Genomic size of CENP-A domain is proportional to total alpha satellite array size at human centromeres and expands in cancer cells. 
  • Genomics of human health and aging. 
  • Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. 
  • Geriatric assessment and comorbidity. 
  • Geriatric assessment for oncologists: rationale and future directions. 
  • Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research. 
  • Geriatric evaluation and management units in the care of the frail elderly cancer patient. 
  • Geriatric oncology health services research: Cancer and Aging Research Group infrastructure core. 
  • Geriatric principles of treatment applied to medical oncology: an overview. 
  • Geriatrics. 
  • Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. 
  • Getting beyond screening for frailty in older patients with cancer. 
  • Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers. 
  • Global analysis of genomic instability caused by DNA replication stress in Saccharomyces cerevisiae. 
  • Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. 
  • Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. 
  • Global economic consequences of selected surgical diseases: a modelling study. 
  • Global role of the immune system in identifying cancer initiation and limiting disease progression. 
  • Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. 
  • Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. 
  • Glucose Metabolism in Cancer: The Saga of Pyruvate Kinase Continues. 
  • Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. 
  • Glutamine Metabolism in Cancer: Understanding the Heterogeneity. 
  • Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. 
  • Glutamine stability in biological tissues evaluated by fluorometric analysis. 
  • Going for Broke: A Longitudinal Study of Patient-Reported Financial Sacrifice in Cancer Care. 
  • Going to extremes: determinants of extraordinary response and survival in patients with cancer. 
  • Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. 
  • Gold nanoparticles-mediated photothermal therapy and immunotherapy. 
  • Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. 
  • Gordon's first law. 
  • Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. 
  • Grading of late effects in young adult survivors of childhood cancer followed in an ambulatory adult setting. 
  • Granulocyte colony-stimulating factors: finding the right indication. 
  • Grief, interrupted. 
  • Group trajectory analysis helps to identify older cancer survivors who benefit from distance-based lifestyle interventions. 
  • Growth factor receptors as molecular targets for cancer diagnosis and therapy. 
  • Growth-rate model predicts in vivo tumor response from in vitro data. 
  • Guidelines and definitions for research on epithelial-mesenchymal transition. 
  • Guidelines for the use of survivorship care plans: a systematic quality appraisal using the AGREE II instrument. 
  • Guidelines for the welfare and use of animals in cancer research. 
  • H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. 
  • HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. 
  • HIF-1 and tumour radiosensitivity. 
  • HIV, cancer, and coping: The cumulative burden of a cancer diagnosis among people living with HIV. 
  • HMGB1 released by irradiated tumor cells promotes living tumor cell proliferation via paracrine effect. 
  • HTS-Compatible CometChip Enables Genetic Screening for Modulators of Apoptosis and DNA Double-Strand Break Repair. 
  • Hair regrowth after cancer therapy. 
  • Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. 
  • Harnessing the power of cell-penetrating peptides: activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents. 
  • Health Care Access Measures and Palliative Care Use by Race/Ethnicity among Metastatic Gynecological Cancer Patients in the United States. 
  • Health Care Disparities in Cancer Patients Receiving Radiation: Changes in Insurance Status After Medicaid Expansion Under the Affordable Care Act. 
  • Health Insurance Payer Type and Ethnicity Are Associated with Cancer Clinical Trial Enrollment Among Adolescents and Young Adults. 
  • Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort. 
  • Health behaviors, obesity, and marital status among cancer survivors: a MEPS study. 
  • Health behaviors, quality of life, and psychosocial health among survivors of adolescent and young adult cancers. 
  • Health care costs in the last week of life: associations with end-of-life conversations. 
  • Health care for childhood cancer survivors: insights and perspectives from a Delphi panel of young adult survivors of childhood cancer. 
  • Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. 
  • Health care utilization, lifestyle, and emotional factors and mammography practices in the Childhood Cancer Survivor Study. 
  • Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. 
  • Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors. 
  • Health-Related Quality of Life among Children and Adolescents during Hematopoietic Stem Cell Transplant Recovery. 
  • Health-Related Quality of Life: The Impact on Morbidity and Mortality. 
  • Health-related quality of life and its socio-economic and cultural predictors among advanced cancer patients: evidence from the APPROACH cross-sectional survey in Hyderabad-India. 
  • Health-related quality of life and symptom management research sponsored by the National Cancer Institute. 
  • Health-related quality of life by race, ethnicity, and country of origin among cancer survivors. 
  • Health-related quality of life in adolescents and young adults with cancer who received radiation therapy: a scoping review. 
  • Health-related quality of life measures and immune checkpoint inhibitors: A systematic review. 
  • Healthcare Cost Trajectories in the Last 2 Years of Life Among Patients With a Solid Metastatic Cancer: A Prospective Cohort Study. 
  • Healthy lifestyle choices after cancer treatment. 
  • Heart rate variability is associated with survival in patients with brain metastasis: a preliminary report. 
  • Heat induces gene amplification in cancer cells. 
  • Heating patterns generated by phase modulation of a hexagonal array of interstitial antennas. 
  • Hedgehog Signaling Regulates Treg to Th17 Conversion Through Metabolic Rewiring in Breast Cancer. 
  • Height at diagnosis of malignancies. 
  • Helping patients decide: ten steps to better risk communication. 
  • Hematopoietic growth factors in cancer chemotherapy. 
  • Hematopoietic growth factors in the older cancer patient. 
  • Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. 
  • Hemolytic anemia and cancer. 
  • Hemopoiesis and aging. 
  • Hemopoietic reserve in the older cancer patient: clinical and economic considerations. 
  • Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. 
  • Heparan sulfate signaling in cancer. 
  • Heparin-coated stents do not protect cancer patients from cardiac complications after noncardiac surgery. 
  • Heparin-induced thrombocytopenia in cancer. 
  • Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. 
  • Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group. 
  • Hepatocellular adenoma among adult survivors of childhood and young adult cancer. 
  • Heritable resistance to tyrosine kinase inhibitors. 
  • Herpes Zoster Vaccination: Controversies and Common Clinical Questions. 
  • Heterogeneity of glycolysis in cancers and therapeutic opportunities. 
  • Heterogeneity of tumor-induced gene expression changes in the human metabolic network. 
  • Heuristics for the Optimal Presentation of Bioactive Peptides on Polypeptide Micelles. 
  • High anxiety and depression scores and mental health service use among South Asian advanced cancer patients: A multi-country study. 
  • High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. 
  • High intensity focused ultrasound-induced gene activation in sublethally injured tumor cells in vitro. 
  • High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. 
  • High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-mobility group box 1 (HMGB1) protein: friend and foe. 
  • High-resolution in vivo imaging of fluorescent proteins using window chamber models. 
  • High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. 
  • High-throughput detection of glutathione s-transferase polymorphic alleles in a pediatric cancer population. 
  • Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. 
  • Homecare Encounters: An Organizational Response to Innovative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation During COVID-19. 
  • Hope in the era of precision oncology: a qualitative study of informal caregivers' experiences. 
  • Hope, bias and survival expectations of advanced cancer patients: A cross-sectional study. 
  • Hospice Use Among Patients With Cancer: Trends, Barriers, and Future Directions. 
  • Hospital-associated venous thromboembolism in children: incidence and clinical characteristics. 
  • Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival. 
  • Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. 
  • Houston AANCART best practices: from vision to synergy to reality. 
  • How Advances in Imaging Will Affect Precision Radiation Oncology. 
  • How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. 
  • How Oncology Nurses Are Working on the Cancer Moonshot Initiative. 
  • How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. 
  • How comfortable are primary care physicians and oncologists prescribing medications for comorbidities in patients with cancer? 
  • How do non-physician clinicians respond to advanced cancer patients' negative expressions of emotions? 
  • How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. 
  • How oncologists and their patients with advanced cancer communicate about health-related quality of life. 
  • HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis. 
  • Human Flourishing in Adolescents with Cancer: Experiences of Pediatric Oncology Health Care Professionals. 
  • Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. 
  • Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. 
  • Humoral immune responses: Unsung heroes of the war on cancer. 
  • Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. 
  • Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. 
  • Hydrocarbon emissions and health risks from cookstoves in developing countries. 
  • Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery. 
  • Hyperalimentation and oncologic management: update. 
  • Hyperglycemia, obesity, and cancer risks on the horizon. 
  • Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors. 
  • Hyperthermia and liposomes. 
  • Hyperthermia classic commentary: 'Arrhenius relationships from the molecule and cell to the clinic' by William Dewey, Int. J. Hyperthermia, 10:457-483, 1994. 
  • Hyperthermia mediated liposomal drug delivery. 
  • Hyperthermia quality assurance guidelines. 
  • Hyperthermia-regulated immunogene therapy. 
  • Hyperthermia: an overview of current progress and problems. 
  • Hyperthermic sensitization by the radical initiator 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH). I. In vitro studies. 
  • Hyperthermic treatment of malignant diseases: current status and a view toward the future. 
  • Hypothesis: iron chelation plays a vital role in neutrophilic inflammation. 
  • Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. 
  • Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. 
  • I look funny and I feel bad. Measurement of symptom distress. 
  • I'm not putting on that floral gown: Enforcement and resistance of gender expectations for transgender people with cancer. 
  • I2 imaging: cancer biology and the tumor microenvironment. 
  • IARC monographs: 40 years of evaluating carcinogenic hazards to humans. 
  • IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation. 
  • IDH1 and IDH2 mutations in gliomas. 
  • IL-10 stimulatory effects on human NK cells explored by gene profile analysis. 
  • IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. 
  • IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. 
  • IRT health outcomes data analysis project: an overview and summary. 
  • ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. 
  • ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. 
  • Identification and assessment of prognostic factors. 
  • Identification of Patient-Reported Outcome Phenotypes Among Oncology Patients With Palliative Care Needs. 
  • Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). 
  • Identification of a tumor associated antigen that can induce tumor specific cytotoxicity. 
  • Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm. 
  • Identification of polymorphisms in cancer patients that differentially affect survival with age. 
  • Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. 
  • Identifying Predictors of Longitudinal Decline in the Level of Medical Care Received by Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. 
  • Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop. 
  • Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. 
  • Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. 
  • Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations. 
  • Identifying the Most Important Consultation-Liaison Psychiatry Publications in 2020 Using a Novel Literature Assessment Instrument. 
  • Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research. 
  • Ifosfamide enantiomers: pharmacokinetics in children. 
  • Illness narratives: discursive constructions of self in pediatric oncology. 
  • Image guidance in osteoplasty and fixation. 
  • Image-based determination of 'physiomarkers' for personalized cancer therapy. 
  • Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. 
  • Imaging biomarker roadmap for cancer studies. 
  • Imaging drug resistance with radiolabeled molecules. 
  • Imaging findings of hemorrhagic cystitis in pediatric oncology patients. 
  • Imaging molecular pathways: reporter genes. 
  • Imaging of angiogenesis: clinical techniques and novel imaging methods. 
  • Imaging of human tumors and organs with N-13-labeled L-methionine. 
  • Imaging tumor hypoxia to advance radiation oncology. 
  • Imaging-guided preoperative hookwire localization of nonpalpable extramammary lesions. 
  • Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. 
  • Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. 
  • Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. 
  • Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. 
  • Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. 
  • Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. 
  • Immune evasion pathways and the design of dendritic cell-based cancer vaccines. 
  • Immune monitoring. 
  • Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. 
  • Immune signatures predict prognosis in localized cancer. 
  • Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. 
  • Immunodiagnosis of human malignancy. 
  • Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. 
  • Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. 
  • Immunohistochemical [corrected] detection of the alternate INK4a-encoded tumor suppressor protein p14(ARF) in archival human cancers and cell lines using commercial antibodies: correlation with p16(INK4a) expression. 
  • Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. 
  • Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. 
  • Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. 
  • Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy. 
  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. 
  • Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. 
  • Immunometabolism at the crossroads of obesity and cancer-a Keystone Symposia report. 
  • Immunomodulatory Function of Interleukin-15 and Its Role in Exercise, Immunotherapy, and Cancer Outcomes. 
  • Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. 
  • Immunoregulatory T cells in cancer immunotherapy. 
  • Immunotherapy of cancer using cytokine gene-modified tumor vaccines. 
  • Immunotherapy of cancer using dendritic cells. 
  • Immunotherapy of cancer with dendritic-cell-based vaccines. 
  • Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. 
  • Immunotherapy of surgical malignancies. 
  • Immunothrombotic Activity of Damage-Associated Molecular Patterns and Extracellular Vesicles in Secondary Organ Failure Induced by Trauma and Sterile Insults. 
  • Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention 
  • Impact of Treatment Subsidies and Cash Payouts on Treatment Choices at the End of Life. 
  • Impact of a Hematologic Malignancy Diagnosis and Treatment on Patients and Their Family Caregivers. 
  • Impact of a summer camp experience on daily activity and family interactions among children with cancer. 
  • Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. 
  • Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. 
  • Impact of cancer on health-related quality of life of older Americans. 
  • Impact of chemotherapy dose intensity on cancer patient outcomes. 
  • Impact of childhood cancer on healthy school-age siblings. 
  • Impact of chronic disease on emotional distress in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Impact of insurance type on survivor-focused and general preventive health care utilization in adult survivors of childhood cancer: the Childhood Cancer Survivor Study (CCSS). 
  • Impact of patient navigation in eliminating economic disparities in cancer care. 
  • Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. 
  • Impact of pediatric cancer on family relationships. 
  • Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors. 
  • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. 
  • Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, Mitigation, and Resilience. 
  • Impact of underlying malignancy on emergency department utilization and outcomes. 
  • Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. 
  • Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry. 
  • Impacts of COVID-19 on caregivers of childhood cancer survivors. 
  • Impacts of an Opioid Safety Initiative on US Veterans Undergoing Cancer Treatment. 
  • Implementation of Electronic Patient-Reported Outcomes in Routine Cancer Care at an Academic Center: Identifying Opportunities and Challenges. 
  • Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. 
  • Implementation of a Surgical Oncology Disparities Curriculum for Preclinical Medical Students. 
  • Implementation of a clinical study of a pain management program for pediatric oncology patients 
  • Implementation of machine learning in the clinic: challenges and lessons in prospective deployment from the System for High Intensity EvaLuation During Radiation Therapy (SHIELD-RT) randomized controlled study. 
  • Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. 
  • Implementing a mHealth intervention to increase colorectal cancer screening among high-risk cancer survivors treated with radiotherapy in the Childhood Cancer Survivor Study (CCSS). 
  • Implementing a pediatric oncology nursing multisite trial. 
  • Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives. 
  • Implementing distress management guidelines in ambulatory oncology: a quality improvement project. 
  • Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. 
  • Implementing novel models of posttreatment care for cancer survivors: Enablers, challenges and recommendations. 
  • Implications of Increase in Vascular Permeability in Tumors by VEGF: A Commentary on the Pioneering Work of Harold Dvorak. 
  • Importance of minimum tumor temperature in determining early and long-term responses of spontaneous canine and feline tumors to heat and radiation. 
  • Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians. 
  • Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. 
  • Important impact of gingival and periodontal conditions on outcomes in SCT recipients. 
  • Imprinting evolution and the price of silence. 
  • Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. 
  • Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters. 
  • Improvement Science and Implementation Science in Cancer Care: Identifying Areas of Synergy and Opportunities for Further Integration. 
  • Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service. 
  • Improving Access to Cancer Testing and Treatment in Kenya. 
  • Improving Adherence to Evidence-Based Guidelines for Chemotherapy-Induced Nausea and Vomiting. 
  • Improving Cancer Care for People Living With HIV: A Qualitative Study of Provider Knowledge, Attitudes, and Practice. 
  • Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life. 
  • Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. 
  • Improving Peripheral Intravenous Catheter Care for Children with Cancer Receiving Chemotherapy in Malawi. 
  • Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. 
  • Improving care of chronic conditions for women veterans: identifying opportunities for comparative effectiveness research. 
  • Improving clinician performance of inpatient venous thromboembolism risk assessment and prophylaxis. 
  • Improving evidence developed from population-level experience with targeted agents. 
  • Improving health care for adult survivors of childhood cancer: recommendations from a delphi panel of health policy experts. 
  • Improving sensitivity and specificity of capturing and detecting targeted cancer cells with anti-biofouling polymer coated magnetic iron oxide nanoparticles. 
  • Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. 
  • Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. 
  • Improving the management of chemotherapy-induced neutropenia. 
  • Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. 
  • Improving the quality of cancer care in an aging population: recommendations from an IOM report. 
  • Improving the quality of survivorship for older adults with cancer. 
  • Improving the quantitative accuracy of optical-emission computed tomography by incorporating an attenuation correction: application to HIF1 imaging. 
  • In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. 
  • In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. 
  • In experimental chronic kidney disease or cancer, parathyroid hormone is a novel mediator of cachexia. 
  • In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. 
  • In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. 
  • In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters. 
  • In vivo photoacoustic tomography of total blood flow and potential imaging of cancer angiogenesis and hypermetabolism. 
  • In vivo selection of tumor-targeting RNA motifs. 
  • In-Hospital Mortality and Post-Surgical Complications Among Cancer Patients with Metabolic Syndrome. 
  • Incidence and clinical relevance of abnormal complete blood counts in long-term survivors of childhood cancer. 
  • Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. 
  • Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Incidence of anemia in children with solid tumors or Hodgkin disease. 
  • Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials. 
  • Inclusive Cancer Care: Rethinking Patients Living with HIV and Cancer. 
  • Inconsistent mammography perceptions and practices among women at risk of breast cancer following a pediatric malignancy: a report from the Childhood Cancer Survivor Study. 
  • Incorporating Information From Proxies for Patient-Centered Outcomes in Adult and Pediatric Oncology Settings. 
  • Incorporating biomarkers into cancer and aging research. 
  • Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? 
  • Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells. 
  • Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. 
  • Increasing cardiomyopathy screening in at-risk adult survivors of pediatric malignancies: a randomized controlled trial. 
  • Increasing physical activity in Cancer Survivors through a Text-messaging Exercise motivation Program (ICanSTEP). 
  • Increasing productivity and reducing errors through usability analysis: a case study and recommendations. 
  • Increasing vaccine potency through exosome antigen targeting. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Independent data monitoring committees: an update and overview. 
  • Indeterminate findings on imaging-guided biopsy: should additional intervention be pursued? 
  • Index Symptoms and Prognosis Awareness of Patients With Pancreatic Cancer: A Multi-Site Palliative Care Collaborative. 
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. 
  • Individual prediction of heart failure among childhood cancer survivors. 
  • Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. 
  • Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. 
  • Informal caregiver training on home care and cancer symptom management prior to hospital discharge: a feasibility study. 
  • Information Framing Reduces Initial Negative Attitudes in Cancer Patients' Decisions About Hospice Care. 
  • Informing cancer prevention strategies for African Americans: the relationship of African American acculturation to fruit, vegetable, and fat intake. 
  • Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials. 
  • Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. 
  • Inhibition of ALG3 stimulates cancer cell immunogenic ferroptosis to potentiate immunotherapy. 
  • Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. 
  • Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth. 
  • Inhibitors of monocyte responses to chemotaxins are associated with human neoplasms. 
  • Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses. 
  • Initial assessment of a new instrument to measure quality of life at the end of life. 
  • Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. 
  • Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. 
  • Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. 
  • Initial sequencing and comparative analysis of the mouse genome. 
  • Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. 
  • Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. 
  • Initial testing of cisplatin by the pediatric preclinical testing program. 
  • Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. 
  • Initial testing of topotecan by the pediatric preclinical testing program. 
  • Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model. 
  • Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. 
  • Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies. 
  • Innovation in survivor care: group visits. 
  • Innovations in Intraoperative Tumor Visualization. 
  • Inpatient care for elderly cancer patients: the role for Geriatric Evaluation and Management Units in fulfilling goals for care. 
  • Insulin and longevity: antidiabetic biguanides as geroprotectors. 
  • Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen. 
  • Insulin/IGF-dependent Wnt signaling promotes formation of germline tumors and other developmental abnormalities following early-life starvation in Caenorhabditis elegans. 
  • Insurance Coverage and Forgoing Medical Appointments Because of Cost Among Cancer Survivors After 2016. 
  • Insurance status as a mediator of clinical presentation, type of intervention, and short-term outcomes for patients with metastatic spine disease. 
  • Insurance, chronic health conditions, and utilization of primary and specialty outpatient services: a Childhood Cancer Survivor Study report. 
  • Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. 
  • Integrated outpatient palliative care for patients with advanced cancer: A systematic review and meta-analysis. 
  • Integrating Dignity Therapy and Family Therapy in Palliative Care: A Case Study of Multiple Sclerosis, Depression, and Comorbid Cancer. 
  • Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now. 
  • Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets. 
  • Integration of PET/MR Hybrid Imaging into Radiation Therapy Treatment. 
  • Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience. 
  • Integration of Spiritual Care in Hospital Care System in Iran. 
  • Integration of cancer registry and electronic health record data to construct a childhood cancer survivorship cohort, facilitate risk stratification for late effects, and assess appropriate follow-up care. 
  • Integration of cone-beam CT in stereotactic body radiation therapy. 
  • Integrative Literature Review on Psychological Distress and Coping Strategies Among Survivors of Adolescent Cancer 
  • Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline. 
  • Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. 
  • Integrative annotation of variants from 1092 humans: application to cancer genomics. 
  • Integrative genomic approaches to understanding cancer. 
  • Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism. 
  • Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316). 
  • Intensity, location, and quality of pain in Spanish-speaking children with cancer. 
  • Inter-genomic cross talk between mitochondria and the nucleus plays an important role in tumorigenesis. 
  • Interactive discussion on chemotherapy-related adverse events. 
  • Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy. 
  • Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. 
  • International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification. 
  • International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. 
  • International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children With an Underlying Oncologic Diagnosis. 
  • Interpretation and reporting of positron emission tomography-computed tomographic scans. 
  • Interpreting measures of treatment effect in cancer clinical trials. 
  • Interrater Reliability in Toxicity Identification: Limitations of Current Standards. 
  • Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors. 
  • Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). 
  • Interventions to improve the quality of life and survivorship of older adults with cancer: The funding landscape at NIH, ACS and PCORI. 
  • Interventions to promote adherence with oral agents. 
  • Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. 
  • Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 
  • Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods. 
  • Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. 
  • Intraoperative interstitial microwave-induced hyperthermia and brachytherapy. 
  • Intraoperative irradiation: current and future status. 
  • Intraoperative probes and imaging probes. 
  • Intraoperative radiation therapy. 
  • Intratumor heterogeneity in evolutionary models of tumor progression. 
  • Intratumoral delivery of brachytherapy and immunotherapy by a thermally triggered polypeptide depot. 
  • Intravital fluorescence facilitates measurement of multiple physiologic functions and gene expression in tumors of live animals. 
  • Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'. 
  • Introduction to neutron stimulated emission computed tomography. 
  • Introduction. Neutropenia risk models in oncology. 
  • Introduction: The science of survivorship: moving from risk to risk reduction. 
  • Introduction: tumor as an organ. 
  • Invasive gram-positive bacterial infection in cancer patients. 
  • Inverse techniques in hyperthermia: a sensitivity study. 
  • Investigation into image quality and dose for different patient geometries with multiple cone-beam CT systems. 
  • Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. 
  • Investigation of sliced body volume (SBV) as respiratory surrogate. 
  • Investing in Global Health for Our Future. 
  • Ion channels under the sun. 
  • Ionizing radiation-induced DNA damage, response, and repair. 
  • Irradiation and immunotherapy: From concept to the clinic. 
  • Is birth order associated with adult mortality? 
  • Is breast-feeding in infancy associated with adult longevity? 
  • Is early life body weight a predictor of longevity and tumor risk in rats? 
  • Is it my cancer or am i just getting older?: Impact of cancer on age-related health conditions of older cancer survivors. 
  • Is it possible to optimize a radiotherapy treatment plan? 
  • Is proton beam therapy better than standard radiation therapy? A paucity of practicality puts photons ahead of protons. 
  • Is there a role for survivorship care plans in advanced cancer? 
  • Is there a use for tailored print communications in cancer risk communication? 
  • Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. 
  • Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin β3 recycling, cell migration and cancer metastasis. 
  • It is time to rethink weight loss in cancer. 
  • It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses. 
  • It's time to have 'the talk': cost communication and patient-centered care. 
  • Item response theory analysis of the patient satisfaction with cancer-related care measure: a psychometric investigation in a multicultural sample of 1,296 participants. 
  • JPP Student Journal Club Commentary: The Relationship between Parent and Child Distress in Pediatric Cancer. 
  • Joint classifier and feature optimization for comprehensive cancer diagnosis using gene expression data. 
  • KDM1 class flavin-dependent protein lysine demethylases. 
  • KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. 
  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. 
  • Key roles of necroptotic factors in promoting tumor growth. 
  • Key takeaways for knowledge expansion of early-career scientists conducting Transdisciplinary Research in Energetics and Cancer (TREC): a report from the TREC Training Workshop 2022. 
  • Keynote comment: cancer survivorship and ageing--a double whammy. 
  • Kindlin-3 gives patrolling monocytes a strong grip. 
  • Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study. 
  • Knowledge of indications and utilization of EUS: a survey of oncologists in the United States. 
  • Korean Physicians' Perspectives on Prognostication in Palliative Care: A Qualitative Study. 
  • LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. 
  • Label propagation defines signaling networks associated with recurrently mutated cancer genes. 
  • Lack of Association Between Heart Failure and Incident Cancer. 
  • Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials. 
  • Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. 
  • Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. 
  • Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. 
  • Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. 
  • Laparoscopic feeding jejunostomy tube in oncology patients. 
  • Laparoscopic surgery and the systemic immune response. 
  • Larotrectinib: A Targeted Therapy for Solid Tumors. 
  • Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study. 
  • Late complications after marrow transplantation. 
  • Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. 
  • Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. 
  • Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. 
  • Latitude may modify the effect of TP53 codon 72 polymorphism on cancer risk. 
  • Lay Health Worker-Led Cancer Symptom Screening Intervention and the Effect on Patient-Reported Satisfaction, Health Status, Health Care Use, and Total Costs: Results From a Tri-Part Collaboration. 
  • Leading Causes of Death among Asian American Subgroups (2003-2011). 
  • Length of stay and mortality associated with febrile neutropenia among children with cancer. 
  • Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages. 
  • Let's Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine. 
  • Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. 
  • Leveraging Clinical Informatics Tools to Extract Cumulative Anthracycline Exposure, Measure Cardiovascular Outcomes, and Assess Guideline Adherence for Children With Cancer. 
  • Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. 
  • Leveraging insights into cancer metabolism-a symposium report. 
  • Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. 
  • Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. 
  • Life and death in paradise. 
  • Life expectancy benefits of cancer screening in the end-stage renal disease population. 
  • Life satisfaction and its correlates among older cancer survivors: critical role of psychosocial factors. 
  • Lifecourse socioeconomic status and cancer-related risk factors: Analysis of the WHO study on global ageing and adult health (SAGE). 
  • Lifestyle interventions in cancer survivors: designing programs that meet the needs of this vulnerable and growing population. 
  • Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. 
  • Light-intensity activity attenuates functional decline in older cancer survivors. 
  • Limitations on physical performance and daily activities among long-term survivors of childhood cancer. 
  • Linear and nonlinear rheology of liberase-treated breast cancer tumors. 
  • Linking the history of radiation biology to the hallmarks of cancer. 
  • Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. 
  • Listening to the Patient Voice Adds Value to Cancer Clinical Trials. 
  • LncRNA CamK-A Regulates Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling. 
  • Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. 
  • Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis. 
  • Lonafarnib for cancer and progeria. 
  • Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. 
  • Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. 
  • Long-term biopsychosocial effects of interleukin-2 therapy. 
  • Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. 
  • Long-term care for people treated for cancer during childhood and adolescence. 
  • Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. 
  • Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors. 
  • Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). 
  • Long-term outcomes of myeloid growth factor treatment. 
  • Long-term survivors of childhood cancer: cure and care-the Erice Statement (2006) revised after 10 years (2016). 
  • Longevity in military pilots: 37-year followup of the Navy's "1000 aviators". 
  • Longitudinal analysis of T-cell receptor variable beta chain repertoire in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. 
  • Longitudinal pain and pain interference in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Longitudinal risk-based health care for adult survivors of childhood cancer. 
  • Longitudinal smoking patterns in survivors of childhood cancer: An update from the Childhood Cancer Survivor Study. 
  • Longitudinal trajectories of caregiving experiences among primary informal caregivers of patients with metastatic solid cancer (stage IV). 
  • Longitudinal use of patient reported outcomes in pediatric leukemia and lymphoma reveals clinically relevant symptomatic adverse events. 
  • Loss of Diacylglycerol Kinase α Enhances Macrophage Responsiveness. 
  • Low-intensity alternating electric fields: a potentially safe and effective treatment of cancer? 
  • Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial. 
  • Luminescent difluoroboron β-diketonate PEG-PLA oxygen nanosensors for tumor imaging. 
  • Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. 
  • Lymphadenopathy in children: A streamlined approach for the surgeon - A report from the APSA Cancer Committee. 
  • Lymphatic mapping and sentinel node analysis: current concepts and applications. 
  • Lymphocyte activation, cell-mediated cytotoxicity and their relationship to dietary fat-enhanced mammary tumorigenesis in C3H/OUJ mice. 
  • Lymphodepletional strategies in transplantation. 
  • Lysyl oxidase is essential for hypoxia-induced metastasis. 
  • Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. 
  • Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. 
  • Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry. 
  • Macrophage migratory dysfunction in cancer. A mechanism for subversion of surveillance. 
  • Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. 
  • Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. 
  • Maintenance of Certification and Continuing Medical Education: Are They Still Required? 
  • Major Factors Driving Expert Opinion on Preoperative Breast MRI Do Not Predict Additional Disease. 
  • Major and massive hemoptysis: reassessment of conservative management. 
  • Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. 
  • Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative. 
  • Making the Right Thing Easier to Do: Standardized Integration of Oncology and Palliative Care. 
  • Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. 
  • Malignancy after solid organ transplantation: an overview. 
  • Malignancy in Pediatric-onset Systemic Lupus Erythematosus. 
  • Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. 
  • Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. 
  • Management of Immunotherapy-Related Toxicities, Version 1.2019. 
  • Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Management of cancer in the aged. 
  • Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. 
  • Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Management of terminal cancer in elderly patients. 
  • Managing accrual in cooperative group clinical trials. 
  • Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. 
  • Managing depression in geriatric populations. 
  • Managing painful procedures in children with cancer. 
  • Mapping Cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women. 
  • Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research. 
  • Mapping the Pathways of Resistance to Targeted Therapies. 
  • Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database. 
  • Mast cells impair the development of protective anti-tumor immunity. 
  • Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors. 
  • Material, behavioral, and psychological financial hardship among survivors of childhood cancer in the Childhood Cancer Survivor Study. 
  • Maternal comorbidity and adverse perinatal outcomes in survivors of adolescent and young adult cancer: A cohort study. 
  • Mathematical formulation and analysis of the nonlinear system reconstruction of the online image-guided adaptive control of hyperthermia. 
  • Mathematical modeling of folate metabolism: predicted effects of genetic polymorphisms on mechanisms and biomarkers relevant to carcinogenesis. 
  • Mathematical modeling predicts the effect of folate deficiency and excess on cancer-related biomarkers. 
  • Mathematical modeling: epidemiology meets systems biology. 
  • Maximum likelihood estimation of a stochastic compartment model of cancer latency: lung cancer mortality among white females in the U.S. 
  • Meaning-Centered Pain Coping Skills Training: A Pilot Feasibility Trial of a Psychosocial Pain Management Intervention for Patients with Advanced Cancer. 
  • Measurement of progress against cancer. Extramural Committee to Assess Measures of Progress Against Cancer. 
  • Measurement of psychosocial concerns of adolescents with cancer. 
  • Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors. 
  • Measuring Biologic Resilience in Older Cancer Survivors. 
  • Measuring health-related quality of life in adolescent and young adult cancer survivors with the National Institutes of Health Patient-Reported Outcomes Measurement Information System® : Comparing adolescent, emerging adult, and young adult survivor perspectives. 
  • Measuring parental grief after childhood cancer: potential use of the SCL-90R. 
  • Measuring psychosocial risk in families caring for a child with cancer: the Psychosocial Assessment Tool (PAT2.0). 
  • Measuring the Health Benefits of the Affordable Care Act for Young Women. 
  • Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. 
  • Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. 
  • Mechanisms underlying hypoxia development in tumors. 
  • Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. 
  • Mediating Effects of Frailty Indicators on the Risk of Sepsis After Cancer. 
  • Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Medical cost trajectories and onsets of cancer and noncancer diseases in US elderly population. 
  • Medical oncologists' perspectives of the Veterans Affairs National Precision Oncology Program. 
  • Medical problems associated with aging. 
  • Medical problems occurring after orthotopic liver transplantation. 
  • Medical screening participation in the childhood cancer survivor study. 
  • Medusa cells: cytostructure and cytochemistry of amoeboid eosinophils with pseudopod-like processes. 
  • Meeting report: Translational Research at the Aging and Cancer Interface. 
  • Melatonin increases both life span and tumor incidence in female CBA mice. 
  • Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. 
  • Meningeal mycosis fungoides: clinical and cellular characteristics. 
  • Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. 
  • Mental neuropathy from systemic cancer. 
  • Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype. 
  • Messenger RNA (mRNA) nanoparticle tumour vaccination. 
  • Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. 
  • Meta-analysis of the association between dietary inflammatory index (DII) and cancer outcomes. 
  • Metabolic Barriers to T Cell Function in Tumors. 
  • Metabolic decisions in development and disease-a Keystone Symposia report. 
  • Metabolic dysregulation and cancer mortality in a national cohort of blacks and whites. 
  • Metabolic interactions with cancer epigenetics. 
  • Metabolic landscape of the tumor microenvironment at single cell resolution. 
  • Metabolic pattern formation in the tumor microenvironment. 
  • Metabolic programming and immune suppression in the tumor microenvironment. 
  • Metabolic regulation of Akt: roles reversed. 
  • Metabolic regulation of T lymphocytes. 
  • Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? 
  • Metabolic reprogramming of the immune response in the tumor microenvironment. 
  • Metabolism in the tumor microenvironment: insights from single-cell analysis. 
  • Metabolomics in cancer research and emerging applications in clinical oncology. 
  • Metagenomics and chemotherapy-induced nausea: A roadmap for future research. 
  • Metastases in the pancreas from nonhematologic neoplasms: report of 20 cases evaluated by fine-needle aspiration. 
  • Methionine metabolism in health and cancer: a nexus of diet and precision medicine. 
  • Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. 
  • Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies. 
  • Methods for combining ancillary data in stochastic compartment models of cancer mortality: generalization of heterogeneity models. 
  • Methods for the analysis of mortality risks across heterogeneous small populations: examination of space-time gradients in cancer mortality in North Carolina counties 1970-75. 
  • Methods to assess adverse health-related outcomes in cancer survivors. 
  • Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. 
  • MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. 
  • Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. 
  • Microenvironmental influences on T cell immunity in cancer and inflammation. 
  • Microenvironmental regulation of cancer metastasis by miRNAs. 
  • Microvascular studies on the origins of perfusion-limited hypoxia. 
  • Midterm Success of a Custom, Non-Fluted, Diaphyseal, Press-Fit Stem Used With a Tumor Megaprosthesis System. 
  • Migration of human dendritic cells after injection in patients with metastatic malignancies. 
  • Mila Blooms: A Mobile Phone Application and Behavioral Intervention for Promoting Physical Activity and a Healthy Diet Among Adolescent Survivors of Childhood Cancer. 
  • Military Generation and Its Relationship to Mortality in Women Veterans in the Women's Health Initiative. 
  • Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. 
  • Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization, and health-related behaviors from the childhood cancer survivor study. 
  • Mismatch of posttraumatic stress disorder (PTSD) symptoms and DSM-IV symptom clusters in a cancer sample: exploratory factor analysis of the PTSD Checklist-Civilian Version. 
  • Mismatch repair in replication fidelity, genetic recombination, and cancer biology. 
  • Mismatch repair, genetic stability and tumour avoidance. 
  • Mismatch repair, genetic stability, and cancer. 
  • Mitochondrial alterations may underlie race-specific differences in cancer risk and outcome. 
  • Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury. 
  • Mobile Application to Identify Cancer Treatment-Related Financial Assistance: Results of a Randomized Controlled Trial. 
  • Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. 
  • Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. 
  • Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • Model of tumor dormancy/recurrence after short-term chemotherapy. 
  • Modeling collective cell behavior in cancer: Perspectives from an interdisciplinary conversation. 
  • Modeling folate, one-carbon metabolism, and DNA methylation. 
  • Modeling the tumor extracellular matrix: Tissue engineering tools repurposed towards new frontiers in cancer biology. 
  • Models for delivering survivorship care. 
  • Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade. 
  • Models of cancer survivorship health care: moving forward. 
  • Models of the interaction of mortality and the evolution of risk factor distribution: a general stochastic process formulation. 
  • Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. 
  • Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma. 
  • Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. 
  • Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness. 
  • Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. 
  • Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. 
  • Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. 
  • Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. 
  • Molecular Biology and Evolution of Cancer: From Discovery to Action. 
  • Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. 
  • Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide. 
  • Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology. 
  • Molecular biology of normal development, malignancy and its suppression. 
  • Molecular characterization of the pediatric preclinical testing panel. 
  • Molecular classification of human carcinomas by use of gene expression signatures. 
  • Molecular determinants of sensitivity to antitumor agents. 
  • Molecular genetics: toward an understanding of childhood cancer. 
  • Molecular imaging in oncology. 
  • Molecular imaging of hypoxia. 
  • Molecular mechanisms of transforming growth factor-beta signaling. 
  • Molecular mechanisms underlying the potentially adverse effects of folate. 
  • Molecular pathways and therapeutic targets in lung cancer. 
  • Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. 
  • Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program. 
  • Monitoring cellular immune responses to cancer immunotherapy. 
  • Monoclonal antibodies to tissue-associated antigens as antitumor reagents. 
  • Mood disorders in the medically ill: scientific review and recommendations. 
  • Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. 
  • Mortality model based on delays in progression of chronic diseases: alternative to cause elimination model. 
  • Mortality of older construction and craft workers employed at Department of Energy (DOE) nuclear sites. 
  • Mortality of older construction and craft workers employed at department of energy (DOE) nuclear sites: follow-up through 2011. 
  • Mortality patterns among female and male chrysotile asbestos textile workers. 
  • Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. 
  • Moving forward with myeloid growth factors. 
  • Moving targets: detection and tracking of internal organ motion for treatment planning and patient set-up. 
  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. 
  • Multi-site study of incidence of pressure ulcers and the relationship between risk level, demographic characteristics, diagnoses, and prescription of preventive interventions. 
  • Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: Results from electronic health records data. 
  • Multidimensional Pain Inventory-Screening Chinese version (MPI-sC): psychometric testing in terminal cancer patients in Taiwan. 
  • Multidisciplinary management of cancer pain: a longitudinal retrospective study on a cohort of end-stage cancer patients. 
  • Multifocality and recurrence risk: a quantitative model of field cancerization. 
  • Multiple assay characterization of murine monoclonal antimelanoma antibodies. 
  • Multiple etiologies of tumor hypoxia require multifaceted solutions. 
  • Multisite Quality Improvement Study of a Patient-Pathologist Consultation Program. 
  • Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture. 
  • Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function. 
  • Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. 
  • Muscle-specific functional deficits and lifelong fibrosis in response to paediatric radiotherapy and tumour elimination. 
  • Musculoskeletal syndromes associated with malignancy. 
  • Mutant p53 as an Antigen in Cancer Immunotherapy. 
  • Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. 
  • Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. 
  • Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines. 
  • Mutational processes in cancer preferentially affect binding of particular transcription factors. 
  • Mutations in the MSH3 gene preferentially lead to deletions within tracts of simple repetitive DNA in Saccharomyces cerevisiae. 
  • Mutations of the BRAF gene in human cancer. 
  • Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. 
  • Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Myeloid growth factors. 
  • Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Myelopoiesis during Solid Cancers and Strategies for Immunotherapy. 
  • Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. 
  • Myelotoxicity from chemotherapy. 
  • N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. 
  • NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. 
  • NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. 
  • NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. 
  • NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. 
  • NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. 
  • NCCN Guidelines Insights: Palliative Care, Version 2.2017. 
  • NCCN Guidelines Insights: Survivorship, Version 1.2016. 
  • NCCN Guidelines Insights: Survivorship, Version 2.2019. 
  • NCCN Guidelines Insights: Survivorship, Version 2.2020. 
  • NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. 
  • NCCN Guidelines® Insights: Palliative Care, Version 2.2021. 
  • NCCN Guidelines® Insights: Survivorship, Version 1.2022. 
  • NCCN Task Force Report. prevention and management of mucositis in cancer care. 
  • NCCN Task Force Report: mTOR inhibition in solid tumors. 
  • NCCN clinical practice guidelines in oncology: palliative care. 
  • NCI image archive management workshop: a preliminary report. 
  • NCI initiative: development of novel imaging technologies. 
  • NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. 
  • NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. 
  • NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. 
  • NIH funding trajectories and their correlations with US health dynamics from 1950 to 2004. 
  • Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. 
  • Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. 
  • Nanoparticles for thermal cancer therapy. 
  • Nanopore Flongle Sequencing as a Rapid, Single-Specimen Clinical Test for Fusion Detection. 
  • Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. 
  • Nanoshells for photothermal cancer therapy. 
  • Nanotechnology and tumor imaging: seizing an opportunity. 
  • National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. 
  • National Cancer Institute initiative for development of novel imaging technologies. 
  • National Comprehensive Cancer Network Guidelines: Who Makes Them? What Are They? Why Are They Important? 
  • National estimates of the use of hematopoietic stem-cell transplantation in children with cancer in the United States. 
  • National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. 
  • National survey of patient specific IMRT quality assurance in China. 
  • Nausea and vomiting perspectives among children receiving moderate to highly emetogenic chemotherapy treatment. 
  • Nausea, pain, fatigue, and multiple symptoms in hospitalized children with cancer. 
  • Navigating prognostic communication when children with poor-prognosis cancer experience prolonged disease stability. 
  • Navigating the high costs of cancer care: opportunities for patient engagement. 
  • Near-infrared-resonant gold/gold sulfide nanoparticles as a photothermal cancer therapeutic agent. 
  • Necroptosis regulates tumor repopulation after radiotherapy via RIP1/RIP3/MLKL/JNK/IL8 pathway. 
  • Needs and Lifestyle Challenges of Adolescents and Young Adults With Cancer: Summary of an Institute of Medicine and Livestrong Foundation Workshop. 
  • Negative control of diacylglycerol kinase ζ-mediated inhibition of T cell receptor signaling by nuclear sequestration in mice. 
  • Negative emotions in cancer care: do oncologists' responses depend on severity and type of emotion? 
  • Neonatal neoplasms. 
  • Network calisthenics: control of E2F dynamics in cell cycle entry. 
  • Neuro-ophthalmic side effects of molecularly targeted cancer drugs. 
  • Neuroendocrine Neoplasms: Molecular Imaging and Therapy. 
  • Neurologic complications of systemic cancer. 
  • Neurological complications of systemic cancer. 
  • Neurological manifestations of malignancies. 
  • Neutron-stimulated emission computed tomography of a multi-element phantom. 
  • Neutropenia Precautions for Children Receiving Chemotherapy or Stem Cell Transplantation for Cancer. 
  • Neutrophils Create an ImpeNETrable Shield between Tumor and Cytotoxic Immune Cells. 
  • Never too old? Age should not be a barrier to enrollment in cancer clinical trials. 
  • New Cancer Diagnoses Still Lagging in the United States in Second Full Year of COVID-19 Pandemic. 
  • New Concept of Onco-Hypertension and Future Perspectives. 
  • New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery. 
  • New betulinic acid derivatives as potent proteasome inhibitors. 
  • New drugs for children and adolescents with cancer: the need for novel development pathways. 
  • New functions and signaling mechanisms for the class of adhesion G protein-coupled receptors. 
  • New roles for pyruvate kinase M2: working out the Warburg effect. 
  • New roles of carboxypeptidase E in endocrine and neural function and cancer. 
  • Next Step for Global Adolescent and Young Adult Oncology: A Core Patient-Centered Outcome Set. 
  • Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? 
  • Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. 
  • Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 
  • Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution. 
  • Niclosamide: Beyond an antihelminthic drug. 
  • Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. 
  • No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. 
  • Nocturnal awakenings, sleep environment interruptions, and fatigue in hospitalized children with cancer. 
  • Non-invasive thermometry using magnetic resonance diffusion imaging: potential for application in hyperthermic oncology. 
  • Noncoding RNAs Regulating Cancer Signaling Network. 
  • Noninvasive measurement of tissue blood oxygenation with Cerenkov imaging during therapeutic radiation delivery. 
  • Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. 
  • Novel cancer therapies and their association with diabetes. 
  • Novel imaging provides new insights into mechanisms of oxygen transport in tumors. 
  • Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. 
  • Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. 
  • Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond. 
  • Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. 
  • Novel therapeutic targets of tumor metabolism. 
  • Novice Oncology Nurse Navigator: Core Elements in Establishing Training Needs and Building on Competencies. 
  • Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. 
  • Nurse and physician perspectives on patients with cancer having online access to their laboratory results. 
  • Nurse-facilitated preparation and life completion interventions are acceptable and feasible in the Australian palliative care setting: results from a phase 2 trial. 
  • Nursing advocacy in North Carolina. 
  • Nutrient availability shapes methionine metabolism in p16/MTAP-deleted cells. 
  • Nutrients and the microenvironment to feed a T cell army. 
  • Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: from preclinical findings to clinical strategy. 
  • Nutritional parameters affecting erythrocyte polyamine levels in cancer patients. 
  • Nutritional supplements for older adults: review and recommendations--Part II. 
  • OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. 
  • Obesity, Immunity, and Cancer. 
  • Objective burden, resources, and other stressors among informal cancer caregivers: a hidden quality issue? 
  • Observations on the use of ferromagnetic implants for inducing hyperthermia. 
  • Occupational aspects of scrotal cancer and epithelioma. 
  • Occupational health issues in the chemical and pharmaceutical industries. 
  • Occupational outcomes of adult childhood cancer survivors: A report from the childhood cancer survivor study. 
  • Older Adults with Cancer: A Randomized Controlled Trial of Occupational and Physical Therapy. 
  • Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. 
  • On sample size calculation for comparing survival curves under general hypothesis testing. 
  • On the accuracy of noninvasive thermometry using molecular diffusion magnetic resonance imaging. 
  • On the estimation of the binomial probability in multistage clinical trials. 
  • Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. 
  • Onco-hypertension: An Emerging Specialty. 
  • Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis. 
  • Oncogenic Signaling Pathways in The Cancer Genome Atlas. 
  • Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. 
  • Oncogenic pathway signatures in human cancers as a guide to targeted therapies. 
  • Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. 
  • Oncologic 18F-FDG PET/CT: referring physicians' point of view. 
  • Oncologic image compression using both wavelet and masking techniques. 
  • Oncologist communication about emotion during visits with patients with advanced cancer. 
  • Oncologist-patient-caregiver decision-making discussions in the context of advanced cancer in an Asian setting. 
  • Oncologists' Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology Workforce. 
  • Oncologists' responses to patient and caregiver negative emotions and patient perception of quality of communication: results from a multi-ethnic Asian setting. 
  • Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes. 
  • Oncology Care Model: Short- and Long-Term Considerations in the Context of Broader Payment Reform. 
  • Oncology Navigation Standards of Professional Practice. 
  • Oncology and Palliative Care Integration: Cocreating Quality and Value in the Era of Health Care Reform. 
  • Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting. 
  • Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. 
  • Oncolytic polio virotherapy of cancer. 
  • Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction. 
  • Oncolytic viruses for cancer therapy II. Cell-internal factors for conditional growth in neoplastic cells. 
  • One Voice Is Good, But More Is Better: Symptom and Toxicity Reporting in Pediatric Oncology. 
  • One-stop-shop tumor imaging: buy hypoxia, get lactate free. 
  • Online feedback focusing algorithm for hyperthermia cancer treatment. 
  • Online resources on sexuality and cancer. 
  • Oocyte cryopreservation versus ovarian tissue cryopreservation for adult female oncofertility patients: a cost-effectiveness study. 
  • Open Oncology Notes: A Qualitative Study of Oncology Patients' Experiences Reading Their Cancer Care Notes. 
  • Operative trials: the opportunity beckons-an update on the American College of Surgeons Oncology Group. 
  • Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. 
  • Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies. 
  • Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. 
  • Opportunities for the Cardiovascular Community in the Precision Medicine Initiative. 
  • Opportunities-and hard work-ahead. 
  • Opposite phenotypes of cancer and aging arise from alternative regulation of common signaling pathways. 
  • Optically modulated cancer therapeutic delivery: past, present and future. 
  • Optically tunable nanoparticle contrast agents for early cancer detection: model-based analysis of gold nanoshells. 
  • Optimal cancer care across the spectrum of life and disease. 
  • Optimal designs for phase II clinical trials with heterogeneous patient populations. 
  • Optimal lesion number for evaluation of tumor response in response evaluation criteria in solid tumors. 
  • Optimal management of malignant pleural effusions (results of CALGB 30102). 
  • Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy. 
  • Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity. 
  • Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. 
  • Optimizing dendritic cell function by genetic modification. 
  • Optimizing the measurement of health-related quality of life in adolescents and young adults with cancer. 
  • Oral candidiasis in cancer patients. 
  • Oral ondansetron pharmacokinetics: the effect of chemotherapy. 
  • Organ doses and cancer risk assessment in patients exposed to high doses from recurrent CT exams. 
  • Organizational and physician factors associated with patient enrollment in cancer clinical trials. 
  • Osteopontin: regulation in tumor metastasis. 
  • Our cells get stressed too! Implications for human disease. 
  • Out-of-Pocket Costs, Financial Distress, and Underinsurance in Cancer Care. 
  • Outcomes after assisted reproductive technology in women with cancer: a systematic review and meta-analysis. 
  • Outcomes of a randomized controlled trial assessing a smartphone Application to reduce unmet needs among people diagnosed with CancEr (ACE). 
  • Outcomes of surgical revascularization for lower extremity arterial thromboembolism in patients with advanced malignancy. 
  • Outcomes research related to patient decision making in oncology. 
  • Outpatient percutaneous central venous access in cancer patients. 
  • Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial. 
  • Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. 
  • Ovarian vein thrombosis in oncology patients: CT detection and clinical significance. 
  • Overcoming obstacles in the design of cancer anorexia/weight loss trials. 
  • Overcoming recruitment challenges in palliative care clinical trials. 
  • Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. 
  • Overview of melanoma vaccines and promising approaches. 
  • Overview of spontaneous intraabdominal tumor hemorrhage: etiologies, imaging findings, and management. 
  • Oxygen for relief of dyspnea: what is the evidence? 
  • Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. 
  • Oxygen-Enhanced MRI Is a Major Advance in Tumor Hypoxia Imaging. 
  • P-value calculation for multistage phase II cancer clinical trials. 
  • P53, cell cycle control and apoptosis: implications for cancer. 
  • PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy. 
  • PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. 
  • PET/CT in cancer patient management. Commentary. 
  • PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. 
  • PI3K stimulates DNA synthesis and cell-cycle progression via its p55PIK regulatory subunit interaction with PCNA. 
  • PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. 
  • PIN1, the cell cycle and cancer. 
  • PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. 
  • PTEN loss in the continuum of common cancers, rare syndromes and mouse models. 
  • Paediatrics: Addressing the health burden of childhood cancer survivors - improvements are needed. 
  • Pain in cancer survivors. 
  • Pain in children: progress and challenges 
  • Pain regulation by non-neuronal cells and inflammation. 
  • Palliative Care Awareness Among Advanced Cancer Patients and Their Family Caregivers in Singapore. 
  • Palliative Care Use Among People Living With HIV and Cancer: An Analysis of the National Cancer Database (2004-2018). 
  • Palliative Care Version 1.2016. 
  • Palliative Performance Scale Score at 1 Week After Palliative Care Unit Admission is More Useful for Survival Prediction in Patients With Advanced Cancer in South Korea. 
  • Palliative care and oncology: integration leads to better care. 
  • Palliative care and oncology: integration leads to better care. 
  • Palliative care and the search for value in health reform. 
  • Palliative care for patients with hematologic malignancies: are we meeting patients' needs early enough? 
  • Palliative care, Version 1.2014. Featured updates to the NCCN Guidelines. 
  • Palliative care. 
  • Palliative care. Clinical practice guidelines in oncology. 
  • Palliative chemotherapy: oxymoron or misunderstanding? 
  • Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. 
  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. 
  • Pan-cancer analysis of whole genomes. 
  • Pan-cancer prognostic models of clinical outcomes: statistical exercise or clinical tools? 
  • Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. 
  • Papilloma of the choroid plexus in a Weimaraner dog. 
  • Paradoxical relationship between chromosomal instability and survival outcome in cancer. 
  • Parental perspectives on a behavioral health music intervention for adolescent/young adult resilience during cancer treatment: report from the children's oncology group. 
  • Parenting a child with cancer: a couple-based approach. 
  • Parenting concerns, quality of life, and psychological distress in patients with advanced cancer. 
  • Parenting while living with advanced cancer: A qualitative study. 
  • Partial Inferior Vena Cava Reconstruction with Cryopreserved Aortic Homograft Following Resection for Malignancy. 
  • Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). 
  • Participation of ATM, SMG1, and DDX5 in a DNA Damage-Induced Alternative Splicing Pathway. 
  • Particle therapy and treatment of cancer. 
  • Partner-delivered reflexology: effects on cancer pain and anxiety. 
  • Partner-guided cancer pain management at the end of life: a preliminary study. 
  • Partners empowered: a couple-based intervention for newly diagnosed cancer. 
  • Pathogenic Germline Variants in 10,389 Adult Cancers. 
  • Pathogenic mechanisms of vessel damage in vasculitis syndromes. 
  • Pathology Reporting of Gastric Endoscopic Resections: Recommendations From the International Collaboration on Cancer Reporting. 
  • Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology. 
  • Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care? 
  • Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. 
  • Patient and provider preferences for survivorship care plans. 
  • Patient experiences with communication about sex during and after treatment for cancer. 
  • Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. 
  • Patient symptoms and family coping. Predictors of hospice utilization patterns. 
  • Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. 
  • Patient-oncologist communication in advanced cancer: predictors of patient perception of prognosis. 
  • Patient-oncologist cost communication, financial distress, and medication adherence. 
  • Patient-provider communication about sexual concerns in cancer: a systematic review. 
  • Patient-reported distress as an early warning sign of unmet palliative care needs and increased healthcare utilization in patients with advanced cancer. 
  • Patient-reported outcome monitoring in a routine paediatric oncology setting: challenges and opportunities. 
  • Patient-reported outcomes as end points and outcome indicators in solid tumours. 
  • Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. 
  • Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. 
  • Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. 
  • Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients. 
  • Patient/Provider Discussions About Clinical Trial Participation and Reasons for Nonparticipation Among Adolescent and Young Adult Women with Cancer. 
  • Patients' Awareness of Advanced Disease Status, Psychological Distress and Quality of Life Among Patients With Advanced Cancer: Results From the APPROACH Study, India. 
  • Patients' understanding of oncology clinical endpoints: A literature review. 
  • Patients, caregivers, and clinicians differ in performance status ratings: Implications for pediatric cancer clinical trials. 
  • Patterns and predictors of clustered risky health behaviors among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Patterns of somatic mutation in human cancer genomes. 
  • Patterns of symptoms and functional impairments in children with cancer. 
  • Pearls collections: What we can learn about infectious disease and cancer. 
  • Pediatric Cancer in Northern Tanzania: Evaluation of Diagnosis, Treatment, and Outcomes. 
  • Pediatric Education Discharge Support Strategies for Newly Diagnosed Children With Cancer. 
  • Pediatric and Teen Ovarian Tissue Removed for Cryopreservation Contains Follicles Irrespective of Age, Disease Diagnosis, Treatment History, and Specimen Processing Methods. 
  • Pediatric cancer outcomes after the implementation of a residential hostel in Tanzania. 
  • Pediatric oncology nursing. 
  • Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. 
  • Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. 
  • Perceived quality of care and its associated factors among Chinese patients with advanced cancer: findings from the APPROACH study in Beijing. 
  • Perceived stigma and its correlates among Asian patients with advanced cancer: A multi-country APPROACH study. 
  • Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness. 
  • Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. 
  • Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. 
  • Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers. 
  • Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. 
  • Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH. 
  • Perifosine as a potential novel anti-telomerase therapy. 
  • Perifosine: update on a novel Akt inhibitor. 
  • Perioperative management of special populations: immunocompromised host (cancer, HIV, transplantation). 
  • Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? 
  • Peripheral neuropathy in children and adolescents treated for cancer. 
  • Personalized Cancer Follow-Up Care Pathways: A Delphi Consensus of Research Priorities. 
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 
  • Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. 
  • Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. 
  • Perspectives of Childhood Cancer Symptom-Related Distress: Results of the State of the Science Survey. 
  • Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. 
  • Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. 
  • Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. 
  • Pharmacogenomics in cancer therapy: is host genome variability important? 
  • Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. 
  • Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. 
  • Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. 
  • Pharmacokinetic and phase I evaluation of carboplatin in dogs. 
  • Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. 
  • Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. 
  • Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. 
  • Pharmacologic approaches to radiation protection. 
  • Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. 
  • Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response. 
  • Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. 
  • Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. 
  • Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. 
  • Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. 
  • Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. 
  • Phase I Study of Muscadine Grape Extract for Patients With Advanced Cancer. 
  • Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. 
  • Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. 
  • Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. 
  • Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. 
  • Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. 
  • Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. 
  • Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. 
  • Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. 
  • Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. 
  • Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid. 
  • Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors. 
  • Phase I participants' views of quality of life and trial participation burdens. 
  • Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. 
  • Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. 
  • Phase I studies of recombinant interferon-gamma. 
  • Phase I studies with the novel nucleoside analog gemcitabine. 
  • Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies. 
  • Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. 
  • Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. 
  • Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. 
  • Phase I study of mitomycin C and menadione in advanced solid tumors. 
  • Phase I study of pazopanib plus TH-302 in advanced solid tumors. 
  • Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer. 
  • Phase I study of recombinant human endostatin in patients with advanced solid tumors. 
  • Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. 
  • Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. 
  • Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. 
  • Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. 
  • Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. 
  • Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy. 
  • Phase I trial of interleukin-2 plus doxorubicin. 
  • Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. 
  • Phase I trial of pazopanib in patients with advanced cancer. 
  • Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. 
  • Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. 
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. 
  • Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. 
  • Phase II cancer clinical trials for biomarker-guided treatments. 
  • Phase II cancer clinical trials with heterogeneous patient populations. 
  • Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. 
  • Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. 
  • Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. 
  • Phosphorylated MED1 links transcription recycling and cancer growth. 
  • PhyloOncology: Understanding cancer through phylogenetic analysis. 
  • Physical activity in patients with advanced-stage cancer: a systematic review of the literature. 
  • Physical and psychological health in rare cancer survivors. 
  • Physical function in men and women with cancer. Effects of anemia and conditioning. 
  • Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. 
  • Physical therapy and chiropractic use among childhood cancer survivors with chronic disease: impact on health-related quality of life. 
  • Physician Experience and Attitudes Toward Addressing the Cost of Cancer Care. 
  • Physician allocation of Medicare resources for patients with advanced cancer. 
  • Physician and Patient and Caregiver Health Attitudes and Their Effect on Medicare Resource Allocation for Patients With Advanced Cancer. 
  • Physiological basis of fatigue. 
  • Physiological roles of the Ca2+/CaM-dependent protein kinase cascade in health and disease. 
  • Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. 
  • Phytochemicals and cancer risk: a review of the epidemiological evidence. 
  • Pills of PTEN? In and out for tumor suppression. 
  • Piloting a computer assisted telephone interview: the FUCHSIA Women's Study. 
  • Place of death for patients with cancer in the United States, 1999 through 2015: Racial, age, and geographic disparities. 
  • Plasma proteins as indices of response to nutritional therapy in cancer patients. 
  • Plasmonic assay for amplification-free cancer biomarkers detection in clinical tissue samples. 
  • Plasmonic nanoprobes: from chemical sensing to medical diagnostics and therapy. 
  • Platelet-rich plasma and peripheral nerve regeneration: a potential contraindication to its use after tumor excision. 
  • Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. 
  • Pleural fluid in infants and children. 
  • Point/counterpoint: we do not need randomized clinical trials to demonstrate the superiority of proton therapy. 
  • Polarity and stratification of the epidermis. 
  • Polarity in skin development and cancer. 
  • Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 
  • Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. 
  • Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. 
  • Polypharmacy in patients with advanced cancer and the role of medication discontinuation. 
  • Polypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer. 
  • Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. 
  • Population impact of mortality reduction: the effects of elimination of major causes of death on the 'saved' population. 
  • Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors. 
  • Position statement on Cancer Nursing's potential to reduce the growing burden of cancer across the world. 
  • Positron emission tomography in radiation treatment planning: the potential of metabolic imaging. 
  • Possible role of cell cycle-dependent morphology, geometry, and mechanical properties in tumor cell metastasis. 
  • Post-prenylation-processing enzymes as new targets in oncogenesis. 
  • Post-transcriptional regulation of MTA family by microRNAs in the context of cancer. 
  • Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey. 
  • Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. 
  • Practical Considerations for Integrating PET/CT into Radiation Therapy Planning. 
  • Practical approach to diagnostic CT combined with PET. 
  • Practical considerations in the nutritional management of the cancer patient. 
  • Practical radiation oncology for surgeons. 
  • Pre-diagnostic Sleep Duration and Sleep Quality in Relation to Subsequent Cancer Survival. 
  • Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients. 
  • Precision Medicine and PET-Computed Tomography in Pediatric Malignancies. 
  • Precision Medicine and PET/Computed Tomography: Challenges and Implementation. 
  • Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. 
  • Precision oncology: A primer for pediatric surgeons from the APSA cancer committee. 
  • Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. 
  • Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. 
  • Predicting Emergency Visits and Hospital Admissions During Radiation and Chemoradiation: An Internally Validated Pretreatment Machine Learning Algorithm. 
  • Predicting Persistent Opioid Use, Abuse, and Toxicity Among Cancer Survivors. 
  • Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE). 
  • Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. 
  • Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. 
  • Predicting the effect of temporal variations in PO2 on tumor radiosensitivity. 
  • Predicting the risk of bacteremia in childen with fever and neutropenia. 
  • Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer. 
  • Prediction of genome-wide DNA methylation in repetitive elements. 
  • Prediction of heating patterns of a microwave interstitial antenna array at various insertion depths. 
  • Predictive Value of Coronary Artery Calcium in Patients Receiving Computed Tomography Pulmonary Angiography for Suspected Pulmonary Embolism in the Emergency Department. 
  • Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. 
  • Predictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims. 
  • Predictors of Intervention Session Completion in a Randomized Clinical Trial of a Behavioral Cancer Pain Intervention. 
  • Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy. 
  • Predictors of acute and posttraumatic stress symptoms in parents following their child's cancer diagnosis. 
  • Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. 
  • Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. 
  • Preface. 
  • Preference for Aggressive End-of-Life Care among Advanced Cancer Patients in Wuhan, China: A Cross-Sectional Study. 
  • Preferences for end-of-life care among community-dwelling older adults and patients with advanced cancer: A discrete choice experiment. 
  • Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. 
  • Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. 
  • Preliminary results of a phase III trial of spontaneous animal tumors to heat and/or radiation: early normal tissue response and tumor volume influence on initial response. 
  • Premature release of data from clinical trials of ezetimibe. 
  • Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. 
  • Preparation for intrusive procedures using noninvasive techniques in children with cancer: state of the art vs. new trends. 
  • Preparation of peptide-loaded dendritic cells for cancer immunotherapy. 
  • Prevalence and Outcome of HIV-associated Malignancies Among HIV-infected Children Enrolled into Care at Kilimanjaro Christian Medical Center 2006 to 2014: A Hospital-based Retrospective Analytical Study. 
  • Prevalence and correlates of postdiagnosis initiation of complementary and alternative medicine among patients at a comprehensive cancer center. 
  • Prevalence and factors associated with diagnosed depression among hospitalized cancer patients with metastatic disease. 
  • Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. 
  • Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. 
  • Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. 
  • Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. 
  • Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. 
  • Prevention of chemotherapy and radiation toxicity with glutamine. 
  • Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care. 
  • Price of Cancer Care and Its Tax on Quality of Life. 
  • Primary care cancer control interventions including Latinos: a review. 
  • Primary isolated hepatosplenic sarcoidosis mimicking malignancy and causing symptomatic hypercalcaemia. 
  • Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. 
  • Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. 
  • Production of extracellular proteolytic enzymes by neoplastic and normal epithelial cells. 
  • Profile of cancer-related symptoms prior to chemotherapy. 
  • Profiles of Symptom Suffering and Functioning in Children and Adolescents Receiving Chemotherapy. 
  • Prognostic Communication Between Oncologists and Parents of Children With Advanced Cancer. 
  • Prognostic accuracy of Acute Physiology and Chronic Health Evaluation II scores in critically ill cancer patients. 
  • Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. 
  • Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. 
  • Prognostic awareness and its association with health outcomes in the last year of life. 
  • Prognostic value of serum carcinoembryonic antigen levels in patients who undergo lung transplantation. 
  • Programming human dendritic cells with mRNA. 
  • Programs for adult survivors of childhood cancer. 
  • Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 
  • Progressive sensory neuropathy in patients without carcinoma: a disorder with distinctive clinical and electrophysiological findings. 
  • Project PLACE: Enhancing community and academic partnerships to describe and address health disparities. 
  • Promoter hypermethylation profile of kidney cancer. 
  • Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602). 
  • Promoting Oncologist Well-Being to Foster Delivery of Ethical, High-Quality Cancer Care: Priorities for 2020 and Beyond. 
  • Promoting Strategies to Increase HPV Vaccination in the Pediatric Primary Care Setting. 
  • Promoting healthy lifestyles in older cancer survivors to improve health and preserve function. 
  • Promoting informed decision making: hormone replacement therapy. 
  • Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. 
  • Proper use and recognized role of TPN in the cancer patient. 
  • Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. 
  • Prophylaxis for venous thromboembolism: guidelines translated for the clinician. 
  • Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? 
  • Proportionate mortality among union members employed at three Texas refineries. 
  • Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. 
  • Prospective multicenter trial of esophageal Z-stent placement for malignant dysphagia and tracheoesophageal fistula. 
  • Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. 
  • Prospective thermal dosimetry: the key to hyperthermia's future. 
  • Prospective trial of a video educational tool for radiation oncology patients. 
  • Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. 
  • Prospects for the immunological management of lethal tumors. 
  • Protecting Confidentiality in Cancer Registry Data With Geographic Identifiers. 
  • Protecting the hedgerow: p53 and hedgehog pathway interactions. 
  • Protein Geranylgeranyltransferase Type 1 as a Target in Cancer. 
  • Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. 
  • Protein prenylation: unique fats make their mark on biology. 
  • Protocol for the isolation of CD8+ tumor-infiltrating lymphocytes from human tumors and their characterization by single-cell immune profiling and multiome. 
  • Providing patient education: impact on quantity and quality of family health history collection. 
  • Provision of spiritual support to patients with advanced cancer by religious communities and associations with medical care at the end of life. 
  • Pruritus in systemic disease: mechanisms and management. 
  • Psychological and behavioral approaches to cancer pain management. 
  • Psychological approaches to understanding and treating disease-related pain. 
  • Psychometric and clinical assessment of the 13-item reduced version of the fatigue scale-adolescent instrument. 
  • Psychometric characteristics of the Muslim Religiosity Scale in Iranian patients with cancer. 
  • Psychometric evaluation and design of patient-centered communication measures for cancer care settings. 
  • Psychometric evaluation of the patient satisfaction with logistical aspects of navigation (PSN-L) scale using item response theory. 
  • Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study. 
  • Psychoneuroimmunology and the faith factor. 
  • Psychosocial functioning in parents of adult survivors of childhood cancer. 
  • Psychosocial issues in cancer pain. 
  • Psychosocial stress moderates the relationship of cancer history with natural killer cell activity. 
  • Psychosomatic symptoms in parents 2 years after the death of a child with cancer. 
  • Public education and cancer control. 
  • Public response to cost-quality tradeoffs in clinical decisions. 
  • Pulmonary function abnormalities in long-term survivors of childhood cancer. 
  • Pulsatile blood flow effects on temperature distribution and heat transfer in rigid vessels. 
  • Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. 
  • Putative biomarkers for predicting tumor sample purity based on gene expression data. 
  • Qualitative Analysis of Palliative Care for Pediatric Patients With Cancer at Bugando Medical Center: An Evaluation of Barriers to Providing End-of-Life Care in a Resource-Limited Setting. 
  • Quality Measurement and Pay for Performance. 
  • Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. 
  • Quality measures for palliative care in patients with cancer: a systematic review. 
  • Quality of Life and Impact of Cancer: Differences in Rural and Nonrural Non-Hodgkin's Lymphoma Survivors. 
  • Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials. 
  • Quality of palliative care for patients with advanced cancer in a community consortium. 
  • Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial. 
  • Quantitation of tumor uptake with molecular breast imaging. 
  • Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms. 
  • Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. 
  • Quantitative approaches to clinical diagnosis of cancer in elderly patients. 
  • Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs. 
  • Quantitative imaging in oncology patients: Part 1, radiology practice patterns at major U.S. cancer centers. 
  • Quantitative imaging in oncology patients: Part 2, oncologists' opinions and expectations at major U.S. cancer centers. 
  • Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. 
  • Quintuple-modality (SERS-MRI-CT-TPL-PTT) plasmonic nanoprobe for theranostics. 
  • REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks. 
  • RIP3: a molecular switch for necrosis and inflammation. 
  • RNA regulons in cancer and inflammation. 
  • RNA transfected dendritic cells as cancer vaccines. 
  • RNA-Based Vaccines in Cancer Immunotherapy. 
  • RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. 
  • RNA-transfected dendritic cells in cancer immunotherapy. 
  • ROS production and angiogenic regulation by macrophages in response to heat therapy. 
  • RTOG quality assurance guidelines for clinical trials using hyperthermia administered by ultrasound. 
  • RTOG quality assurance guidelines for clinical trials using hyperthermia for deep-seated malignancy. 
  • RTOG quality assurance guidelines for clinical trials using hyperthermia. 
  • RTOG quality assurance guidelines for interstitial hyperthermia. 
  • Racial and Ethnic Disparities in Coexisting Cancer and COVID-19 Mortality. 
  • Racial and ethnic disparities in cancer pain management. 
  • Racial differences in use of cancer prevention services among older Americans. 
  • Racial disparities in cancer care in the Veterans Affairs health care system and the role of site of care. 
  • Racial, Ethnic, and Socioeconomic Discrepancies in Opioid Prescriptions Among Older Patients With Cancer. 
  • Radiation Biology for Radiation Oncology Residents: An Alternative View. 
  • Radiation Dose and Volume to the Pancreas and Subsequent Risk of Diabetes Mellitus: A Report from the Childhood Cancer Survivor Study. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Cancer Prevention and Control Committee. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Tumor Utilization Committee. 
  • Radiation injury of the kidney. 
  • Radiation risks from diagnostic computed tomography in the emergency department. 
  • Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study. 
  • Radiation-Mediated Tumor Growth Inhibition Is Significantly Enhanced with Redox-Active Compounds That Cycle with Ascorbate. 
  • Radical irradiation of extracranial oligometastases. 
  • Radiobiological basis of SBRT and SRS. 
  • Radiogenomics: what it is and why it is important. 
  • Radioimmunotherapy with alpha-particle emitting radionuclides. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. 
  • Radiotherapy Treatment Planning in the Age of AI: Are We Ready Yet? 
  • Radiotherapy in the Barwon South Western Region: a rural perspective. 
  • Raising the bar: how HIF-1 helps determine tumor radiosensitivity. 
  • Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance. 
  • Randomized trial in malignant biliary obstruction: plastic vs partially covered metal stents. 
  • Rank tests for clustered survival data when dependent subunits are randomized. 
  • Rank tests for matched survival data. 
  • Rapid determination of oxygen saturation and vascularity for cancer detection. 
  • Rare codons regulate KRas oncogenesis. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. 
  • Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies. 
  • Re-setting the biologic rationale for thermal therapy. 
  • Re: initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. 
  • Reach out to enhance wellness home-based diet-exercise intervention promotes reproducible and sustainable long-term improvements in health behaviors, body weight, and physical functioning in older, overweight/obese cancer survivors. 
  • Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. 
  • Reactive oxygen species: from health to disease. 
  • Real-World Approaches to Quality Improvement in Oncology. 
  • Real-time MRI-guided hyperthermia treatment using a fast adaptive algorithm. 
  • Real-time rectilinear 3-D ultrasound using receive mode multiplexing. 
  • Real-time rectilinear volumetric imaging. 
  • Real-time tumor localization with single x-ray projection at arbitrary gantry angles using a convolutional neural network (CNN). 
  • Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans. 
  • Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015. 
  • Realizing the opportunities of genomics in health care. 
  • Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. 
  • Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. 
  • Recent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy. 
  • Recent areas of development for dendritic cell vaccines. 
  • Recent clinical progress in virus-based therapies for cancer. 
  • Recent developments in therapeutic cancer vaccines. 
  • Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. 
  • Recent trends in US mortality in early and middle adulthood: racial/ethnic disparities in inter-cohort patterns. 
  • Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer. 
  • Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. 
  • Recombinant Poliovirus for Cancer Immunotherapy. 
  • Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence. 
  • Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. 
  • Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. 
  • Recommendations on the use of 18F-FDG PET in oncology. 
  • Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group. 
  • Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. 
  • Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events. 
  • Reconstruction with vascularized composite tissue in patients with excessive injury following surgery and irradiation. 
  • Recovery and survival from aging-associated diseases. 
  • Recruiting participants to cancer prevention clinical trials: lessons from successful community oncology networks. 
  • Recruitment strategies and rates of a multi-site behavioral intervention for adolescents and young adults with cancer. 
  • Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers. 
  • Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. 
  • Reducing bias in cancer research: application of propensity score matching. 
  • Reducing central venous catheter-related bloodstream infections in children with cancer. 
  • Reducing patient eligibility criteria in cancer clinical trials. 
  • Reducing the global cancer burden among young adults. 
  • Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop. 
  • Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. 
  • Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. 
  • Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. 
  • Refinement of treatment setup and target localization accuracy using three-dimensional cone-beam computed tomography for stereotactic body radiotherapy. 
  • Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. 
  • Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan. 
  • Regulation of HIF-1alpha stability through S-nitrosylation. 
  • Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome. 
  • Regulation of inflammation in the adipose tissue in cancer cachexia: effect of exercise. 
  • Regulation of protein kinase C and role in cancer biology. 
  • Regulator of G-protein signaling (RGS) proteins in cancer biology. 
  • Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Relation of comorbidities and patient navigation with the time to diagnostic resolution after abnormal cancer screening. 
  • Relations of Current and Past Cancer with Severe Outcomes among 104,590 Hospitalized COVID-19 Patients: The COVID EHR Cohort at the University of Wisconsin. 
  • Relations of meaning in life and sense of coherence to distress in cancer patients: a meta-analysis. 
  • Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. 
  • Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. 
  • Relationship between anxiety level and radiological investigation. Comparison among different diagnostic imaging exams in a prospective single-center study. 
  • Relationship between cancer patients' predictions of prognosis and their treatment preferences. 
  • Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. 
  • Relationship between the generalized equivalent uniform dose formulation and the Poisson statistics-based tumor control probability model. 
  • Relationship between use of electronic health record features and health care quality: results of a statewide survey. 
  • Relationship of cancer and aging. 
  • Relationship of external influence to parental distress in decision making regarding children with a life-threatening illness. 
  • Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. 
  • Relaxation techniques in children with cancer: the nurse's role. 
  • Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. 
  • Relevance of religion and spirituality in German patients with chronic diseases. 
  • Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. 
  • Religion and medicine IV: religion, physical health, and clinical implications. 
  • Religiosity and Beliefs About the Transmission of Cancer, Chemotherapy, and Radiation Through Physical Contact in Saudi Arabia. 
  • Religious activity and depression among community-dwelling elderly persons with cancer: the moderating effect of race. 
  • Remembering Our True North: Realizing Exceptional Cancer Quality in an Era of Exceptional Change. 
  • Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. 
  • Replicating dissemination and identifying mechanisms of implementation of an empirically supported treatment. 
  • Reply to Comment on "Use of Patient Registries and Administrative Datasets for the Study of Pediatric Cancer". 
  • Reply to D.A. Palma. 
  • Reply to J.J. Tao et al. 
  • Reply to L.K. Mell et al. 
  • Reply to T.H. Oo. 
  • Reply to the Importance of a collaborative health-related quality of life measurement strategy for adolescents and young adults with cancer. 
  • Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. 
  • Reply. 
  • Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding. 
  • Report and abstracts of the sixth international workshop on human chromosome 1 mapping 2000. Iowa City, Iowa, USA. 30 September-3 October 2000. 
  • Report of the fifth international workshop on human chromosome 1 mapping 1999. 
  • Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. 
  • Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. 
  • Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. 
  • Repositioning metformin for cancer prevention and treatment. 
  • Reprogramming of cellular metabolic pathways by human oncogenic viruses. 
  • Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. 
  • Rescuing imperfect antigens for immuno-oncology. 
  • Research challenges in adolescent and young adult cancer survivor research. 
  • Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? 
  • Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia. 
  • Resident education in the era of patient safety: a nationwide analysis of outcomes and complications in resident-assisted oncologic surgery. 
  • Resident memory T cells in tumor-distant tissues fortify against metastasis formation. 
  • Resilience in older adults with cancer: A scoping literature review. 
  • Resolved: psychosocial interventions can improve clinical outcomes in organic disease (pro). 
  • Respiratory Capacity and Reserve Predict Cell Sensitivity to Mitochondria Inhibitors: Mechanism-Based Markers to Identify Metformin-Responsive Cancers. 
  • Respiratory signal prediction based on adaptive boosting and multi-layer perceptron neural network. 
  • Response rates to a mailed survey targeting childhood cancer survivors: a comparison of conditional versus unconditional incentives. 
  • Response to 'Supra-linear dose-response in the A-bomb study'. 
  • Response to treatment series: part 1 and introduction, measuring tumor response--challenges in the era of molecular medicine. 
  • Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy. 
  • Retinal manifestations of oncologic and hematologic conditions. 
  • Retrospective analysis of cancer survival across South-Western Victoria in Australia. 
  • Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. 
  • Review of chronic graft-versus-host disease in children after allogeneic stem cell transplantation: nursing perspective. 
  • Review of electronic patient-reported outcomes systems used in cancer clinical care. 
  • Review of radiation issues for computed tomography. 
  • Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. 
  • Revisiting patient-related barriers to cancer pain management in the context of the US opioid crisis. 
  • Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. 
  • Rewiring of glycolysis in cancer cell metabolism. 
  • Rheumatologic manifestations of cancer. 
  • Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. 
  • Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. 
  • Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors. 
  • Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy. 
  • Rigid and Deformable Image Registration for Radiation Therapy: A Self-Study Evaluation Guide for NRG Oncology Clinical Trial Participation. 
  • Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors. 
  • Risk and impact of pulmonary complications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. 
  • Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. 
  • Risk assessment in oncology clinical practice. From risk factors to risk models. 
  • Risk assessment models to estimate cancer probabilities. 
  • Risk communication: coping with imperfection. 
  • Risk factors for cancer. 
  • Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. 
  • Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. 
  • Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies. 
  • Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. 
  • Risk factors for postoperative spinal wound infections after spinal decompression and fusion surgeries. 
  • Risk factors for suicide among older adults with cancer. 
  • Risk of mortality in patients with cancer who experience febrile neutropenia. 
  • Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers. 
  • Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers. 
  • Risk of suicide among individuals with a history of childhood cancer. 
  • Risk perception measures' associations with behavior intentions, affect, and cognition following colon cancer screening messages. 
  • Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up. 
  • Risky feelings: why a 6% risk of cancer does not always feel like 6%. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • Role of G12 proteins in oncogenesis and metastasis. 
  • Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. 
  • Role of deformable cancer cells on wall shear stress-associated-VEGF secretion by endothelium in microvasculature. 
  • Role of dendritic cell metabolic reprogramming in tumor immune evasion. 
  • Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases. 
  • Role of financial toxicity in perpetuating health disparities. 
  • Role of incipient angiogenesis in cancer metastasis. 
  • Role of pain medications, consultants, and other services in improved pain control of elderly adults with cancer in geriatric evaluation and management units. 
  • Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. 
  • Role of transforming growth factor Beta in human cancer. 
  • Role of transforming growth factor beta in human disease. 
  • Role of transforming growth factor-beta superfamily signaling pathways in human disease. 
  • Roles for the type III TGF-beta receptor in human cancer. 
  • Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment? 
  • Routine screening for depression in radiation oncology patients. 
  • Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. 
  • Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors. 
  • SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors. 
  • SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. 
  • SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. 
  • SOD enzymes and their mimics in cancer: pro vs anti-odixative mode of action-part II. 
  • SOD enzymes and their mimics in cancer: pro vs anti-oxidative mode of action. Part I. 
  • STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. 
  • SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases. 
  • Safe administration of hyperbaric oxygen after bleomycin: a case series of 15 patients. 
  • Safe handling: implementing hazardous drug precautions 
  • Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. 
  • Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. 
  • Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. 
  • Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials. 
  • Safety and technique of ferumoxytol administration for MRI. 
  • Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. 
  • Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. 
  • Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice. 
  • Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]. 
  • Sample type bias in the analysis of cancer genomes. 
  • Sampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer, and bulimia nervosa. 
  • Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. 
  • Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. 
  • Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. 
  • Screening adult survivors of childhood cancer with the distress thermometer: a comparison with the SCL-90-R. 
  • Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer. 
  • Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. 
  • Screening for distress in cancer patients: the NCCN rapid-screening measure. 
  • Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. 
  • Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis. 
  • Second moment method for evaluating human health risks from groundwater contaminated by trichloroethylene. 
  • Second primary cancers in survivors of childhood cancer. 
  • Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. 
  • Seeing into cells. The promise of in vivo molecular imaging in oncology. 
  • Selection bias, phase II trials, and the FDA accelerated approval process. 
  • Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. 
  • Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. 
  • Self-Reported Sexual Function Measures Administered to Female Cancer Patients: A Systematic Review, 2008-2014. 
  • Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection 
  • Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUDa). 
  • Self-efficacy and adjustment in cancer patients: a preliminary report. 
  • Self-hypnosis as antiemetic therapy in children receiving chemotherapy. 
  • Self-reported financial burden and satisfaction with care among patients with cancer. 
  • Semaphorin 7A modulates cytokine-induced memory-like responses by human natural killer cells. 
  • Semiparametric Bayes multiple testing: Applications to tumor data. 
  • Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. 
  • Senior adult oncology clinical practice guidelines in oncology. 
  • Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . 
  • Senior adult oncology. 
  • Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment. 
  • Sequential clinical trials in cancer research. 
  • Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56δ stabilizes its antiapoptotic activity. 
  • Serial labeling index determination as a predictor of response in human solid tumors. 
  • Serine, glycine and one-carbon units: cancer metabolism in full circle. 
  • Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. 
  • Sex and race specific mortality differentials in multiple cause of death data. 
  • Sex differences in oncogenic mutational processes. 
  • Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS®). 
  • Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. 
  • Shared care of adult survivors of childhood cancers. 
  • Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy. 
  • Shortened telomere length is associated with increased risk of cancer: a meta-analysis. 
  • Should interstitial thermometry be used for deep hyperthermia? 
  • Should modulation of p50 be a therapeutic target in the critically ill? 
  • Should the presence of carcinogens in breast milk discourage breast feeding? 
  • Shrinkage-based diagonal discriminant analysis and its applications in high-dimensional data. 
  • Sickness behavior clustering in children with cancer. 
  • Side population cells in human cancers. 
  • SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. 
  • Signaling by the transforming growth factor-beta receptors. 
  • Signatures of neutral evolution in exponentially growing tumors: A theoretical perspective. 
  • Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. 
  • Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. 
  • Simulation techniques in hyperthermia treatment planning. 
  • Simultaneous 4D-CBCT reconstruction with sliding motion constraint. 
  • Simultaneous detection of the tumor suppressor FHIT gene and protein using the multi-functional biochip. 
  • Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors. 
  • Six-Year Checkup: Narrowing the Scope of Practical Radiation Oncology. 
  • Skp2 regulates Myc protein stability and activity. 
  • Sleep, emotional distress, and physical health in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Sleep-wake functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS(®)). 
  • Slip-sliding away: serial changes and homoplasy in repeat number in the Drosophila yakuba homolog of human cancer susceptibility gene BRCA2. 
  • Slogans and donor pages of cancer centres: do they convey discordant messages? 
  • Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Social Media: Support for Survivors and Young Adults With Cancer 
  • Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. 
  • Socio-Economic and Rural-Urban Differences in Healthcare and Catastrophic Health Expenditure Among Cancer Patients in China: Analysis of the China Health and Retirement Longitudinal Study. 
  • Socio-economic inequalities in suffering at the end of life among advanced cancer patients: results from the APPROACH study in five Asian countries. 
  • Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. 
  • Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. 
  • Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study. 
  • Solidifying roles, responsibilities, and the process of navigation across the continuum of cancer care: The Professional Oncology Navigation Task Force. 
  • Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. 
  • Somatostatin and the treatment of cancer. 
  • Sounding out the hidden data: A concise review of deep learning in photoacoustic imaging. 
  • Spatial Moran models, II: cancer initiation in spatially structured tissue. 
  • Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. 
  • Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. 
  • Special techniques in diagnostic electron microscopy. 
  • Specialized palliative care services are associated with improved short- and long-term caregiver outcomes. 
  • Specialty care for adult survivors of childhood cancer. 
  • Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. 
  • Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development. 
  • Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. 
  • Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. 
  • Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. 
  • Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. 
  • SplicerAV: a tool for mining microarray expression data for changes in RNA processing. 
  • Spontaneous and treatment-induced cancer rejection in humans. 
  • Spontaneous tumor cell killing by human blood monocytes and human peritoneal macrophages: lack of alteration by endotoxin or quenchers of reactive oxygen species. 
  • Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care. 
  • Stability of temperatures during hyperthermia treatments. 
  • Stakeholder-informed conceptual framework for financial burden among adolescents and young adults with cancer. 
  • Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. 
  • Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. 
  • Standards for palliative care delivery in oncology settings. 
  • Standards, Guidelines, and Quality Measures for Successful Specialty Palliative Care Integration Into Oncology: Current Approaches and Future Directions. 
  • State-of-the-art of regulatory dendritic cells in cancer. 
  • Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. 
  • Statins and cancer risk: what do we know and where do we go from here? 
  • Statistical aspect of translational and correlative studies in clinical trials. 
  • Statistical challenges in preprocessing in microarray experiments in cancer. 
  • Statistical inference for cancer trials with treatment switching. 
  • Statistical issues and advances in cancer precision medicine research. 
  • Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials. 
  • Statistical issues in translational cancer research. 
  • Steady-state fluorescence imaging of neoplasia. 
  • Stem cell factor is a potent synergistic factor in hematopoiesis. 
  • Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. 
  • Stereotactic body radiotherapy treatment of extracranial metastases. 
  • Stereotactic body radiotherapy: a critical review for nonradiation oncologists. 
  • Stimulation of clonal tumor cell growth in vitro by inhibiting the serum polyamine oxidase activity. 
  • Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. 
  • Strand-specific mismatch repair in mammalian cells. 
  • Strategies for Referring Cancer Patients in a Smoking Cessation Program. 
  • Strategies for optimizing the response of cancer and normal tissues to radiation. 
  • Strength of accumulating evidence and data monitoring committee decision making. 
  • Striving to improve patient-reported outcomes for cancer survivors as the war wages on. 
  • Stroke impact on mortality and psychologic morbidity within the Childhood Cancer Survivor Study. 
  • Stromelysin-3 suppresses tumor cell apoptosis in a murine model. 
  • Structural adaptation and heterogeneity of normal and tumor microvascular networks. 
  • Structural adaptation of normal and tumour vascular networks. 
  • Structural and reliability analysis of a patient satisfaction with cancer-related care measure: a multisite patient navigation research program study. 
  • Structural basis of Rev1-mediated assembly of a quaternary vertebrate translesion polymerase complex consisting of Rev1, heterodimeric polymerase (Pol) ζ, and Pol κ. 
  • Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. 
  • Studies of tumor metabolism--II. Mössbauer spectroscopy of 57Co-bleomycin. 
  • Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). 
  • Study design and methods for the pilot study of muscadine grape extract supplement to improve fatigue among older adult cancer survivors (FOCUS) trial. 
  • Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. 
  • Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. 
  • Studying cancer in minorities: a look at the numbers. 
  • Studying the influence of angiogenesis in in vitro cancer model systems. 
  • Subjective Toxicity Profiles of Children in Treatment for Cancer: A New Guide to Supportive Care? 
  • Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor. 
  • Subxiphoid pericardiotomy in the diagnosis and management of large pericardial effusions associated with malignancy. 
  • Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. 
  • Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. 
  • Sudden death in cancer patients receiving lithium. 
  • Suicide risk among cancer survivors: Head and neck versus other cancers. 
  • Suicide risk following a new cancer diagnosis among Veterans in Veterans Health Administration care. 
  • Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. 
  • Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. 
  • Summing it up: an integrative review of studies of cancer survivorship care plans (2006-2013). 
  • Supplemental security income and social security disability insurance coverage among long-term childhood cancer survivors. 
  • Supporting cancer family caregivers: How can frontline oncology clinicians help? 
  • Surface-enhanced Raman scattering for cancer diagnostics: detection of the BCL2 gene. 
  • Surgery Scheduling in a Crisis: Effect on Cancer Patients. 
  • Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. 
  • Surrogate markers in antiangiogenesis clinical trials. 
  • Surrogate markers of effective anti-tumor immunity. 
  • Surrogate markers of response to cancer immunotherapy. 
  • Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. 
  • Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. 
  • Survival of human papillomavirus-associated cancers: Filling in the gaps. 
  • Survivor profiles predict health behavior intent: the Childhood Cancer Survivor Study. 
  • Survivor typologies predict medical surveillance participation: the childhood cancer survivor study. 
  • Survivors of childhood cancer and their guardians. 
  • Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. 
  • Survivors of childhood cancer in the United States: prevalence and burden of morbidity. 
  • Survivors of childhood cancer: an Australian audit of vaccination status after treatment. 
  • Survivorship after childhood, adolescent, and young adult cancer. 
  • Survivorship care plans in research and practice. 
  • Survivorship care plans: is there buy-in from community oncology providers? 
  • Survivorship navigation outcome measures: a report from the ACS patient navigation working group on survivorship navigation. 
  • Survivorship, Version 1.2021. 
  • Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Survivorship: childhood cancer survivors. 
  • Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program. 
  • Sustainability of cancer registration in the Kilimanjaro Region of Tanzania--a qualitative assessment. 
  • Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. 
  • Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. 
  • Symptom Communication Preferences and Communication Barriers for Young Adult Cancer Survivors and Their Health Care Providers. 
  • Symptom Distress: Implementation of Palliative Care Guidelines to Improve Pain, Fatigue, and Anxiety in Patients With Advanced Cancer. 
  • Symptom clusters in children with cancer. 
  • Symptom experiences of children and adolescents with cancer. 
  • Symptom management in the elderly cancer patient: fatigue, pain, and depression. 
  • Symptom management research in children with cancer. 
  • Symptom prevalence and physiologic biomarkers among adolescents using a mobile phone intervention following hematopoietic stem cell transplantation. 
  • Synergistic effects of hyperoxic gas breathing and reduced oxygen consumption on tumor oxygenation: a theoretical model. 
  • Synthesis and biological evaluation of largazole zinc-binding group analogs. 
  • Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. 
  • Synthesis, characterization, and functionalization of gold nanoparticles for cancer imaging. 
  • Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. 
  • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. 
  • System for High-Intensity Evaluation During Radiation Therapy (SHIELD-RT): A Prospective Randomized Study of Machine Learning-Directed Clinical Evaluations During Radiation and Chemoradiation. 
  • System-Level Health-Care Integration and the Costs of Cancer Care Across the Disease Continuum. 
  • Systematic Analysis of Splice-Site-Creating Mutations in Cancer. 
  • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. 
  • Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. 
  • Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. 
  • Systematic review and consensus definitions for standardised endpoints in perioperative medicine: postoperative cancer outcomes. 
  • Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. 
  • Systematic review of financial burden assessment in cancer: Evaluation of measures and utility among adolescents and young adults and caregivers. 
  • Systemic Therapy Decision Making in Advanced Cancer: A Qualitative Analysis of Patient-Oncologist Encounters. 
  • Systemic anti-tumour effects of local thermally sensitive liposome therapy. 
  • T cell metabolic fitness in antitumor immunity. 
  • T cell stemness and dysfunction in tumors are triggered by a common mechanism. 
  • T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. 
  • T2-weighted four dimensional magnetic resonance imaging with result-driven phase sorting. 
  • TGF-β superfamily co-receptors in cancer. 
  • TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology. 
  • Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. 
  • Tailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer. 
  • Tailoring cognitive-behavioral treatment for cancer pain. 
  • Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland. 
  • Targeted Therapy and Immunosuppression in the Tumor Microenvironment. 
  • Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. 
  • Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. 
  • Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. 
  • Targeted inhibition of VEGF receptor 2: an update on ramucirumab. 
  • Targeted nanotechnology for cancer imaging. 
  • Targeted therapies for cancer 2004. 
  • Targeted therapy using alpha emitters. 
  • Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. 
  • Targeting Fluorescent Nanodiamonds to Vascular Endothelial Growth Factor Receptors in Tumor. 
  • Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. 
  • Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. 
  • Targeting RNA in mammalian systems with small molecules. 
  • Targeting RNA with small molecules: from fundamental principles towards the clinic. 
  • Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. 
  • Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs. 
  • Targeting cell surface F1F0 ATP synthase in cancer therapy. 
  • Targeting depression interviewing. 
  • Targeting phosphorylation of eukaryotic initiation factor-2α to treat human disease. 
  • Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. 
  • Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. 
  • Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients. 
  • Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. 
  • Targeting the endothelium in cancer--the importance of the interaction of hemostatic mechanisms and the vascular wall for tumor growth and angiogenesis. 
  • Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition. 
  • Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. 
  • Targeting the molecular effects of a hypoxic tumor microenvironment. 
  • Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. 
  • Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. 
  • Technology evaluation: BLP-25, Biomira Inc. 
  • Technology evaluation: ISIS-2503, Isis Pharmaceuticals. 
  • Technology evaluation: Theratope, Biomira Inc. 
  • Technology evaluation: gene therapy (IL-2), Valentis Inc. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. 
  • Telomerase, cell immortality, and cancer. 
  • Telomere Attrition in Childhood Cancer Survivors. 
  • Telomere structure and maintenance gene variants and risk of five cancer types. 
  • Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes. 
  • Temperature matters! And why it should matter to tumor immunologists. 
  • Temperature sensitive peptides: engineering hyperthermia-directed therapeutics. 
  • Temporal Trends and Predictors of Opioid Use Among Older Patients With Cancer. 
  • Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. 
  • Temporal trends in U. S. multiple cause of death mortality data: 1968 to 1977. 
  • Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. 
  • Testing hypotheses derived from the Roy Adaptation Model. 
  • Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. 
  • The "Inside" Story on Tumor-Expressed PD-L1. 
  • The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. 
  • The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. 
  • The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. 
  • The Adolescent and Young Adult (AYA) Horizon Study: An AYA Cancer Survivorship Cohort. 
  • The Adolescent and Young Adult with Cancer: A Developmental Life Course Perspective. 
  • The Affordable Care Act and suicide incidence among adults with cancer. 
  • The Affordable Care Act's Medicaid Expansion and Impact Along the Cancer-Care Continuum: A Systematic Review. 
  • The Bird's Nest Filter. An alternative to long-term oral anticoagulation in patients with advanced malignancies. 
  • The Burden of Polypharmacy in Patients Near the End of Life. 
  • The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. 
  • The Cancer Genetics Network: recruitment results and pilot studies. 
  • The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy. 
  • The Complex Integration of T-cell Metabolism and Immunotherapy. 
  • The DNA damage response: implications for tumor responses to radiation and chemotherapy. 
  • The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice. 
  • The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. 
  • The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition. 
  • The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress. 
  • The Global Burden of Cancer 2013. 
  • The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. 
  • The IAEA's activities in radiological protection in digital imaging. 
  • The Immune Landscape of Cancer. 
  • The Impact of Health Delivery Integration on Cancer Outcomes. 
  • The Impact of Optimism on Cancer-Related and Postsurgical Cancer Pain: A Systematic Review. 
  • The Importance of Cancer Screening. 
  • The Influence of Patient-Provider Language Concordance in Cancer Care: Results of the Hispanic Outcomes by Language Approach (HOLA) Randomized Trial. 
  • The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer. 
  • The Lambert-Eaton myasthenic syndrome. 
  • The Landscape of Cell and Gene Therapies for Solid Tumors. 
  • The Level of Self-Care Measures for Everyday Life in Persons Who Received Chemotherapy. 
  • The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. 
  • The Molecular Link from Diet to Cancer Cell Metabolism. 
  • The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. 
  • The NF1 gene revisited - from bench to bedside. 
  • The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. 
  • The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. 
  • The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond. 
  • The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. 
  • The Oncology Geriatric Education Retreat: commentary and conclusions. 
  • The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. 
  • The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma. 
  • The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. 
  • The RNAissance period. 
  • The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic. 
  • The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients. 
  • The Skp2 Pathway: A Critical Target for Cancer Therapy. 
  • The Surprise Question and Identification of Palliative Care Needs among Hospitalized Patients with Advanced Hematologic or Solid Malignancies. 
  • The Translational Research Working Group developmental pathway for image-based assessment modalities. 
  • The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. 
  • The Valley of Death in anticancer drug development: a reassessment. 
  • The Warburg Effect: How Does it Benefit Cancer Cells? 
  • The Weak Link: Optimization of the Ligand-Nanoparticle Interface To Enhance Cancer Cell Targeting by Polymer Micelles. 
  • The accuracy of predicting survival in individual patients with cancer. 
  • The acquired immunodeficiency syndrome in intravenous drug abusers and patients with a sexual risk: clinical and postmortem comparisons. 
  • The application of monoclonal antibodies in the cytologic evaluation of tumors. 
  • The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer. 
  • The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies. 
  • The association between oral health and general health and quality of life in older male cancer patients. 
  • The association between social support and chemotherapy-related toxicity in older patients with cancer. 
  • The association between waist circumference and risk of mortality considering body mass index in 65- to 74-year-olds: a meta-analysis of 29 cohorts involving more than 58 000 elderly persons. 
  • The association of age, literacy, and race on completing patient-reported outcome measures in pediatric oncology. 
  • The association of self-blame with treatment preferences in a multi-country cohort of advanced cancer patients from the APPROACH study. 
  • The benefit of prevention: engaging the public through strategic collaborations. 
  • The biology of tobacco and nicotine: bench to bedside. 
  • The cancer aging interface: a research agenda. 
  • The cancer and leukemia group B cancer in the elderly committee: addressing a major cancer need. 
  • The cancer is over, now what?: Understanding risk, changing outcomes. 
  • The cancer stem cell hypothesis: failures and pitfalls. 
  • The case against independent monitoring committees. 
  • The challenge of measuring intra-individual change in fatigue during cancer treatment. 
  • The challenge of systematic reviews of diagnostic and staging studies in cancer. 
  • The clinical course of pulmonary embolism. 
  • The concurrent chemoradiation paradigm--general principles. 
  • The consequences of enhanced cell-autonomous glucose metabolism. 
  • The control and execution of programmed cell death: an update. 
  • The convergence of cancer prevention and therapy in early-phase clinical drug development. 
  • The corporate presence at oncology meetings. 
  • The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. 
  • The cost-effectiveness of treating childhood cancer in 4 centers across sub-Saharan Africa. 
  • The crosstalk between autophagy and apoptosis: where does this lead? 
  • The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. 
  • The data center of the European Organization for Research on Treatment of Cancer. 
  • The design of a heterocellular 3D architecture and its application to monitoring the behavior of cancer cells in response to the spatial distribution of endothelial cells. 
  • The development and testing of aptamers for cancer. 
  • The dichotomy of p53 regulation by noncoding RNAs. 
  • The dual role of IL-10. 
  • The economic burden of anemia in cancer patients receiving chemotherapy. 
  • The economic impact of HPV vaccines: not just cervical cancer. 
  • The economics of febrile neutropenia: implications for the use of colony-stimulating factors. 
  • The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. 
  • The effect of duration of intervention and locus of control on dietary change. 
  • The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. 
  • The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. 
  • The effect of pre-transplant pain and chronic disease self-efficacy on quality of life domains in the year following hematopoietic stem cell transplantation. 
  • The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. 
  • The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. 
  • The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors. 
  • The effects of nutrition and treatment of cancer on host immunocompetence. 
  • The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors. 
  • The engine driving the ship: metabolic steering of cell proliferation and death. 
  • The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. 
  • The evolving metabolic landscape of chromatin biology and epigenetics. 
  • The evolving role of gene-based treatment in surgery. 
  • The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? 
  • The experiences of older caregivers of cancer patients following hospital discharge. 
  • The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. 
  • The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians. 
  • The functions and regulation of the PTEN tumour suppressor: new modes and prospects. 
  • The future of biology in driving the field of hyperthermia. 
  • The global need for education on cancer health. 
  • The imaging viewpoint: how imaging affects determination of progression-free survival. 
  • The immunologic constant of rejection. 
  • The impact of anaemia and its treatment on employee disability and medical costs. 
  • The impact of cellular metabolism on chromatin dynamics and epigenetics. 
  • The impact of goal adjustment and caregiver burden on psychological distress among caregivers of cancer patients. 
  • The impact of item order on ratings of cancer risk perception. 
  • The impact of the Patient Protection and Affordable Care Act on insurance coverage and cancer-directed treatment in HIV-infected patients with cancer in the United States. 
  • The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. 
  • The impact of tumor physiology on camptothecin-based drug development. 
  • The implications of IDH mutations for cancer development and therapy. 
  • The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. 
  • The importance of identifying and validating prognostic factors in oncology. 
  • The importance of the person/patient/survivor's lived experience across the cancer control continuum. 
  • The incidence of venous thromboembolism in cancer patients: a real-world analysis. 
  • The influence of relationships on children's and adolescents' participation in research 
  • The integration of hyperthermia and drug delivery. 
  • The management of imaging dose during image-guided radiotherapy: report of the AAPM Task Group 75. 
  • The measured electrical properties of normal and malignant human tissues from 50 to 900 MHz. 
  • The message isn't as mean as we may think. 
  • The multifaceted roles of nitric oxide in cancer. 
  • The need for a re-evaluation of best supportive care studies reported to date. 
  • The older cancer patient. 
  • The older cancer patient. 
  • The oligometastatic state - separating truth from wishful thinking. 
  • The pattern of gene amplification is determined by the chromosomal location of hairpin-capped breaks. 
  • The pediatric preclinical testing program: description of models and early testing results. 
  • The peptidyl-prolyl isomerase Pin1. 
  • The performance of a reduced-order adaptive controller when used in multi-antenna hyperthermia treatments with nonlinear temperature-dependent perfusion. 
  • The personal financial burden of cancer for the working-aged population. 
  • The pervasive presence of fluctuating oxygenation in tumors. 
  • The potential of Zn(II) N-alkylpyridylporphyrins for anticancer therapy. 
  • The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. 
  • The potential role of intrinsic hypoxia markers as prognostic variables in cancer. 
  • The prevalence of perceived stigma and self-blame and their associations with depression, emotional well-being and social well-being among advanced cancer patients: evidence from the APPROACH cross-sectional study in Vietnam. 
  • The prevalence of potentially modifiable functional deficits and the subsequent use of occupational and physical therapy by older adults with cancer. 
  • The progress and promise of molecular imaging probes in oncologic drug development. 
  • The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. 
  • The relationship between hypoxia and angiogenesis. 
  • The relationship between the tumor physiologic microenvironment and angiogenesis. 
  • The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). 
  • The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. 
  • The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. 
  • The role of Osteopontin in tumor metastasis. 
  • The role of a palliative care intervention in moderating the relationship between depression and survival among individuals with advanced cancer. 
  • The role of adaptive and functional imaging modalities in radiation therapy: approach and application from a radiation oncology perspective. 
  • The role of amifostine as a radioprotector. 
  • The role of community-based and philanthropic organizations in meeting cancer patient and caregiver needs. 
  • The role of dendritic cell precursors in tumour vasculogenesis. 
  • The role of hypoxia in canine cancer. 
  • The role of p53 in cell-cycle control and apoptosis: implications for cancer. 
  • The role of quantitative PCR for the immune monitoring of cancer patients. 
  • The role of the extracellular matrix protein TGFBI in cancer. 
  • The role of tumor phenotype in the surgical treatment of early-stage breast cancer. 
  • The self-efficacy of family caregivers for helping cancer patients manage pain at end-of-life. 
  • The shunt problem: control of functional shunting in normal and tumour vasculature. 
  • The stem cell niche in health and malignancy. 
  • The strengths and limitations of meta-analyses based on aggregate data. 
  • The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. 
  • The therapeutic implications of immunosuppressive tumor aerobic glycolysis. 
  • The tumor dormant state. 
  • The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. 
  • The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. 
  • The two-edged sword of curing childhood cancer. 
  • The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. 
  • The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. 
  • The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. 
  • The use of hydralazine to manipulate tumour temperatures during hyperthermia. 
  • The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. 
  • The utility of cost discussions between patients with cancer and oncologists. 
  • The utility of thermal dose as a predictor of tumor and normal tissue responses to combined radiation and hyperthermia. 
  • The value of current nutrition information. 
  • The visual communication of risk. 
  • Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid. 
  • Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: A review. 
  • Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. 
  • Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review. 
  • There is a mismatch between the medicare benefit package and the preferences of patients with cancer and their caregivers. 
  • There is substantial agreement among interspecies estimates of DNA repair activity. 
  • Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. 
  • Thermal medicine, heat shock proteins and cancer. 
  • Thioredoxin and hematologic malignancies. 
  • Three instruments to assess fatigue in children with cancer: the child, parent and staff perspectives. 
  • Three-Dimensional Dosimetric Validation of a Magnetic Resonance Guided Intensity Modulated Radiation Therapy System. 
  • Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. 
  • Thromboembolism in hospitalized neutropenic cancer patients. 
  • Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. 
  • Thrombolysis for acute ischemic stroke in patients with cancer: a population study. 
  • Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. 
  • Thrombosis and cancer: emerging data for the practicing oncologist. 
  • Time to add screening for financial hardship as a quality measure? 
  • Time to cancer treatment and reproductive outcomes after fertility preservation among adolescent and young adult women with cancer. 
  • Time to define high-quality palliative care in oncology. 
  • Time trends in the prevalence of cancer and non-cancer diseases among older U.S. adults: Medicare-based analysis. 
  • Time trends of incidence of age-associated diseases in the US elderly population: Medicare-based analysis. 
  • Tissue factor and fibrin in tumor angiogenesis. 
  • Tissue factor, thrombin, and cancer. 
  • Tissue self-affinity and polarized light scattering in the born approximation: a new model for precancer detection. 
  • To die or grow: Parkinson's disease and cancer. 
  • To find the road traveled to tumor immunity: the trafficking itineraries of molecular chaperones in antigen-presenting cells. 
  • Tobacco Use Among Siblings of Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study. 
  • Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. 
  • Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. 
  • Top 10 Tips Palliative Care Clinicians Should Know About Radiation Oncology. 
  • Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in Cancer. 
  • Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. 
  • Toward a Shared Vision for Cancer Genomic Data. 
  • Toward a systems engineering approach to cancer drug delivery. 
  • Towards a genomic-based diagnosis. 
  • Towards a more comprehensive understanding of cancer burden in North Carolina: priorities for intervention. 
  • Towards precision prevention: Technologies for identifying healthy individuals with high risk of disease. 
  • Trade-off between cancer and aging: what role do other diseases play? Evidence from experimental and human population studies. 
  • Trade-off in the effect of the APOE gene on the ages at onset of cardiocascular disease and cancer across ages, gender, and human generations. 
  • Trade-off in the effects of the apolipoprotein E polymorphism on the ages at onset of CVD and cancer influences human lifespan. 
  • Trade-offs between cancer and other diseases: do they exist and influence longevity? 
  • Trade-offs in the effects of the apolipoprotein E polymorphism on risks of diseases of the heart, cancer, and neurodegenerative disorders: insights on mechanisms from the Long Life Family Study. 
  • Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors. 
  • Trajectories of Health-related quality of life in patients with Advanced Cancer during the Last Year of Life: findings from the COMPASS study. 
  • Trajectories of Suffering in the Last Year of Life Among Patients With a Solid Metastatic Cancer. 
  • Trajectories of physical symptom burden and psychological distress during the last year of life in patients with a solid metastatic cancer. 
  • Trajectory of overall health from self-report and factors contributing to health declines among cancer survivors. 
  • Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. 
  • Transcription recycling assays identify PAF1 as a driver for RNA Pol II recycling. 
  • Transcriptional analysis of tumor-specific T-cell responses in cancer patients. 
  • Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. 
  • Transforming epidemiology for 21st century medicine and public health. 
  • Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. 
  • Transforming growth factor-beta signaling in cancer. 
  • Transforming oncology care: payment and delivery reform for person-centered care. 
  • Transgelin-2: Biochemical and Clinical Implications in Cancer and Asthma. 
  • Transient finite element analysis of thermal methods used to estimate SAR and blood flow in homogeneously and nonhomogeneously perfused tumour models. 
  • Translational Research Working Group developmental pathway for immune response modifiers. 
  • Transport of drugs from blood vessels to tumour tissue. 
  • Transvascular drug delivery in solid tumors. 
  • Traveling With Cancer: A Guide for Oncologists in the Modern World. 
  • Treating cancer with embryonic stem cells: rationale comes from aging studies. 
  • Treatment of chemotherapy-induced alopecia. 
  • Treatment of coronary artery disease in cancer survivors: an emerging challenge. 
  • Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. 
  • Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. 
  • Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. 
  • Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how? 
  • Treatment, Not Terror: Time for Unique Problem-Solving Partnerships for Cancer Care in Resource-Challenged Environments. 
  • Trends in Insurance Status Among Patients Diagnosed With Cancer Before and After Implementation of the Affordable Care Act. 
  • Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. 
  • Trends in the use of feeding tubes in North Carolina hospitals. 
  • Triadic agreement about advanced cancer treatment decisions: Perceptions among patients, families, and oncologists. 
  • Triadic treatment decision-making in advanced cancer: a pilot study of the roles and perceptions of patients, caregivers, and oncologists. 
  • Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. 
  • Triple stimulus-responsive polypeptide nanoparticles that enhance intratumoral spatial distribution. 
  • Truth in the most optimistic way. 
  • Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. 
  • Tumor Heterogeneity and Therapeutic Resistance. 
  • Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? 
  • Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. 
  • Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. 
  • Tumor heterogeneity. 
  • Tumor marker response to SARS-CoV-2 infection among patients with cancer. 
  • Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. 
  • Tumor microenvironment and the immune response. 
  • Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield? 
  • Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. 
  • Tumor oxygenation: a matter of supply and demand. 
  • Tumor physiology and cell kinetics. 
  • Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development. 
  • Tumor potential in rat wounds after short- and long-term administration of platelet-rich plasma: an update. 
  • Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. 
  • Tumor stem cell cloning in agar-containing capillaries. 
  • Tumor temperature distributions predict hyperthermia effect. 
  • Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. 
  • Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. 
  • Tumor-intrinsic and immune modulatory roles of receptor-interacting protein kinases. 
  • Tumor-suppressor p53: implications for tumor development and prognosis. 
  • Tumors as elusive targets of T-cell-based active immunotherapy. 
  • Tumors of the Epiphyses. 
  • Tumour maintenance is mediated by eNOS. 
  • Turning lemons into lemonade: learning from negative studies in cancer immunotherapy. 
  • Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. 
  • Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. 
  • U.S. Physicians' Opinions About Accommodating Religiously Based Requests for Continued Life-Sustaining Treatment. 
  • U.S. cancer mortality 1950-1978: a strategy for analyzing spatial and temporal patterns. 
  • US physicians' attitudes toward genetic testing for cancer susceptibility. 
  • Ultrasonic imaging using optoelectronic transmitters. 
  • Ultrasound guided biopsy: what's new? 
  • Uncertain benefit: investigators' views and communications in early phase gene transfer trials. 
  • Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. 
  • Underdiagnosis and Undertreatment of Modifiable Cardiovascular Risk Factors Among Survivors of Childhood Cancer. 
  • Underlying mechanisms of change in cancer prevalence in older U.S. adults: contributions of incidence, survival, and ascertainment at early stages. 
  • Underrepresentation of older adults in cancer trials--reply. 
  • Understanding Effective Delivery of Patient and Family Education in Pediatric Oncology_{A Systematic Review From the Children's Oncology Group [Formula: see text]} . 
  • Understanding Multiple Behavioral Risk Factors for Cancer in Rural Women. 
  • Understanding and Utilizing Patient Preferences in Cancer Treatment Decisions. 
  • Understanding cognition in older patients with cancer. 
  • Understanding metabolism with flux analysis: From theory to application. 
  • Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. 
  • Understanding on the association between informal caregiver characteristics and cognitive function of adults with cancer: a scoping review protocol. 
  • Understanding the relationship between the Centers for Medicare and Medicaid Services' Hospital Compare star rating, surgical case volume, and short-term outcomes after major cancer surgery. 
  • Understanding the response to immunotherapy in humans. 
  • Understanding the tumor microenvironment and radioresistance by combining functional imaging with global gene expression. 
  • Unearthing the Janus-face cholesterogenesis pathways in cancer. 
  • Unemployment among adult survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. 
  • Unintentional weight loss, its associated burden, and perceived weight status in people with cancer. 
  • Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. 
  • United States Cutaneous Oncodermatology Management (USCOM) II: A Multidisciplinary-Guided Algorithm for the Prevention and Management of Acute Radiation Dermatitis in Cancer Patients. 
  • United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer. 
  • Unmet needs and depression among carers of people newly diagnosed with cancer. 
  • Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients. 
  • Unsuspected pulmonary embolism: prospective detection on routine helical CT scans. 
  • Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. 
  • Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. 
  • Updating the Wnt pathways. 
  • Urinary incontinence and health-related quality of life among older Americans with and without cancer: a cross-sectional study. 
  • Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. 
  • Use of SMART-generated cDNA for gene expression studies in multiple human tumors. 
  • Use of alternative therapies in menopause. 
  • Use of an electronic patient-reported outcome measurement system to improve distress management in oncology. 
  • Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. 
  • Use of email and telephone prompts to increase self-monitoring in a Web-based intervention: randomized controlled trial. 
  • Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. 
  • Use of fertility preservation services in female reproductive-aged cancer patients. 
  • Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. 
  • Use of laser scanning cytometry to study tumor microenvironment. 
  • Use of patient registries and administrative datasets for the study of pediatric cancer. 
  • Use of research biopsies in clinical trials: are risks and benefits adequately discussed? 
  • Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. 
  • Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. 
  • Use of the Internet for health information by the chronically ill. 
  • Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. 
  • User-Centered App Design for Acutely Ill Children and Adolescents. 
  • Uses of epoetin for anemia in oncology. 
  • Using Latent Class Modeling to Jointly Characterize Economic Stress and Multipollutant Exposure. 
  • Using a geriatric oncology assessment to link with services (GOAL). 
  • Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. 
  • Using cognitive interviews to evaluate items for measuring sexual functioning across cancer populations: improvements and remaining challenges. 
  • Using community-based participatory research methods to reach women with health messages: results from the North Carolina BEAUTY and Health Pilot Project. 
  • Using digital health to facilitate compliance with standardized pediatric cancer treatment guidelines in Tanzania: protocol for an early-stage effectiveness-implementation hybrid study. 
  • Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. 
  • Using improvement science to promote evidence-based practice in a childhood cancer and hematology center. 
  • Using leadership and advocacy to improve cancer pain management--based on a presentation at the cancer pain, suffering and spirituality course. 
  • Using lithium as a neuroprotective agent in patients with cancer. 
  • Using prospect theory to understand end-of-life decisions. 
  • Using real-world evidence to support a changing paradigm for cancer screening: A commentary. 
  • Using weighted power mean for equivalent square estimation. 
  • Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy. 
  • Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels. 
  • Utilizing Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting Normal Tissues. 
  • VA Cancer Research: A Legacy and A Future. 
  • VEGF inhibition and renal thrombotic microangiopathy. 
  • VEGF inhibitors in cancer therapy. 
  • VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. 
  • Vaccination Against SARS-CoV-2 Decreases Risk of Adverse Events in Patients who Develop COVID-19 Following Cancer Surgery. 
  • Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. 
  • Vaccination to Prevent Cancer. 
  • Vaccine Therapies for Cancer: Then and Now. 
  • Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. 
  • Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. 
  • Validation of the Belief Into Action Scale (BIAC) in Portuguese Cancer Patients Receiving Chemotherapy. 
  • Validation of the Duke University Religion Index (DUREL) in Portuguese Cancer Patients Undergoing Chemotherapy. 
  • Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure. 
  • Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. 
  • Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • Validity and reliability of a new instrument to measure cancer-related fatigue in adolescents. 
  • Value of high-cost cancer care: a behavioral science perspective. 
  • Variability in St. John's wort formulations is an important consideration. 
  • Variability in blood flow and pO2 in tumors in response to carbogen breathing. 
  • Variability of body weight and health outcomes in the Framingham population. 
  • Variation in Patient-Reported Decision-Making Roles in the Last Year of Life among Patients with Metastatic Cancer: A Longitudinal Study. 
  • Variation in Physician-Specific Episode Payments for Major Cancer Surgery and Implications for the Merit-Based Incentive Program. 
  • Variations in pain, sleep, and activity during hospitalization in children with cancer. 
  • Varieties of uncertainty and the validity of informed consent. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. 
  • Venous Thromboembolism in Patients with Cancer Receiving Specialist Palliative Care. 
  • Venous thromboembolic disease. 
  • Venous thromboembolic disease. 
  • Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. 
  • Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. 
  • Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. 
  • Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. 
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. 
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. 
  • Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. 
  • Vinblastine-related pain in tumors. 
  • Visual and semiquantitative analysis of 82Rb uptake in malignant tumors on PET/CT: first systematic analysis. 
  • Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. 
  • Vitamin D supplementation for prevention of cancer: The D2d cancer outcomes (D2dCA) study. 
  • Vitamin K in the treatment of cancer. 
  • Voices: The Future of Metabolism. 
  • Volume and activity quantitation with iodine-123 SPECT. 
  • Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • WNT inhibition creates a BRCA-like state in Wnt-addicted cancer. 
  • WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. 
  • WRN helicase is a synthetic lethal target in microsatellite unstable cancers. 
  • Weekly administration of cis-dichlorodiammineplatinum(II) in childhood solid tumors: a Southwest Oncology Group study. 
  • Weight management and physical activity throughout the cancer care continuum. 
  • Weight-based chemotherapy dosing in obese patients with cancer: back to the future. 
  • What are the criteria for response to cachexia treatment? 
  • What do I have to lose? Effects of a psycho-educational intervention on cancer patient preference for resuscitation. 
  • What do these scores mean? Presenting patient-reported outcomes data to patients and clinicians to improve interpretability. 
  • What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing. 
  • What is the role of friends when contributing care at the end of life? Findings from an Australian population study. 
  • What is your understanding of your illness? A communication tool to explore patients' perspectives of living with advanced illness. 
  • What length of hospice use maximizes reduction in medical expenditures near death in the US Medicare program? 
  • What potential does plasmonics-amplified synergistic immuno photothermal nanotherapy have for treatment of cancer? 
  • What really matters in cancer?: Putting people back into the heart of cancer policy. 
  • What should we do about work related cancer? 
  • What you and your patients need to know about vitamin D. 
  • What's New in Genetic Testing for Cancer Susceptibility? 
  • When do older adults turn to the internet for health information? Findings from the Wisconsin Longitudinal Study. 
  • When money is saved by reducing healthcare costs, where do US primary care physicians think the money goes? 
  • When oncology nurses become oncology patients. 
  • When to Integrate Palliative Care in the Trajectory of Cancer Care. 
  • White paper on microbial anti-cancer therapy and prevention. 
  • Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. 
  • Whole-body hyperthermia. Rationale and potential use for cancer treatment. 
  • Why Are We Failing to Do What Works? Musings on Outpatient Palliative Care Integration in Cancer Care. 
  • Why Do Patients Undergoing Extremity Prosthetic Reconstruction for Metastatic Disease Get Readmitted? 
  • Why do cancer patients die in the emergency department?: an analysis of 283 deaths in NC EDs. 
  • Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. 
  • Wild-type and mutant retinoblastoma protein in paraffin sections. 
  • Wild-type p53: tumors can't stand it. 
  • Will AI Improve Tumor Delineation Accuracy for Radiation Therapy? 
  • Will biosimilars gain momentum? 
  • Will hyperthermia conquer the elusive hypoxic cell? Implications of heat effects on tumor and normal-tissue microcirculation. 
  • Will they come and will they stay? 
  • Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. 
  • Wire-reinforced ureteral stents to rescue from nephrostomy tube in extrinsic ureteral obstruction. 
  • Wnt Signaling and Drug Resistance in Cancer. 
  • Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. 
  • Wnts and the hallmarks of cancer. 
  • Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. 
  • Workshop on imaging science development for cancer prevention and preemption. 
  • X-Ray Psoralen Activated Cancer Therapy (X-PACT). 
  • X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. 
  • XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. 
  • Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. 
  • Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. 
  • Young women's experiences with complementary therapies during cancer described through illness blogs. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies]. 
  • [Chicken RNA tumor viruses: a model for virus-induced carcinogenesis]. 
  • [The effect of a urinary incontinence self-management program for rural older women]. 
  • [The mechanism of the antitumor effect of total/subtotal radiotherapy with non-tumoricidal doses of radiation]. 
  • [Variation of mortality risk among cancer patients and individualized therapy]. 
  • alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. 
  • c-Myc is required for maintenance of glioma cancer stem cells. 
  • c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. 
  • gammadelta T cells: a new frontier for immunotherapy? 
  • mir-17-92: a polycistronic oncomir with pleiotropic functions. 
  • p38 MAPK in development and cancer. 
  • p53 and ATM: cell cycle, cell death, and cancer. 
  • p73 G4C14-to-A4T14 gene polymorphism and interaction with p53 exon 4 Arg72Pro on cancer susceptibility: a meta-analysis of the literature. 
  • permGPU: Using graphics processing units in RNA microarray association studies. 
  • rHuEPO and improved treatment outcomes: potential modes of action. 
  • siRNA-based approaches in cancer therapy. 
  • γδ T cells share the spotlight in cancer. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bradford, William Dalton, Professor of Pathology, Pathology
  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Dement, John McCray, Professor Emeritus in Family Medicine and Community Health, Family Medicine & Community Health,Occupational & Environmental Medicine
  • Erickson, Harold Paul, James B. Duke Distinguished Professor Emeritus, Cell Biology
  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Hartemink, Alexander J., Professor in the Department of Computer Science, Biology
  • Hirschey, Matthew, Associate Professor of Medicine, Cell Biology
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Cell Biology
  • McConnell, Eleanor Schildwachter, Associate Professor in the School of Nursing, School of Nursing
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • O'Daniel, Jennifer Colleen, Assistant Professor of Radiation Oncology, Radiation Oncology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Strand de Oliveira, Justine, Professor Emeritus in Family Medicine and Community Health, Family Medicine and Community Health, Physician Assistant Program
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society